



00270

PATENT TRADEMARK OFFICE

Attorney's Docket No.: GNVPN.031USA 09/807802  
JC03 Rec'd PCT/PTO 17 APR 2001TRANSMITTAL LETTER TO THE U.S. ELECTED OFFICE  
(EO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

PCT/US99/25694

International Application No.

2 November 1999

International Filing Date

5 November 1998

Priority Date Claimed

ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES,  
VECTORS AND HOST CELLS CONTAINING SAME

Title of Invention

James M. Wilson and Weidong Xiao

Applicant(s) for EO/US

Box PCT

Assistant Commissioner for Patents

Washington, DC 20231

Attn: EO/US

Sir:

Applicant herewith submits to the United States Elected Office  
(EO/US) the following items under 35 USC 371:

- (1) This express request to immediately begin national examination procedures (35 USC 371(f)).
- (2) A copy of the cover sheet for the published International Application along with a copy of the specification as filed: 109 pages, including 5 pages of claims, 13 sheets of drawings, 59 pages of Sequence Listing, and a copy of the 4 pages International Search Report.
- (3) a copy of the 5 page Request form.
- (4) a first Preliminary Amendment for entry prior to calculation of the filing fees.
- (5) our check in the amount of \$1,420.00, covering the basic national fee as set forth in 37 CFR 1.492(a)(5) and based on the first Preliminary Amendment (16 total claims; 10 independent; and no multiple dependent).
- (6) A Second Preliminary Amendment.

Express Mail No.

ET03364824345

- (7) Our check in the amount of \$90.00, covering the extra claim fees after entry of the second Preliminary Amendment (25 total claims; 10 independent; and no multiple dependent).
- (8) Two (2) pages partially-executed Combined Declaration and Power of Attorney form by first inventor.
- (9) A 59 pages Sequence Listing (provided in specification).
- (10) A 3.5" computer-readable diskette.
- (11) A 1 page Statement under 37 CFR §1.821(f) and §1.825(a) and (b).

Copies of the following miscellaneous items are also enclosed:

- (12) Copy of the 3 page Demand for International Preliminary Examination.
- (13) Copy of the 10 page Written Opinion.
- (14) Copy of the 11 page International Preliminary Examination Report.

The Combined Declaration and Power of Attorney form of the second inventor will be filed by the appropriate deadline under 37 CFR §1.495(c)(2) with the surcharge under 37 CFR §1.492(e).

Please charge any additional fees which may be required to effect entry into the National Phase and credit any overpayment to Deposit Account No. 08-3040.

Please direct all communications concerning this application to the undersigned.

Respectfully submitted,  
HOWSON AND HOWSON  
Attorneys for the Applicants

By Cathy A. Kodroff  
Cathy A. Kodroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9210  
Telefacsimile: (215) 540-5818

GNVPN.031USA

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of	) Group Art Unit:
	)
James M. Wilson et al	) Examiner:
	)
Appln. No. 09/807,802	)
	)
Filed: April 17, 2001	)
	)
For: ADENO-ASSOCIATED VIRUS	) February 20, 2002
SEROTYPE I NUCLEIC ACID	)
SEQUENCES, VECTORS AND HOST	)
CELLS CONTAINING SAME	)

Commissioner for Patents  
Box Sequence  
Washington, DC 20231

STATEMENT PURSUANT TO 37 CFR §1.825(a)&(b)

Sir:


A substitute Sequence Listing and a computer readable form of the substitute Sequence Listing are provided herewith. This Sequence Listing contains updated background information and is in PatentIn Version 3.1. No substantive changes have been made. The substitute Sequence Listing and computer readable copy contain no new matter.

This affirms that to the best of my knowledge and belief the content of the pages of the substitute Sequence Listing and this computer readable copy of said pages of the substitute Sequence Listing provided herewith are the same.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for the Applicants

By

  
Cathy A. Koff  
Registration No. 33,980  
Spring House Corporate Center  
P.O. Box 457  
Spring House, PA 19477  
(215) 540-9206

GNVPN.031USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of	) Group Art Unit:
	)
James M. Wilson et al	) Examiner:
	)
Appln. No.	)
	)
Filed: Herewith	)
	)
For: ADENO-ASSOCIATED VIRUS	) April 17, 2001
SEROTYPE I NUCLEIC ACID	)
SEQUENCES, VECTORS AND HOST	)
CELLS CONTAINING SAME	)

Assistant Commissioner for Patents  
Washington, DC 20231

**PRELIMINARY AMENDMENT**

Sir:

Please amend the application as set forth below.

**In the Claims**

Cancel claims 7, 8, 12, 13, 15, 21 and 22 without prejudice.

**REMARKS**

After entry of this preliminary amendment, the pending claims are claims 1-6, 9-11, 14, 16-20, and 23. Claims 7, 8, 12, 13, 15, 21 and 22 are cancelled. No new matter is introduced by this preliminary amendment.

Express Mail No. ET03364824345



Applicants respectfully request that this preliminary amendment be entered prior to calculating the filing fees.

The Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicant

By Cathy A. Kodroff  
Cathy A. Kodroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9200  
Telefacsimile: (215) 540-5818

09/807802

JC02 Rec'd PCT/PTO 1 7 APR 2001

GNVPN.031USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of	) Group Art Unit:
	)
James M. Wilson et al	) Examiner:
	)
Appln. No.	)
	)
Filed: Herewith	)
	)
For: ADENO-ASSOCIATED VIRUS	) April 17, 2001
SEROTYPE I NUCLEIC ACID	)
SEQUENCES, VECTORS AND HOST	)
CELLS CONTAINING SAME	)

Assistant Commissioner for Patents  
Washington, DC 20231

**SECOND PRELIMINARY AMENDMENT**

Sir:

Please amend the application as follows.

In the Specification

Page 1, line 6, before "Field of the Invention", insert the following new paragraph:

-- Cross-Reference to Related Applications

This is a 371 of PCT/US99/25694, which claims the benefit of the priority of US Patent Application No. 60/107,114, filed November 5, 1998. --

Please enter the attached Abstract of the Disclosure on the attached page as new page 38.

Express Mail No ET033648243US

In the Claims

Add new claims 24-32 as follows.

24. The recombinant vector according to claim 3, wherein said vector further comprises AAV-1 capsid proteins having the sequence of SEQ ID NO: 13, 15 or 17 or functional fragments thereof.

25. The recombinant vector according to claim 3, wherein said vector further comprises adenovirus sequences.

26. The host cell transduced with a recombinant viral vector according to claim 3.

27. The host cell transduced with a nucleic acid molecule according to claim 1.

28. The host cell transduced with a nucleic acid molecule according to claim 2.

29. The host cell transduced with a nucleic acid molecule according to claim 10.

30. The host cell transduced with a nucleic acid molecule according to claim 11.

31. The pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 3.







14. A host cell stably transduced with an AAV-1 P5 promoter having the sequence of nt 236 to 299 of SEQ ID NO: 1.

16. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 7.

17. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 8.

18. A method for AAV-mediated delivery of a transgene comprising the step of delivering to a host cell an AAV virion which comprises:

(a) a capsid comprising at least one capsid protein encoded by an AAV-1 cap gene; and

(b) a DNA molecule comprising a transgene under the control of regulatory sequences directing its expression.

19. A method for AAV-mediated delivery of a transgene to a host comprising the steps of:

(a) assaying a sample from the host to determine the presence of neutralizing antibodies specific against any serotype of AAV; and

(b) delivering to the host an AAV virion which comprises:

(i) a capsid comprising at least one capsid protein encoded by a cap gene of an AAV serotype against which the host has no antibodies as determined in step (a); and

(ii) a DNA molecule comprising a transgene under the control of regulatory sequences directing its expression.

20. The method according to claim 19, comprising the additional step of repeating steps (a) and (b).

23. A method for producing a selected gene product comprising the steps of transfecting a mammalian cell with the molecule according to claim 1 or a functional fragment thereof and culturing said cell under conditions suitable to express said gene product.

24. The recombinant vector according to claim 3, wherein said vector further comprises AAV-1 capsid proteins having the sequence of SEQ ID NO: 13, 15 or 17 or functional fragments thereof.

25. The recombinant vector according to claim 3, wherein said vector further comprises adenovirus sequences.

26. The host cell transduced with a recombinant viral vector according to claim 3.

27. The host cell transduced with a nucleic acid molecule according to claim 1.

28. The host cell transduced with a nucleic acid molecule according to claim 2.

29. The host cell transduced with a nucleic acid molecule according to claim 10.

30. The host cell transduced with a nucleic acid molecule according to claim 11.

31. The pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 3.



32. The method for delivery of a transgene comprising the step of delivering to a host cell a recombinant virus comprising a recombinant vector according to claim 3.

ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID  
SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME

This work was supported by the National Institutes of Health, grant no. P30  
DK47757-06 and PO1 HD32649-04. The US government may have certain rights in  
5 this invention.

Field of the Invention

This invention relates generally to viral vector, and more particularly, to  
recombinant viral vectors useful for gene delivery.

Background of the Invention

10 Adeno-associated viruses are small, single-stranded DNA viruses which  
require helper virus to facilitate efficient replication [K.I. Berns, *Parvoviridae: the  
viruses and their replication*, p. 1007-1041, in F.N. Fields et al., Fundamental  
virology, 3rd ed., vol. 2, (Lippencott-Raven Publishers, Philadelphia, PA) (1995)].  
The 4.7 kb genome of AAV is characterized by two inverted terminal repeats (ITR)  
15 and two open reading frames which encode the Rep proteins and Cap proteins,  
respectively. The Rep reading frame encodes four proteins of molecular weight 78  
kD, 68 kD, 52 kD and 40 kD. These proteins function mainly in regulating AAV  
replication and integration of the AAV into a host cell's chromosomes. The Cap  
reading frame encodes three structural proteins in molecular weight 85 kD (VP 1), 72  
20 kD (VP2) and 61 kD (VP3) [Berns, cited above]. More than 80% of total proteins in  
AAV virion comprise VP3. The two ITRs are the only cis elements essential for AAV  
replication, packaging and integration. There are two conformations of AAV ITRs  
called "flip" and "flop". These differences in conformation originated from the  
replication model of adeno-associated virus which use the ITR to initiate and reinitiate  
25 the replication [R.O. Snyder et al., J. Virol., 67:6096-6104 (1993); K.I. Berns,  
Microbiological Reviews, 54:316-329 (1990)].

AAVs have been found in many animal species, including primates, canine,  
fowl and human [F.A. Murphy et al., "The Classification and Nomenclature of  
Viruses: Sixth Report of the International Committee on Taxonomy of Viruses",

Archives of Virology, (Springer-Verlag, Vienna) (1995)]. In addition to five known primate AAVs (AAV-1 to AAV-5), AAV-6, another serotype closely related to AAV-2 and AAV-1 has also been isolated [E. A. Rutledge et al., J. Virol., 72:309-319 (1998)]. Among all known AAV serotypes, AAV-2 is perhaps the most well-  
5 characterized serotype, because its infectious clone was the first made [R.J. Samulski et al., Proc. Natl. Acad. Sci. USA, 79:2077-2081 (1982)]. Subsequently, the full sequences for AAV-3A, AAV-3B, AAV-4 and AAV-6 have also been determined [Rutledge, cited above; J.A. Chiorini et al., J. Virol., 71:6823-6833 (1997); S. Muramatsu et al., Virol., 221:208-217 (1996)]. Generally, all AAVs share more than  
10 80% homology in nucleotide sequence.

A number of unique properties make AAV a promising vector for human gene therapy [Muzyczka, Current Topics in Microbiology and Immunology, 158:97-129 (1992)]. Unlike other viral vectors, AAVs have not been shown to be associated with any known human disease and are generally not considered pathogenic. Wild type  
15 AAV is capable of integrating into host chromosomes in a site specific manner [R. M. Kotin et al., Proc. Natl. Acad. Sci. USA, 87:2211-2215 (1990)- R.J. Samulski, EMBO J., 10(12):3941-3950 (1991)]. Recombinant AAV vectors can integrate into tissue cultured cells in chromosome 19 if the rep proteins are supplied in *trans* [C. Balague et al., J. Virol., 71:3299-3306 (1997); R. T. Surosky et al., J. Virol.,  
20 71:7951-7959 (1997)]. The integrated genomes of AAV have been shown to allow long term gene expression in a number of tissues, including, muscle, liver, and brain [K. J. Fisher, Nature Med., 3(3):306-312 (1997); R. O. Snyder et al., Nature Genetics, 16:270-276 (1997); X. Xiao et al., Experimental Neurology, 144:113-124 (1997); Xiao, J. Virol., 70(11):8098-8108 (1996)].

25 AAV-2 has been shown to be present in about 80-90% of the human population. Earlier studies showed that neutralizing antibodies for AAV-2 are prevalent [W. P. Parks et al., J. Virol., 2:716-722 (1970)]. The presence of such antibodies may significantly decrease the usefulness of AAV vectors based on AAV-2 despite its other merits. What are needed in the art are vectors characterized by the

advantages of AAV-2, including those described above, without the disadvantages, including the presence of neutralizing antibodies.

### Summary of the Invention

In one aspect, the invention provides an isolated AAV-1 nucleic acid molecule  
5 which is selected from among SEQ ID NO: 1, the strand complementary to SEQ ID NO: 1, and cDNA and RNA sequences complementary to SEQ ID NO: 1 and its complementary strand.

In another aspect, the present invention provides AAV ITR sequences, which include the 5' ITR sequences, nt 1 to 143 of SEQ ID NO: 1; the 3' ITR sequences, nt  
10 4576 to 4718 of SEQ ID NO: 1, and fragments thereof.

In yet another aspect, the present invention provides a recombinant vector comprising an AAV-1 ITR and a selected transgene. Preferably, the vector comprises both the 5' and 3' AAV-1 ITRs between which the selected transgene is located.

In still another aspect, the invention provides a recombinant vector comprising  
15 an AAV-1 P5 promoter having the sequence of nt 236 to 299 of SEQ ID NO: 1 or a functional fragment thereof.

In a further aspect, the present invention provides a nucleic acid molecule encoding an AAV-1 rep coding region and an AAV-1 cap coding region.

In still another aspect, the present invention provides a host cell transduced with a  
20 recombinant viral vector of the invention. The invention further provides a host cell stably transduced with an AAV-1 P5 promoter of the invention.

In still a further aspect, the present invention provides a pharmaceutical composition comprising a carrier and a vector of the invention.

In yet another aspect, the present invention provides a method for AAV--  
25 mediated delivery of a transgene to a host involving the step of delivering to a selected host a recombinant viral vector comprising a selected transgene under the control of sequences which direct expression thereof and an adeno-associated virus 1 (AAV-1) virion.

Fig. 5A is a bar chart illustrating expression levels of  $\alpha$ 1AT in liver following delivery of  $\alpha$ 1AT as described in Example 7.

Fig. 5B is a bar chart demonstrating expression levels of epo in liver following delivery of epo as described in Example 7.

Fig. 5C is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-1 following delivery of  $\alpha$ 1AT or epo to liver as described in Example 7.

5 Fig. 5D is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-2 following delivery of  $\alpha$ 1AT or epo to liver as described in Example 7.

Fig. 6A is a bar chart illustrating expression levels of  $\alpha$ 1AT in muscle following delivery of  $\alpha$ 1AT as described in Example 7.

10 Fig. 6B is a bar chart demonstrating expression levels of epo in muscle following delivery of epo as described in Example 7.

Fig. 6C is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-1 following delivery of  $\alpha$ 1AT or epo to muscle as described in Example 7.

Fig. 6D is a bar chart demonstrating neutralizing antibodies (NAB) directed to AAV-2 following delivery of  $\alpha$ 1AT or epo to muscle as described in Example 7.

## 15 Detailed Description of the Invention

The present invention provides novel nucleic acid sequences for an adeno-- associated virus of serotype 1 (AAV-1). Also provided are fragments of these AAV-1 sequences. Among particularly desirable AAV-1 fragments are the inverted terminal repeat sequences (ITRs), rep and cap. Each of these fragments may be readily  
20 utilized, e.g., as a cassette, in a variety of vector systems and host cells. Such fragments may be used alone, in combination with other AAV-1 sequences or fragments, or in combination with elements from other AAV or non-AAV viral sequences. In one particularly desirable embodiment, a cassette may contain the AAV-1 ITRs of the invention flanking a selected transgene. In another desirable  
25 embodiment, a cassette may contain the AAV-1 rep and/or cap proteins, e.g., for use in producing recombinant (rAAV) virus.

Thus, the AAV-1 sequences and fragments thereof are useful in production of rAAV, and are also useful as antisense delivery vectors, gene therapy vectors, or vaccine vectors. The invention further provides nucleic acid molecules, gene delivery

vectors, and host cells which contain the AAV-1 sequences of the invention. Also provided a novel methods of gene delivery using AAV vectors.

As described herein, the vectors of the invention containing the AAV-1 capsid proteins of the invention are particularly well suited for use in applications in which the neutralizing antibodies diminish the effectiveness of other AAV serotype based vectors, as well as other viral vectors. The rAAV vectors of the invention are particularly advantageous in rAAV readministration and repeat gene therapy.

These and other embodiments and advantages of the invention are described in more detail below. As used throughout this specification and the claims, the term “comprising” is inclusive of other components, elements, integers, steps and the like.

# I. AAV-1 NUCLEIC ACID AND PROTEIN SEQUENCES

The AAV-1 nucleic acid sequences of the invention include the DNA sequences of SEQ ID NO: 1 (Figs. 1A-1C), which consists of 4718 nucleotides. The AAV-1 nucleic acid sequences of the invention further encompass the strand which is complementary to SEQ ID NO: 1, as well as the RNA and cDNA sequences corresponding to SEQ ID NO: 1 and its complementary strand. Also included in the nucleic acid sequences of the invention are natural variants and engineered modifications of SEQ ID NO: 1 and its complementary strand. Such modifications include, for example, labels which are known in the art, methylation, and substitution of one or more of the naturally occurring nucleotides with an analog.

Further included in this invention are nucleic acid sequences which are greater than 85%, preferably at least about 90%, more preferably at least about 95%, and most preferably at least about 98 - 99% identical or homologous to SEQ ID NO:1. The term “percent sequence identity” or “identical” in the context of nucleic acid sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over the full-length sequence, or a fragment at least about nine nucleotides, usually at least about 20 - 24 nucleotides, at least about 28 - 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different



algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using Fasta, a program in GCG Version 6.1. Fasta provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences  
 5 (Pearson, 1990, herein incorporated by reference). For instance, percent sequence identity between nucleic acid sequences can be determined using Fasta with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) as provided in GCG Version 6.1, herein incorporated by reference.

The term "substantial homology" or "substantial similarity," when referring to  
 10 a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 95 - 99% of the sequence.

Also included within the invention are fragments of SEQ ID NO: 1, its  
 15 complementary strand, cDNA and RNA complementary thereto. Suitable fragments are at least 15 nucleotides in length, and encompass functional fragments which are of biological interest. Certain of these fragments may be identified by reference to Figs. 1A-1C. Examples of particularly desirable functional fragments include the AAV-1 inverted terminal repeat (ITR) sequences of the invention. In contrast to the 145 nt  
 20 ITRs of AAV-2, AAV-3, and AAV-4, the AAV-1 ITRs have been found to consist of only 143 nucleotides, yet advantageously are characterized by the T-shaped hairpin structure which is believed to be responsible for the ability of the AAV-2 ITRs to direct site-specific integration. In addition, AAV-1 is unique among other AAV serotypes, in that the 5' and 3' ITRs are identical. The full-length 5' ITR sequences of  
 25 AAV-1 are provided at nucleotides 1-143 of SEQ ID NO: 1 (Fig. 1A) and the full-length 3' ITR sequences of AAV-1 are provided at nt 4576-4718 of SEQ ID NO: 1 (Fig. 1C). One of skill in the art can readily utilize less than the full-length 5' and/or 3' ITR sequences for various purposes and may construct modified ITRs using conventional techniques, e.g., as described for AAV-2 ITRs in Samulski et al, Cell,  
 30 33:135-143 (1983).



Another desirable functional fragment of the AAV-1 genome is the P5 promoter of AAV-1 which has sequences unique among AAV P5 promoters, while maintaining critical regulatory elements and functions. This promoter is located within nt 236 - 299 of SEQ ID NO: 1 (Fig. 1A). Other examples of functional fragments of interest include the sequences at the junction of the rep/cap, e.g., the sequences spanning nt 2306-2223, as well as larger fragments which encompass this junction which may comprise 50 nucleotides on either side of this junction. Still other examples of functional fragments include the sequences encoding the rep proteins. Rep 78 is located in the region of nt 334 - 2306 of SEQ ID NO: 1; Rep 68 is located in the region of nt 334-2272, and contains an intron spanning nt 1924-2220 of SEQ ID NO: 1. Rep 52 is located in the region of nt 1007 - 2304 of SEQ ID NO: 1, rep 40 is located in the region of nt 1007 - 2272, and contains an intron spanning nt 1924-2246 of SEQ ID NO: 1. Also of interest are the sequences encoding the capsid proteins, VP 1 [nt 2223-4431 of SEQ ID NO: 1], VP2 [nt 2634-4432 of SEQ ID NO: 1] and VP3 [nt 2829-4432 of SEQ ID NO: 1]. Other fragments of interest may include the AAV-1 P19 sequences, AAV-1 P40 sequences, the rep binding site, and the terminal resolute site (TRS).

The invention further provides the proteins and fragments thereof which are encoded by the AAV-1 nucleic acids of the invention. Particularly desirable proteins include the rep and cap proteins, which are encoded by the nucleotide sequences identified above. These proteins include rep 78 [SEQ ID NO:5], rep 68 [SEQ ID NO:7], rep 52 [SEQ ID NO:9], rep 40 [SEQ ID NO: 11], vpl [SEQ ID NO: 13], vp2 [SEQ ID NO: 15], and vp3 [SEQ IID NO: 17] and functional fragments thereof while the sequences of the rep and cap proteins have been found to be closely related to those of AAV-6, there are differences in the amino acid sequences (see Table 1 below), as well as differences in the recognition of these proteins by the immune system. However, one of skill in the art may readily select other suitable proteins or protein fragments of biological interest. Suitably, such fragments are at least 8 amino acids in length. However, fragments of other desired lengths may be readily utilized.

Such fragments may be produced recombinantly or by other suitable means, e.g., chemical synthesis.

The sequences, proteins, and fragments of the invention may be produced by any suitable means, including recombinant production, chemical synthesis, or other synthetic means. Such production methods are within the knowledge of those of skill  
5 in the art and are not a limitation of the present invention.

## II. VIRAL VECTORS

In another aspect, the present invention provides vectors which utilize the AAV-1 sequences of the invention, including fragments thereof, for delivery of a  
10 heterologous gene or other nucleic acid sequences to a target cell. Suitably, these heterologous sequences (i.e., a transgene) encode a protein or gene product which is capable of being expressed in the target cell. Such a transgene may be constructed in the form of a "minigene". Such a "minigene" includes selected heterologous gene sequences and the other regulatory elements necessary to transcribe the gene and  
15 express the gene product in a host cell. Thus, the gene sequences are operatively linked to regulatory components in a manner which permit their transcription. Such components include conventional regulatory elements necessary to drive expression of the transgene in a cell containing the viral vector. The minigene may also contain a selected promoter which is linked to the transgene and located, with other regulatory  
20 elements, within the selected viral sequences of the recombinant vector.

Selection of the promoter is a routine matter and is not a limitation of this invention. Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the timing and amount of the transgene to be expressed. For example, desirable promoters include the cytomegalovirus (CMV)  
25 immediate early promoter/enhancer [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the Rous sarcoma virus LTR promoter/enhancer, and the chicken cytoplasmic  $\beta$ -actin promoter [T. A. Kost et al, Nucl. Acids Res., 11(23):8287 (1983)]. Still other desirable promoters are the albumin promoter and an AAV P5 promoter. Optionally, the selected promoter is used in conjunction with a heterologous enhancer, e.g., the  $\beta$ -

actin promoter may be used in conjunction with the CMV enhancer. Yet other suitable or desirable promoters and enhancers may be selected by one of skill in the art.

The minigene may also desirably contain nucleic acid sequences heterologous to the viral vector sequences including sequences providing signals required for efficient polyadenylation of the transcript (poly-A or pA) and introns with functional splice donor and acceptor sites. A common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally is inserted in the minigene downstream of the transgene sequences and upstream of the viral vector sequences. A common intron sequence is also derived from SV-40, and is referred to as the SV40 T intron sequence. A minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional [see, e.g., Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2d edit., Cold Spring Harbor Laboratory, New York (1989) and references cited therein] and many such sequences are available from commercial and industrial sources as well as from Genebank.

The selection of the transgene is not a limitation of the present invention. Suitable transgenes may be readily selected from among desirable reporter genes, therapeutic genes, and optionally, genes encoding immunogenic polypeptides. Examples of suitable reporter genes include  $\beta$ -galactosidase ( $\beta$ -gal), an alkaline phosphatase gene, and green fluorescent protein (GFP). Examples of therapeutic genes include, cytokines, growth factors, hormones, and differentiation factors, among others. The transgene may be readily selected by one of skill in the art. See, e.g., WO 98/09657, which identifies other suitable transgenes.

Suitably, the vectors of the invention contain, at a minimum, cassettes which consist of fragments of the AAV-1 sequences and proteins. In one embodiment, a vector of the invention comprises a selected transgene, which is flanked by a 5' ITR and a 3' ITR, at least one of which is an AAV-1 ITR of the invention. Suitably,

vectors of the invention may contain a AAV-1 P5 promoter of the invention. In yet another embodiment, a plasmid or vector of the invention contains AAV-1 rep sequences. In still another embodiment, a plasmid or vector of the invention contains at least one of the AAV-1 cap proteins of the invention. Most suitably, these AAV-1-derived vectors are assembled into viral vectors, as described herein

A. AAV Viral Vectors

In one aspect, the present invention provides a recombinant AAV-1 viral vector produced using the AAV-1 capsid proteins of the invention. The packaged rAAV-1 virions of the invention may contain, in addition to a selected minigene, other AAV-1 sequences, or may contain sequences from other AAV serotypes.

Methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, J. Virol., 70:520-532 (1993) and US Patent 5,478,745. In one suitable method, a selected host cell is provided with the AAV sequence encoding a rep protein, the gene encoding the AAV cap protein and with the sequences for packaging and subsequent delivery. Desirably, the method utilizes the sequences encoding the AAV-1 rep and/or cap proteins of the invention.

In one embodiment, the rep/cap genes and the sequences for delivery are supplied by co-transfection of vectors carrying these genes and sequences. In one currently preferred embodiment, a cis (vector) plasmid, a trans plasmid containing the rep and cap genes, and a plasmid containing the adenovirus helper genes are co-transfected into a suitable cell line, e.g., 293. Alternatively, one or more of these functions may be provided in trans via separate vectors, or may be found in a suitably engineered packaging cell line.

An exemplary cis plasmid will contain, in 5' to 3' order, AAV 5' ITR, the selected transgene, and AAV 3' ITR. In one desirable embodiment, at least one of the AAV ITRs is a 143 nt AAV-1 ITR. However, other AAV serotype ITRs may be readily selected. Suitably, the full-length ITRs are utilized. However, one of skill in

the art can readily prepare modified AAV ITRs using conventional techniques. Similarly, methods for construction of such plasmids is well known to those of skill in the art.

5 A trans plasmid for use in the production of the rAAV-1 virion particle may be prepared according to known techniques. In one desired embodiment, this plasmid contains the rep and cap proteins of AAV-1, or functional fragments thereof. Alternatively, the rep sequences may be from another selected AAV serotype.

10 The cis and trans plasmid may then be co-transfected with a wild-type helper virus (e.g., Ad2, Ad5, or a herpesvirus), or more desirably, a replication - defective adenovirus, into a selected host cell. Alternatively, the cis and trans plasmid may be co-transfected into a selected host cell together with a transfected plasmid which provides the necessary helper functions. Selection of a suitable host cell is well within the skill of those in the art and include such mammalian cells as 293 cells, HeLa cells, among others.

15 Alternatively, the cis plasmid and, optionally the trans plasmid, may be transfected into a packaging cell line which provides the remaining helper functions necessary for production of a rAAV containing the desired AAV-1 sequences of the invention. An example of a suitable packaging cell line, where an AAV-2 capsid is desired, is B-50, which stably expresses AAV-2 rep and cap genes under the control  
20 of a homologous P5 promoter. This cell line is characterized by integration into the cellular chromosome of multiple copies (at least 5 copies) of P5-rep-cap gene cassettes in a concatomer form. This B-50 cell line was deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, on September 18, 1997 under Accession No. CRL-12401 pursuant to the  
25 provisions of the Budapest Treaty. However, the present invention is not limited as to the selection of the packaging cell line.

Exemplary transducing vectors based on AAV-1 capsid proteins have been tested both *in vivo* and *in vitro*, as described in more detail in Example 4. In these studies, it was demonstrated that recombinant AAV vector with an AAV-1  
30 virion can transduce both mouse liver and muscle. These, and other AAV-1 based

gene therapy vectors which may be generated by one of skill in the art are beneficial for gene delivery to selected host cells and gene therapy patients since the neutralization antibodies of AAV-1 present in much of the human population exhibit different patterns from other AAV serotypes and therefore do not neutralize the AAV-1 virions. One of skill in the art may readily prepare other rAAV viral vectors containing the AAV-1 capsid proteins provided herein using a variety of techniques known to those of skill in the art. One may similarly prepare still other rAAV viral vectors containing AAV-1 sequence and AAV capsids of another serotype.

#### B Other Viral Vectors

One of skill in the art will readily understand that the AAV-1 sequences of the invention can be readily adapted for use in these and other viral vector systems for *in vitro*, *ex vivo* or *in vivo* gene delivery. Particularly well suited for use in such viral vector systems are the AAV-1 ITR sequences, the AAV-1 rep, the AAV-1 cap, and the AAV-1 P5 promoter sequences.

For example, in one desirable embodiment, the AAV-1 ITR sequences of the invention may be used in an expression cassette which includes AAV-1 5' ITR, a non-AAV DNA sequences of interest (e.g., a minigene), and 3' ITR and which lacks functional rep/cap. Such a cassette containing an AAV-1 ITR may be located on a plasmid for subsequent transfection into a desired host cell, such as the cis plasmid described above. This expression cassette may further be provided with an AAV capsid of a selected serotype to permit infection of a cell or stably transfected into a desired host cell for packaging of rAAV virions. Such an expression cassette may be readily adapted for use in other viral systems, including adenovirus systems and lentivirus systems. Methods of producing Ad/AAV vectors are well known to those of skill in the art. One desirable method is described in PCT/US95/14018. However, the present invention is not limited to any particular method.

Another aspect of the present invention is the novel AAV-1 P5 promoter sequences which are located in the region spanning nt 236 - 299 of SEQ ID NO: 1. This promoter is useful in a variety of viral vectors for driving expression of a desired transgene.



Recombinant vectors generated as described above are useful for delivery of the DNA of interest to cells.





Dosages of the viral vector will depend primarily on factors such as the condition being treated, the age, weight and health of the patient, and may thus vary among patients. For example, a therapeutically effective human dosage of the viral vector is generally in the range of from about 1 ml to about 100 ml of solution containing concentrations of from about  $1 \times 10^9$  to  $1 \times 10^{16}$  genomes virus vector. A preferred human dosage may be about  $1 \times 10^{13}$  to  $1 \times 10^{16}$  AAV genomes. The dosage will be adjusted to balance the therapeutic benefit against any side effects and

such dosages may vary depending upon the therapeutic application for which the recombinant vector is employed. The levels of expression of the transgene can be monitored to determine the frequency of dosage resulting in viral vectors, preferably AAV vectors containing the minigene. Optionally, dosage regimens similar to those described for therapeutic purposes may be utilized for immunization using the compositions of the invention. For *in vitro* production, a desired protein may be obtained from a desired culture following transfection of host cells with a rAAV containing the gene encoding the desired protein and culturing the cell culture under conditions which permits expression. The expressed protein may then be purified and isolated, as desired. Suitable techniques for transfection, cell culturing, purification, and isolation are known to those of skill in the art.

The following examples illustrate several aspects and embodiments of the invention.

#### Example 1 - Generation of Infectious Clone of AAV-1

The replicated form DNA of AAV-1 was extracted from 293 cells that were infected by AAV-1 and wild type adenovirus type 5.

##### A. Cell Culture and Virus

AAV-free 293 cells and 84-31 cells were provided by the human application laboratory of the University of Pennsylvania. These cells were cultured in Dulbecco's Modified Eagle Medium with 10% fetal bovine serum (Hyclone), penicillin (100 U/ml) and streptomycin at 37°C in a moisturized environment supplied with 5% CO<sub>2</sub>. The 84-31 cell line constitutively expresses adenovirus genes E1a, E1b, E4/ORF6, and has been described previously [K. J. Fisher, *J. Virol.*, 70:520-532 (1996)]. AAV-1 (ATCC VR-645) seed stock was purchased from American Type Culture Collection (ATCC, Manassas, VA). AAV viruses were propagated in 293 cells with wild type Ad5 as a helper virus.

##### B. Recombinant AAV Generation

The recombinant AAV viruses were generated by transfection using an adenovirus free method. Briefly, the cis plasmid (with AAV ITR), trans plasmid (with

AAV rep gene and cap gene) and helper plasmid (pF $\Delta$ 13, with essential regions from the adenovirus genome) were simultaneously co-transfected into 293 cells in a ratio of 1:1:2 by calcium phosphate precipitation. The pF $\Delta$ 13 helper plasmid has an 8 kb deletion in the adenovirus E2B region and has deletions in most of the late genes.

5 This helper plasmid was generated by deleting the RsrII fragment from pFG140 (Microbix, Canada). Typically, 50  $\mu$ g of DNA (cis:trans:PF $\Delta$ 13 at ratios of 1:1:2, respectively) was transfected onto a 15 cm tissue culture dish. The cells were harvested 96 hours post-transfection, sonicated and treated with 0.5% sodium deoxycholate (37°C for 10 min). Cell lysates were then subjected to two rounds of a

10 CsCl gradient. Peak fractions containing AAV vector were collected, pooled, and dialyzed against PBS before injecting into animals. To make rAAV virus with AAV-1 virion, the pAV1H or p5E18 (2/1) was used as the *trans* plasmid to provide rep and cap function.

For the generation of rAAV based on AAV-2, p5E18 was used as the

15 *trans* plasmid since it greatly improved the rAAV yield. This plasmid, p5E18(2/2), expresses AAV-2 Rep and Cap and contains a P5 promoter relocated to a position 3' to the Cap gene, thereby minimizing expression of Rep78 and Rep68. The strategy was initially described by Li et al, *J. Virol.*, 71:5236-5243 (1997). P5E18(2/2) was constructed in the following way. The previously described pMMTV-*trans* vector

20 (i.e., the mouse mammary tumor virus promoter substituted for the P5 promoter in an AAV-2-based vector) was digested with *Sma*I and *Cla*I, filled in with the Klenow enzyme, and then recircularized with DNA ligase. The resulting construct was digested with *Xba*I, filled in, and ligated to the blunt-ended BamHI-*Xba*I fragment from pCR-p5, constructed in the following way. The P5 promoter of AAV was

25 amplified by PCR and the amplified fragment was subsequently cloned into pCR2.1 (Invitrogen) to yield pCR-P5. The helper plasmid pAV1H was constructed by cloning the *Bfa*I fragment of pAAV-2 into pBluescript II-SK(+) at the *Bco*RV and *Sma*I sites. The 3.0-kb *Xba*I-*Kpn*I fragment from p5E18(2/2), the 2.3-kb *Xba*I-*Kpn*I fragment from pAV1H, and the 1.7-kb *Kpn*I fragment from p5E18(2/2) were incorporated into

30 a separate plasmid P5E18(2/1), which contains AAV-2 Rep, AAV-1 Cap, and the

AAV-2 P5 promoter located 3' to the Cap gene. Plasmid p5E18(2/1) produced 10- to 20-fold higher quantities of the vector than pAV1H (i.e.,  $10^{12}$  genomes/50 15-cm<sup>2</sup> plates).

### C. DNA Techniques

5 Hirt DNA extraction was performed as described in the art with minor modification [R.J. Samulski et al., Cell, 33:135-143 (1983)]. More particularly, Hirt solution without SDS was used instead of using original Hirt solution containing SDS. The amount of SDS present in the original Hirt solution was added after the cells had been fully suspended. To construct AAV-1 infectious clone, the Hirt DNA from  
10 AAV-1 infected 293 cells was repaired with Klenow enzyme (New England Biolabs) to ensure the ends were blunt. The treated AAV-1 Hirt DNA was then digested with *Bam*HI and cloned into three vectors, respectively. The internal *Bam*HI was cloned into pBlueScript II-SK+ cut with *Bam*HI to get pAV1-BM. The left and right fragments were cloned into pBlueScript II-SK+ cut with *Bam*HI + EcoRV to obtain  
15 pAV1-BL and pAV1-BR, respectively. The AAV sequence in these three plasmids were subsequently assembled into the same vector to get AAV-1 infectious clone pAAV-1. The helper plasmid for recombinant AAV-1 virus generation was constructed by cloning the Bfa I fragment of pAAV-1 into pBlueScript II-SK+ at the EcoRV site.

20 Analysis of the Hirt DNA revealed three bands, a dimer at 9.4 kb, a monomer at 4.7 kb and single-stranded DNA at 1.7 kb, which correlated to different replication forms of AAV-1. The monomer band was excised from the gel and then digested with *Bam*HI. This resulted in three fragments of 1.1 kb, 0.8 kb and 2.8 kb. This pattern is in accordance with the description by Bantel-schaal and zur Hausen,  
25 Virol., 134(1):52-63 (1984). The 1.1 kb and 2.8 kb *Bam*HI fragments were cloned into pBlueScript-KS(+) at *Bam*HI and EcoRV site. The internal 0.8 kb fragment was cloned into *Bam*HI site of pBlueScript-KS(+).

These three fragments were then subcloned into the same construct to obtain a plasmid (pAAV-1) that contained the full sequence of AAV-1. The pAAV-1  
30 was then tested for its ability to rescue from the plasmid backbone and package

The AAV-1 genome exhibited similarities to other serotypes of adeno-associated viruses. Overall, it shares more than 80% identity with other known AAV viruses as determined by the computer program Megalign using default settings [DNASTAR, Madison, WI]. The key features in AAV-2 can also be found in AAV-1. First, AAV-1 has the same type of inverted terminal repeat which is capable of forming T-shaped hairpin structures, despite the differences at the nucleotide level

(Figs. 2 and 3). The sequences of right ITRs and left ITRs of AAV-1 are identical. The AAV TR sequence is subdivided into A, A', B, B', C, C', D and D' [Bern, cited above].

These AAV ITR sequences are also virtually the same as those found in AAV-6 right ITR, there being one nucleotide difference in each of A and A' sequence, and the last nucleotide of the D sequence. Second, the AAV-2 rep binding motif [GCTCGCTCGCTCGCTG (SEQ ID NO: 20)] is well conserved. Such motif can also be found in the human chromosome 19 AAV-2 pre-integration region. Finally, non-structural and structural coding regions, and regulatory elements similar to those of other AAV serotypes also exist in AAV-1 genome.

Although the overall features of AAV terminal repeats are very much conserved, the total length of the AAV terminal repeat exhibits divergence. The terminal repeat of AAV-1 consists of 143 nucleotides while those of AAV-2, AAV-3, and AAV-4 are about 145 or 146 nucleotides. The loop region of AAV-1 ITR most closely resembles that of AAV-4 in that it also uses TCT instead of the TTT found in AAV-2 and AAV-3. The possibility of sequencing error was eliminated using restriction enzyme digestion, since these three nucleotides are part of the SacI site (gagctc, nt 69-74 of SEQ ID NO: 1). The p5 promoter region of AAV-1 shows more variations in nucleotide sequences with other AAV serotypes. However, it still maintains the critical regulatory elements. The two copies of YY1 [See, Fig. 1A-1C] sites seemed to be preserved in all known AAV serotypes, which have been shown to be involved in regulating AAV gene expression. In AAV-4, there are 56 additional nucleotides inserted between YY1 and E-box/USF site, while in AAV-1, there are 26 additional nucleotides inserted before the E-box/USF site. The p19 promoter, p40 promoter and polyA can also be identified from the AAV-1 genome by analogy to known AAV serotypes, which are also highly conserved.

Thus, the analysis of AAV terminal repeats of various serotypes showed that the A and A' sequence is very much conserved. One of the reasons may be the Rep binding motif (GCTC)<sub>3</sub>GCTG [SEQ ID NO: 20]. These sequences appear to be essential for AAV DNA replication and site-specific integration. The same sequence



has also been shown to be preserved in a monkey genome [Samulski, personal communication]. The first 8 nucleotides of the D sequence are also identical in all known AAV serotypes. This is in accordance with the observation of the Srivastava group that only the first 10 nucleotides are essential for AAV packaging [X.S. Wang et al, J. Virol., 71:3077-3082 (1997); X.S. Wang et al, J. Virol., 71:1140-1146 (1997)]. The function of the rest of the D sequences still remain unclear. They may be somehow related to their tissue specificities. The variation of nucleotide in B and C sequence may also suggest that the secondary structure of the ITRs is more critical for its biological function, which has been demonstrated in many previous publications.

#### Example 3 - Comparison of AAV-1 Sequences

The nucleotide sequences of AAV-1, obtained as described above, were compared with known AAV sequences, including AAV-2, AAV-4 and AAV-6 using DNA Star Megalign. This comparison revealed a stretch of 71 identical nucleotides shared by AAV-1, AAV-2 and AAV-6. See, Figs. 1A-1C.

This comparison further suggested that AAV-6 is a hybrid formed by homologous recombination of AAV-1 and AAV-2. See, Figs. 3A and 3B. These nucleotides divide the AAV-6 genome into two regions. The 5' half of AAV-6 of 522 nucleotides is identical to that of AAV-2 except in 2 positions. The 3' half of AAV-6 including the majority of the rep gene, complete cap gene and 3' ITR is 98% identical to AAV-1.

Biologically, such recombination may enable AAV-1 to acquire the ability to transmit through the human population. It is also interesting to note that the ITRs of AAV-6 comprise one AAV-1 ITR and one AAV-2 ITR. The replication model of defective parvovirus can maintain this special arrangement. Studies on AAV integration have shown that a majority of AAV integrants carries deletions in at least one of the terminal repeats. These deletions have been shown to be able to be repaired through gene conversion using the other intact terminal repeat as a template. Therefore, it would be very difficult to maintain AAV-6 as a homogenous population

when an integrated copy of AAV-6 is rescued from host cells with helper virus infection. The AAV-6 with two identical AAV-2 ITRs or two identical AAV-1 ITRs should be the dominant variants. The AAV-6 with two AAV-1 ITRs has been observed by Russell's group [Rutledge, cited above (1998)]. So far there is no report on AAV-6 with two AAV-2 ITRs. Acquisition of AAV-2 P5 promoter by AAV-6 may have explained that AAV-6 have been isolated from human origin while AAV-1 with the same virion has not. The regulation of P5 promoter between different species of AAV may be different *in vivo*. This observation suggests the capsid proteins of AAV were not the only determinants for tissue specificity.

Although it is clear that AAV-6 is a hybrid of AAV-1 and AAV-2, AAV-6 has already exhibited divergence from either AAV-1 or AAV-2. There are two nucleotide differences between AAV-6 and AAV-2 in their first 450 nucleotides. There are about 1% differences between AAV-6 and AAV-1 in nucleotide levels from nucleotides 522 to the 3' end. There also exists a quite divergent region (nucleotide 4486-4593) between AAV-6 and AAV-1 (Figs. 1A-1C). This region does not encode any known proteins for AAVs. These differences in nucleotide sequences may suggest that AAV-6 and AAV-1 have gone through some evolution since the recombination took place. Another possible explanation is that there exists another variant of AAV-1 which has yet to be identified. So far, there is no evidence to rule out either possibility. It is still unknown if other hybrids (AAV-2 to AAV-4, etc.) existed in nature.

The coding region of AAV-1 was deduced by comparison with other known AAV serotypes. Table 1 illustrates the coding region differences between AAV-1 and AAV-6. The amino acid residues are deduced according to AAV-2.

With reference to the amino acid position of AAV-1, Table 1 lists the amino acids of AAV-1 which have been changed to the corresponding ones of AAV-6. The amino acids of AAV-1 are shown to the left of the arrow. Reference may be made to SEQ ID NO: 5 of the amino acid sequence of AAV-1 Rep 78 and to SEQ ID NO: 13 for the amino acid sequence of AAV-1 VP1.



Table 1

Coding region variations between AAV-1 and AAV-6

Rep protein (Rep78)			Cap protein (VP1)	
Position(s)	Amino acids		Position(s)	Amino acids
28	S→N		129	L→F
191	Q→H		418	E→D
192	H→D		531	E→K
308	E→D		584	F→L
			598	A→V
			642	N→H

It was surprising to see that the sequence of the AAV-1 coding region is almost identical to that of AAV-6 from position 452 to the end of coding region (99%). The first 508 nucleotides of AAV-6 have been shown to be identical to those of AAV-2 [Rutledge, cited above (1998)]. Since the components of AAV-6 genome seemed to be AAV-2 left ITR – AAV-2 p5 promoter – AAV-1 coding region – AAV-1 right ITR, it was concluded that AAV-6 is a naturally occurred hybrid between AAV-1 and AAV-2.

#### Example 4 - Gene Therapy Vector Based on AAV-1

Recombinant gene transfer vectors based on AAV-1 viruses were constructed by the methods described in Example 1. To produce a hybrid recombinant virus with AAV-1 virion and AAV-2 ITR, the AAV-1 trans plasmid (pAV1H) and the AAV-2 cis-lacZ plasmid (with AAV-2 ITR) were used. The AAV-2 ITR was used in this vector in view of its known ability to direct site-specific integration. Also constructed for use in this experiment was an AAV-1 vector carrying the green fluorescent protein (GFP) marker gene under the control of the immediate early promoter of CMV using pAV1H as the trans plasmid.

A. rAAV-1 Viruses Transfect Host Cells in Vitro

84-31 cells, which are subclones of 293 cells (which express adenovirus E1a, E1b) which stably express E4/ORF5, were infected with rAAV-1 GFP or rAAV-lacZ. High levels of expression of GFP and lacZ was detected in the cultured 84-31 cells. This suggested that rAAV-1 based vector was very similar to AAV-2 based vectors in ability to infect and expression levels.

B. rAAV-1 Viruses Transfect Cells in Vivo

The performance of AAV-1 based vectors was also tested *in vivo*. The rAAV-1 CMV- $\alpha$ 1AT virus was constructed as follows. The EcoRI fragment of pAT85 (ATCC) containing human  $\alpha$ 1-antitrypsin ( $\alpha$ 1AT) cDNA fragment was blunted and cloned into PCR (Promega) at a SmaI site to obtain PCR- $\alpha$ 1AT. The CMV promoter was cloned into PCR- $\alpha$ 1AT at the XbaI site. The Alb- $\alpha$ 1AT expression cassette was removed by XhoI and ClaI and cloned into pAV1H at the XbaI site. This vector plasmid was used to generate AAV-1-CMV- $\alpha$ 1AT virus used in the experiment described below.

For screening human antibodies against AAV, purified AAV virus is lysed with Ripa buffer (10 mM Tris pH 8.2, 1% Triton X-100, 1% SDS, 0.15 M NaCl) and separated in 10% SDS-PAGE gel. The heat inactivated human serum was used at a 1 to 1000 dilution in this assay. The rAAV-1 CMV- $\alpha$ 1AT viruses were injected into Rag-1 mice through tail vein injection at different dosages. The concentration of human  $\alpha$ 1-antitrypsin in mouse serum was measured using ELISA. The coating antibody is rabbit anti-human human  $\alpha$ 1-antitrypsin (Sigma). The goat-antihuman  $\alpha$ 1-antitrypsin (Sigma) was used as the primary detection antibodies. The sensitivity of this assay is around 0.3 ng/ml to 30 ng/ml. The expression of human  $\alpha$ -antitrypsin in mouse blood can be detected in a very encouraging level. This result is shown in Table 2.

Table 2

Human Antitrypsin Expressed in Mouse Liver

Amount of virus injected	Week 2 (ng/ml)	Week 4 (ng/ml)
2x10 <sup>10</sup> genomes	214.2	171.4
1x10 <sup>10</sup> genomes	117.8	109.8
5x10 <sup>10</sup> genomes	64.5	67.8
2.5x10 <sup>10</sup> genomes	30.9	58.4

5  
10  
rAAV-1 CMV-lacZ viruses were also injected into the muscle of C57BL6 mice and similar results were obtained. Collectively, these results suggested that AAV-1 based vector would be appropriate for both liver and muscle gene delivery.

Example 5 - Neutralizing Antibodies Against AAV-1

15  
Simple and quantitative assays for neutralizing antibodies (NAB) to AAV-1 and AAV-2 were developed with recombinant vectors. A total of 33 rhesus monkeys and 77 normal human subjects were screened.

A. *Nonhuman Primates*

20  
25  
Wild-caught juvenile rhesus monkeys were purchased from Covance (Alice, Tex.) and LABS of Virginia (Yemassee, SC) and kept in full quarantine. The monkeys weighed approximately 3 to 4 kg. The nonhuman primates used in the Institute for Human Gene Therapy research program are purposefully bred in the United States from specific-pathogen-free closed colonies. All vendors are US Department of Agriculture class A dealers. The rhesus macaques are therefore not infected with important simian pathogens, including the tuberculosis agent, major simian lentiviruses (simian immunodeficiency virus and simian retroviruses), and cercopithecine herpesvirus. The animals are also free of internal and external parasites. The excellent health status of these premium animals minimized the potential for extraneous variables. For this study, serum was obtained from monkeys prior to initiation of any protocol.

NAB titers were analyzed by assessing the ability of serum antibody to inhibit the transduction of reporter virus expressing green fluorescent protein (GFP) (AAV1-GFP or AAV2-GFP) into 84-31 cells. Various dilutions of antibodies preincubated with reporter virus for 1 hour at 37°C were added to 90% confluent cell  
5 cultures. Cells were incubated for 48 hours and the expression of green fluorescent protein was measured by FluoroImaging (Molecular Dynamics). NAB titers were calculated as the highest dilution at which 50% of the cells stained green.

Analysis of NAB in rhesus monkeys showed that 61% of animals tested positive for AAV-1; a minority (24%) has NAB to AAV-2. Over one-third of  
10 animals had antibodies to AAV-1 but not AAV-2 (i.e., were monospecific for AAV-1), whereas no animals were positive for AAV-2 without reacting to AAV-1. These data support the hypothesis that AAV-1 is endemic in rhesus monkeys. The presence of true AAV-2 infections in this group of nonhuman primates is less clear, since cross-neutralizing activity of an AAV-1 response to AAV-2 can not be ruled out. It is  
15 interesting that there is a linear relationship between AAV-2 NAB and AAV-1 NAB in animals that had both.

#### B. *Humans*

For these neutralization antibody assays, human serum samples were incubated at 56°C for 30 min to inactivate complement and then diluted in DMEM.  
20 The virus (rAAV or rAd with either lacZ or GFP) was then mixed with each serum dilution (20X, 400X, 2000X, 4000X, etc.) and incubated for 1 hour at 37°C before applied to 90% confluent cultures of 84-31 cells (for AAV) or Hela cells (for adenovirus) in 96-well plates. After 60 minutes of incubation at culture condition, 100 µl additional media containing 20% FCS was added to make final culture media  
25 containing 10% FCS.

The result is summarized in Table 3.

Table 3

Adenovirus	AAV-1	AAV-2	# of samples	Percentage
-	-	-	41	53.2%
+	-	-	16	20.8%
-	+	-	0	0.0%
-	-	+	2	2.6%
-	+	+	2	2.6%
+	-	+	3	3.9%
+	+	-	0	0.0%
+	+	+	13	16.9%
Total			77	100%

The human neutralizing antibodies against these three viruses seemed to be unrelated since the existence of neutralizing antibodies against AAV are not indications for antibodies against adenovirus. However, AAV requires adenovirus as helper virus, in most of the cases, the neutralizing antibodies against AAV correlated with the existence of neutralizing antibodies to adenovirus. Among the 77 human serum samples screened, 41% of the samples can neutralize the infectivity of recombinant adenovirus based on Ad5. 15/77 (19%) of serum samples can neutralize the transduction of rAAV-1 while 20/77 (20%) of the samples inhibit rAAV-2 transduction at 1 to 80 dilutions or higher. All serum samples positive in neutralizing antibodies for AAV-1 in are also positive for AAV-2. However, there are five (6%) rAAV-2 positive samples that failed to neutralize rAAV-1. In samples that are positive for neutralizing antibodies, the titer of antibodies also varied in the positive ones. The results from screening human sera for antibodies against AAVs supported the conclusion that AAV-1 presents the same epitome as that of AAV-2 to interact

with cellular receptors since AAV-1 neutralizing human serums can also decrease the infectivity of AAV-2. However, the profile of neutralizing antibodies for these AAVs is not identical, there are additional specific receptors for each AAV serotype.

#### Example 6 - Recombinant AAV Viruses Exhibit Tissue Tropism

5           The recombinant AAV-1 vectors of the invention and the recombinant AAV-2 vectors [containing the gene encoding human  $\alpha$ 1-antitrypsin ( $\alpha$ 1AT) or murine erythropoietin (Epo) from a cytomegalovirus-enhanced  $\beta$ -actin promoter (CB)] were evaluated in a direct comparison to equivalent copies of AAV-2 vectors containing the same vector genes.

10           Recombinant viruses with AAV-1 capsids were constructed using the techniques in Example 1. To make rAAV with AAV-1 virions, pAV1H or p5E18 (2/1) was used as the *trans* plasmid to provide Rep and Cap functions. For the generation of the rAAV based on AAV-2, p5E18(2/2) was used as the *trans* plasmid, since it greatly improved the rAAV yield. [Early experiments indicated similar *in vivo* performances of AAV-1 vectors produced with pAV1H and p5E19 (2/1). All  
15           subsequent studies used AAV-1 vectors derived from p5E18(2/1) because of the increased yield.]

          Equivalent stocks of the AAV-1 and AAV-2 vectors were injected intramuscularly ( $5 \times 10^{10}$  genomes) or liver via the portal circulation ( $1 \times 10^{11}$   
20           genomes) into immunodeficient mice, and the animals (four groups) were analyzed on day 30 for expression of transgene. See, Figs. 4A and 4B.

          AAV-2 vectors consistently produced 10- to 50-fold more serum erythropoietin or  $\alpha$ 1-antitrypsin when injected into liver compared to muscle. (However, the AAV-1-delivered genes did achieve acceptable expression levels in the  
25           liver.) This result was very different from that for AAV-1 vectors, with which muscle expression was equivalent to or greater than liver expression. In fact, AAV-1 outperformed AAV-2 in muscle when equivalent titers based on genomes were administered.

Example 7 - Gene Delivery via rAAV-1

C57BL/6 mice (6- to 8-week old males, Jackson Laboratories) were analyzed for AAV mediated gene transfer to liver following intrasplenic injection of vector (i.e., targeted to liver). A total of  $10^{11}$  genome equivalents of rAAV-1 or rAAV-2 vector  
5 were injected into the circulation in 100  $\mu$ l buffered saline. The first vector contained either an AAV-1 capsid or an AAV-2 capsid and expressed  $\alpha$ 1AT under the control of the chicken  $\beta$ -actin (CB) promoter. Day 28 sera were analyzed for antibodies against AAV-1 or AAV-2 and serum  $\alpha$ 1AT levels were checked. Animals were then injected with an AAV-1 or AAV-2 construct expressing erythropoietin (Epo, also under the  
10 control of the CB promoter). One month later sera was analyzed for serum levels of Epo. The following groups were analyzed (Figs. 5A-5D).

In Group 1, vector 1 was AAV-2 expressing  $\alpha$ 1AT and vector 2 was AAV-2 expressing Epo. Animals generated antibodies against AAV-2 following the first vector administration which prevented the readministration of the AAV-2 based  
15 vector. There was no evidence for cross-neutralizing the antibody to AAV-1.

In Group 2, vector 1 was AAV-1 expressing  $\alpha$ 1AT while vector 2 was AAV-1 expressing Epo. The first vector administration did result in significant  $\alpha$ 1AT expression at one month associated with antibodies to neutralizing antibodies to AAV-1. The animals were not successfully readministered with the AAV-1 Epo  
20 expressing construct.

In Group 3, the effectiveness of an AAV-2 vector expressing Epo injected into a naive animal was measured. The animals were injected with PBS and injected with AAV-2 Epo vector at day 28 and analyzed for Epo expression one month later. The neutralizing antibodies were evaluated at day 28 so we did not expect to see anything  
25 since they received PBS with the first vector injection. This shows that in naive animals AAV-2 is very efficient at transferring the Epo gene as demonstrated by high level of serum Epo one month later.

Group 4 was an experiment similar to Group 3 in which the animals originally received PBS for vector 1 and then the AAV-1 expressing Epo construct 28 days  
30 later. At the time of vector injection, there obviously were no antibodies to either



An AAV-1 cis plasmid is constructed as follows. A 160 bp Xho-NruI AAV-1 fragment containing the AAV-1 5' ITR is obtained from pAV1-BL. pAV1-BL was



generated as described in Example 1. The Xho-NruI fragment is then cloned into a second pAV1-BL plasmid at an XbaI site to provide the plasmid with two AAV-1 ITRs. The desired transgene is then cloned into the modified pAV-1BL at the NruI and BamHI site, which is located between the AAV-1 ITR sequences. The resulting  
5 AAV-1 cis plasmid contains AAV-1 ITRs flanking the transgene and lacks functional AAV-1 rep and cap.

Recombinant AAV is produced by simultaneously transfecting three plasmids into 293 cells. These include the AAV-1 cis plasmid described above; a trans plasmid which provides AAV rep/cap functions and lacks AAV ITRs; and a plasmid providing  
10 adenovirus helper functions. The rep and/or cap functions may be provided in trans by AAV-1 or another AAV serotype, depending on the immunity profile of the intended recipient. Alternatively, the rep or cap functions may be provided in cis by AAV-1 or another serotype, again depending on the patient's immunity profile.

In a typical cotransfection, 50 µg of DNA (cis:trans:helper at ratios of 1:1:2, respectively) is transfected onto a 15 cm tissue culture dish. Cells are harvested 96  
15 hours post transfection, sonicated and treated with 0.5% sodium deoxycholate (37° for 10 min). Cell lysates are then subjected to 2-3 rounds of ultracentrifugation in a cesium gradient. Peak fractions containing rAAV are collected, pooled and dialyzed against PBS. A typical yield is  $1 \times 10^{13}$  genomes/ $10^9$  cells.

20 Using this method, one recombinant virus construct is prepared which contains the AAV-1 ITRs flanking the transgene, with an AAV-1 capsid. Another recombinant virus construct is prepared with contains the AAV-1 ITRs flanking the transgene, with an AAV-2 capsid.

All publications cited in this specification are incorporated herein by reference.  
25 While the invention has been described with reference to a particularly preferred embodiments, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the claims.

What is claimed is.

1. An isolated AAV-1 nucleic acid molecule comprising a sequence selected from the group consisting of:
  - (a) SEQ ID NO: 1;
  - (b) a DNA sequence complementary to SEQ ID NO: 1;
  - (c) cDNA complementary to (a) or (b); and
  - (d) RNA complementary to any of (a) to (c).
2. A nucleic acid molecule comprising an AAV-1 inverted terminal repeat (ITR) sequence selected from the group consisting of:
  - (a) nt 1 to 143 of SEQ ID NO: 1;
  - (b) nt 4576 to 4718 of SEQ ID NO: 1;
  - (c) a nucleic acid sequence complementary to (a) or (b); and
  - (d) a functional fragment of (a), (b), or (c).
3. A recombinant vector comprising a 5' AAV-1 inverted terminal repeat (ITR) and a selected transgene, wherein said ITR has the sequence selected from the group consisting of:
  - (a) nt 1 to 143 of SEQ ID NO: 1;
  - (b) a nucleic acid sequence complementary to (a); and
  - (c) a functional fragment of (a) or (b).
4. The recombinant vector according to claim 3, wherein said vector further comprises a 3' AAV-1 ITR.

5. A recombinant vector comprising a 3' AAV-1 inverted terminal repeat (ITR) and a selected transgene, wherein said ITR has the sequence selected from the group consisting of:

- (a) nt 4576 to 4718 of SEQ ID NO: 1;
- (b) a nucleic acid sequence complementary to (a); and
- (c) a functional fragment of (a) or (b).

6. The recombinant vector according to claim 5, wherein said vector further comprises a 5' AAV-1 ITR.

7. The recombinant vector according to any of claims 3-6, wherein said vector further comprises AAV-1 capsid proteins having the sequence of SEQ ID NO: 13, 15 or 17 or functional fragments thereof.

8. The recombinant vector according to any of claims 3-6, wherein said vector further comprises adenovirus sequences.

9. A recombinant vector comprising an AAV-1 P5 promoter having the sequence of nt 236 to 299 of SEQ ID NO: 1 or a functional fragment thereof.

10. A nucleic acid molecule encoding AAV-1 helper functions, said molecule comprising an AAV rep coding region and an AAV cap coding region, wherein said cap coding region comprises at least one member is selected from the group consisting of:

- (a) vp1, nt 2223 to 4431 of SEQ ID NO: 1;
- (b) vp2, nt 2634 to 4432 of SEQ ID NO: 1; and
- (c) vp3, nt 2829 to 4432 of SEQ ID NO: 1.

11. A nucleic acid molecule encoding AAV-1 helper functions, said molecule comprising an AAV rep coding region and an AAV cap coding region, wherein said rep coding region comprises an AAV-1 rep coding region comprising at least one member selected from the group consisting of:

- (a) rep 78, nt 335 to 2304 of SEQ ID NO: 1;
- (b) rep 68, nt 335 to 2272 of SEQ ID NO: 1 or the cDNA corresponding thereto,
- (c) rep 52, nt 1007 to 2304 of SEQ ID NO: 1; and
- (d) rep 40, nt 1007 to 2272 of SEQ ID NO: 1 or the cDNA corresponding thereto.

12. A host cell transduced with a recombinant viral vector according to any of claims 3-6.

13. A host cell transduced with a nucleic acid molecule according to any of claims 1, 2, 10 or 11.

14. A host cell stably transduced with an AAV-1 P5 promoter having the sequence of nt 236 to 299 of SEQ ID NO: 1.

15. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to any of claims 3-6.

16. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 7.

17. A pharmaceutical composition comprising a carrier and a virus comprising the vector according to claim 8.

18. A method for AAV-mediated delivery of a transgene comprising the step of delivering to a host cell an AAV virion which comprises:

- (a) a capsid comprising at least one capsid protein encoded by an AAV-1 cap gene; and
- (b) a DNA molecule comprising a transgene under the control of regulatory sequences directing its expression.

19. A method for AAV-mediated delivery of a transgene to a host comprising the steps of:

- (a) assaying a sample from the host to determine the presence of neutralizing antibodies specific against any serotype of AAV; and
- (b) delivering to the host an AAV virion which comprises:
  - (i) a capsid comprising at least one capsid protein encoded by a cap gene of an AAV serotype against which the host has no antibodies as determined in step (a); and
  - (ii) a DNA molecule comprising a transgene under the control of regulatory sequences directing its expression.

20. The method according to claim 19, comprising the additional step of repeating steps (a) and (b).

21. Use of an AAV virion which comprises a capsid comprising (a) at least one capsid protein encoded by a cap gene of an AAV serotype against which the host has antibodies, and (b) a DNA molecule comprising a transgene operably linked to regulatory sequences directing its expression,

in the preparation of a medicament for delivery of a transgene to a host, wherein said host has no preexisting neutralizing antibodies against the AAV serotype of said cap gene.

22. A method for delivery of a transgene comprising the step of delivering to a host cell a recombinant virus comprising a recombinant vector according to any of claims 3-8.

23. A method for producing a selected gene product comprising the steps of transfecting a mammalian cell with the molecule according to claim 1 or a functional fragment thereof and culturing said cell under conditions suitable to express said gene product.

## ABSTRACT OF THE DISCLOSURE

The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived  
5 vectors.

1/13

FIG 1A

AAV-1	ttgcccactccctctctgcgcgctcgctcgctcggtggggcctgcggaacaaagggtccgc	60
AAV-2	...g.....ac..a....g.gc.....gc.	60
AAV-6	...g.....ac..a....g.gc.....gc.	60
Rep binding site		
AAV-1	agacggcagagctctgctctgccggccccacccgagcgcgagcgcgcagagagggagtgc	120
AAV-2	c....c.c.g...t...c.g.g.....t..gt.....	120
AAV-6	c....c.c.g...t...c.g.g.....t..gt.....	120
TRS		
AAV-1	ggcaactccatcactaggggtaaaTCGCGAAGCGCCTCCCACGCTGCCGCGTCAGCGCTGA	180
AAV-2	.c.....--..ct.G..G.-----TG.A...G----...	163
AAV-6	.c.....--..ct.G..G.-----TG.A...G----...	163
E box/USE		
AAV-1	CGTAAATTACGTCATAGGG---GAGTGGTCCTGTATTAGCTGTCACGTGAGTGCTTTTGC	237
AAV-2	...G.....TTA.G.A.....AG.....-.....	222
AAV-6	...G.....TTA.G.A.....AG.....-.....	222
YY1 P5/TATA		
AAV-1	GACATTTTGCGACACCACGTGGCCATTTAGGGTATATATGGCCGAGTGAGCGAGCAGGAT	297
AAV-2	.....T....T..CGCT.....T..A.C.....AC.....G.	282
AAV-6	.....T....T..CGCT.....T..A.C.....AC.....G.	282
YY1/p5 RNA Rep 78/68		
AAV-1	CTCCATTTTGAC-CGCGAAATTTGAACGAGCAGCAGCCATGCCGGGCTTCTACGAGATCG	356
AAV-2	.....AG..G..GG.....C.....C.....G..T.....T.	342
AAV-6	.....AG..G..GG.....C.....-.....G..T.....T.	341
AAV-1	TGATCAAGGTGCCGAGCGACCTGGACGAGCACCTGCCGGGCATTTCTGACTCGTTTGTGA	416
AAV-2	....T....C..C.....T....G...T....C.....AGC.....	402
AAV-6	....T....C..C.....T....T....C.....AGC.....	401
AAV-1	GCTGGGTGGCCGAGAAGGAATGGGAGCTGCCCCCGGATTCTGACATGGATCTGAATCTGA	476
AAV-2	A.....T....G..A.....	462
AAV-6	A.....T....G..A.....	461
AAV-1	TTGAGCAGGCACCCCTGACCGTGGCCGAGAAGCTGCAGCGCGACTTCCTGGTCCAATGGC	536
AAV-2	.....T...ACGG.....	522
AAV-6	.....G....	521
AAV-1	GCCGCGTGAGTAAGGCCCCGGAGGCCCTCTTCTTTGTTTCAGTTTCGAGAAGGGCGAGTCCT	596
AAV-2	....T.....T.....G..A..T.....A...AG..	582
AAV-6	.....	581
AAV-1	ACTTCCACCTCCATATTCTGGTGGAGACCACGGGGGTCAAATCCATGGTGCTGGGCGGCT	656
AAV-2	.....A.G..CG.G..C....A....C.....G.....TT....A..T.	642
AAV-6	.....	641
AAV-1	TCCTGAGTCAGATTAGGGACAAGCTGGTGCAGACCATCTACCGCGGGATCGAGCCGACCC	716
AAV-2	.....C.C..A..A...A.T...GA..T.....TT	702
AAV-6	.....	701
AAV-1	TGCCCAACTGGTTCGCGGTGACCAAGACGCGTAATGGCGCCGGAGGGGGGAACAAGGTGG	776
AAV-2	....A.....C..A....CA.A.....C.....	762
AAV-6	.....	761



2/13

FIG 1B

AAV-1	TGGACGAGTGCTACATCCCCAACTACCTCCTGCCCAAGACTCAGCCCGAGCTGCAGTGGG	836
AAV-2	....T.....T...T.G..C.....A..C.....T.....C.....	822
AAV-6	.....	821
	P19/TATA	P19 RNA
AAV-1	CGTGGACTAACATGGAGGAGTATATAAGCGCCTGTTTGAACCTGGCCGAGCGCAAACGGC	896
AAV-2	.....T.....AC.....T.....C.....G..T..CA.G.....T.....T	882
AAV-6	.....C.....GG.....A.....G.....A..C..GG.C.....	881
AAV-1	TCGTGGCGCAGCACCTGACCCACGTCAGCCAGACCCAGGAGCAGAACAAGGAGAATCTGA	956
AAV-2	.G.....T.....G.....GTCG.....G.....A.....A..	942
AAV-6	.....CG.....	941
	Rep 52/40	
AAV-1	ACCCCAATTCTGACGCGCCTGTCATCCGGTCAAAAACCTCCGCGCGCTACATGGAGCTGG	1016
AAV-2	.T.....T.....G..G...A.A.....T..A..CA.G.....	1002
AAV-6	.....A.....	1001
AAV-1	TCGGGTGGCTGGTGGACCGGGGCATCACCTCCGAGAAGCAGTGGATCCAGGAGGACCAGG	1076
AAV-2	.....C.....AA...G..T....G.....	1062
AAV-6	.....	1061
AAV-1	CCTCGTACATCTCCTTCAACGCCGCTTCCAACCTCGCGGTCCCAGATCAAGGCCGCTCTGG	1136
AAV-2	....A.....T..G..C.....A.....T..CT...	1122
AAV-6	.....	1121
AAV-1	ACAATGCCGGCAAGATCATGGCGCTGACCAAATCCGCGCCCGACTACCTGGTAGGCCCCCG	1196
AAV-2	.....G..A.....T...AGC.....T...A....C.....G....AGC	1182
AAV-6	.....	1181
AAV-1	CTCCGCCCCGCGGACATTAAAACCAACCGCATCTACCGCATCCTGGAGCTGAACGGCTACG	1256
AAV-2	AG..CGTG.A.....TCC.G...T..G..T..TAAA..TT....A..A.....G....	1242
AAV-6	.....C.....T.....	1241
AAV-1	AACCTGCCTACGCCGGCTCCGTCTTTCTCGGCTGGGCCCAGAAAAGGTTTCGGGAAGCGCA	1316
AAV-2	.T..CCAA..T..G.CT.....G..A.....AC.....A.....C...A.G.	1302
AAV-6	.C.....A..A....	1301
AAV-1	ACACCATCTGGCTGTTTGGGCCGGCCACCACGGGCAAGACCAACATCGCGGAAGCCATCG	1376
AAV-2	.....T..A..T..C..G.....G.....A.	1362
AAV-6	.....	1361
AAV-1	CCCACGCCGTGCCCTTCTACGGCTGCGTCAACTGGACCAATGAGAACTTTCCCTTCAATG	1436
AAV-2	.....A.T.....G.....A.....C.	1422
AAV-6	.....C.	1421
AAV-1	ATTGCGTCGACAAGATGGTGATCTGGTGGGAGGAGGGCAAGATGACGGCCAAGGTCGTGG	1496
AAV-2	.C..T.....G.....C.....	1482
AAV-6	.....	1481
AAV-1	AGTCCGCCAAGGCCATTCTCGGCGGCAGCAAGGTGCGCGTGGACCAAAGTGCAAGTCGT	1556
AAV-2	....G....A.....A..A.....G..A.....C.	1542
AAV-6	.....	1541
AAV-1	CCGCCCAGATCGACCCCAACCCCGTGATCGTCACCTCCAACACCAACATGTGCGCCGTGA	1616
AAV-2	.G.....A.....G..T.....	1602
AAV-6	.....T.....	1601

3/13

FIG 1C

AAV-1	TTGACGGGAACAGCACCACCTTCGAGCACCAGCAGCCGTTGCAGGACCGGATGTTCAAAT	1676
AAV-2	.....TCA..G.....A.....A.....	1662
AAV-6	.....	1661
AAV-1	TTGAACTCACCCGCCGTCTGGAGCATGACTTTGGCAAGGTGACAAAGCAGGAAGTCAAAG	1740
AAV-2	.....T.....G.....C..C.....	1722
AAV-6	.....	1721
AAV-1	AGTTCTTCCGCTGGGCGCAGGATCACGTGACCGAGGTGGCGCATGAGTTCTACGTCAGAA	1796
AAV-2	.C..T.....G.....AA.....GTT.....A.....A.....A..	1782
AAV-6	.....	1781
P40/TATA		
AAV-1	AGGGTGGAGCCAACAAAAGACCCGCCCCCGATGACGCGGATAAAAGCGAGCCCAAGCGGG	1856
AAV-2	.....G.....AG.....A....T...T.....A....	1842
AAV-6	.....G.....	1841
P40 RNA		
AAV-1	CCTGCCCCCTCAGTCGCGGATCCATCGACGTCAGACGCGGAAGGAGCTCCGGTGGACTTTG	1916
AAV-2	TGC..GAG.....T...C.G.....---..T..A.CA...AC.	1899
AAV-6	.....	1901
▼		
AAV-1	CCGACAGGTACCAAAACAAATGTTCTCGTCACGCGGGCATGCTTCAGATGCTGTTTCCCT	1976
AAV-2	.A.....T.....AA..T.....	1959
AAV-6	.....	1961
AAV-1	GCAAGACATGCGAGAGAATGAATCAGAATTTCAACATTTGCTTCACGCACGGGACGAGAG	2036
AAV-2	...GACA.....CA..T..C.....T.....ACA..A..	2019
AAV-6	....A.....C....	2021
AAV-1	ACTGTTTCAGAGTGCTTCCCCGGCGTGTCAGAATCTCAACCGGTC---GTCAGAAAGAGGA	2093
AAV-2	.....T.....T...---.....C..TTCT...GTC..A.A.G	2076
AAV-6	.....A..T.....---.....	2078
AAV-1	CGTATCGGAAACTCTGTGCCATTTCATCATCTGCTGGGGCGGGCTCCCGAGATTGCTTGCT	2153
AAV-2	.....A.....G..CTA.....A.CA....AAA..TG..A..---C.....A	2133
AAV-6	.....	2138
Rep 78 stop		
AAV-1	CGGCCTGCGATCTGGTCAACGTGGACCTGGATGACTGTGTTTCTGAGCAATAAATGACTT	2213
AAV-2	.T.....T.....TT.....CA.C.T...A.....T..	2193
AAV-6	.....T.....	2193
▽ VP1		
AAV-1	AAACCAGGTATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAG	2273
AAV-2	...T.....CT.....A	2253
AAV-6	.....AC.....G	2258
AAV-1	GGCATTCGCGAGTGGTGGGACTTGAAACCTGGAGCCCCGAAGCCCAAGCCAACCAGCAA	2333
AAV-2	..A..AA.AC.....A.GC.C.....CC.A..ACCA..A..GC..GCAG...GG	2313
AAV-6	.....A.....	2318
AAV-1	AAGCAGGACGACGGCCGGGGTCTGGTGCTTCCTGGCTACAAGTACCTCGGACCCTTCAAC	2393
AAV-2	C.TA.....A..A.....T.....G.....	2373
AAV-6	.....G..C.....G.....C.....	2378

FIG 1D

AAV-1	GGACTCGACAAGGGGGGAGCCCGTCAACGCGGCGGACGCAGCGGCCCTCGAGCACGACAAG	2453
AAV-2	.....A.....G.....A...A.....C.....A	2433
AAV-6	.....T.....	2438
AAV-1	GCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCTGCGGTATAACCACGCCGAC	2513
AAV-2	.....G.....G.CAGC..A.....C.....CAA...C.....	2493
AAV-6	.....A.AGCG..T.....T.....GCG...T.....	2498
AAV-1	GCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACCTCGGGCGAGCA	2573
AAV-2	..G.....C..TA.....A.....	2553
AAV-6	..C.....T..GC.....G.....	2558
AAV-1	GTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAAG	2633
AAV-2	.....G..A...A.....T.....G..C.....CCT.T....	2613
AAV-6	.....A.....T.T.....T.....	2618
<u>VP2</u>		
AAV-1	ACGGCTCCTGGAAAGAAACGTCCGGTAGAGCAGTCGCCACAAGAGCCAGACTCCTCCTCG	2693
AAV-2	.....G.....A..GA.G.....C..T..TGTG.....	2673
AAV-6	.....T.....G..AC.T.....G..G..ACAA.....	2678
AAV-1	GGCATCGGCAAGACAGGCCAGCAGCCCGCTAAAAAGAGACTCAATTTTGGTCAGACTGGC	2753
AAV-2	..A.C...A...G.G.....T..A.G...A...T.G.....A	2733
AAV-6	.....T.....	2738
AAV-1	GACTCAGAGTCAGTCCCCGATCCACAACCTCTCGGAGAACCTCCAGCAACCCCCGCTGCT	2813
AAV-2	..G....C.....A..T..C..C..G.....C.G..A.....G.....T...G.	2793
AAV-6	..T....G....C..C..C..A..A.....G.A..T.....A.....G.....	2798
<u>VP3</u>		
AAV-1	GTGGGACCTACTACAATGGCTTCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGC	2873
AAV-2	C.....A...A...G.....A.....A.....G...	2853
AAV-6	.....	2858
AAV-1	GCCGACGGAGTGGGTAATGCCTCAGGAAATTGGCATTGCGATTCCACATGGCTGGGCGAC	2933
AAV-2	.....T....C.....A.....	2913
AAV-6	.....	2918
AAV-1	AGAGTCATCACCACCAGCACCCGCACCTGGGCCTTGCCACCTACAATAACCACCTCTAC	2993
AAV-2	.....A.....C.....C.....	2973
AAV-6	.....A..A.....T..C.....	2978
AAV-1	AAGCAAATCTCCAGTGCTTCAACGGGGGCCAGCAACGACAACCACTACTTCGGCTACAGC	3053
AAV-2	..A.....T....CCAA...---..A...TCG.....T.....T.....	3030
AAV-6	.....	3038
AAV-1	ACCCCCTGGGGGTATTTTGATTTCACAGATTCCACTGCCACTTTTCACCACGTGACTGG	3113
AAV-2	.....T.....C.....	3090
AAV-6	.....T..C.....	3098
AAV-1	CAGCGACTCATCAACAACAATTGGGGATTCCGGCCCAAGAGACTCAACTTCAAACCTCTTC	3173
AAV-2	..AA.....C.....A.....G.....T	3150
AAV-6	.....G.....	3158
AAV-1	AACATCCAAGTCAAGGAGGTCACGACGAATGATGGCGTCACAACCATCGCTAATAACCTT	3233
AAV-2	.....T.....A.....CA.....C..TACG..G..G..T..C.....	3210
AAV-6	.....G.....	3218

5/13

FIG 1E

AAV-1 ACCAGCACGGTTCAAGTCTTCTCGGACTCGGAGTACCAGCTTCCGTACGTCCTCGGCTCT 3293  
AAV-2 .....G..G..TA.T.....C.....G 3270  
AAV-6 .....T.G..... 3278

AAV-1 GCGCACCAGGGCTGCCTCCCTCCGTTCCTCGGCGGACGTGTTTCATGATTCCGCAATACGGC 3353  
AAV-2 .....T..A..A.....G.....A..A.....C.....G.G..A..G..T..A 3330  
AAV-6 .....G..... 3338

AAV-1 TACCTGACGCTCAACAATGGCAGCCAAGCCGTGGGACGTTTCATCCTTTTACTGCCTGGAA 3413  
AAV-2 .....C..C..G.....C..G..T..G..A..A.....C..T..A.....G 3390  
AAV-6 .....A.....G..A.....G..... 3398

AAV-1 TATTTCCCTTCTCAGATGCTGAGAACGGGCAACAACCTTTACCTTCAGCTACACCTTTGAG 3473  
AAV-2 ..C..T.....C.T..C..A.....T..... 3450  
AAV-6 .....A..G.....T.....C... 3458

AAV-1 GAAGTGCCTTTCCACAGCAGCTACGCGCACAGCCAGAGCCTGGACCGGCTGATGAATCCT 3533  
AAV-2 ..C..T.....T.....T.....T..C..... 3510  
AAV-6 ..C..... 3498

AAV-1 CTCATCGACCAATACCTGTATTACCTGAACAGAACTCAAAATCAGTCCGGAAGTGCCCAA 3593  
AAV-2 .....G.....T...G.....AA.C.C..CAAGT....CCA..ACG 3570  
AAV-6 .....G.....G..... 3578

AAV-1 AACAGGACTTGCTGTTTAGCCGTGGGTCTCCAGCTGGCATGTCTGTTTCAGCCCCAAAAC 3653  
AAV-2 C.GTCAAGGC.T.A....TCT.AG.CCGGAG.GAG..A...TCGG.AC...T.T.GG... 3630  
AAV-6 .....G..... 3638

AAV-1 TGGCTACCTGGACCCTGTTATCGGCAGCAGCGCGTTTCTAAAACAAAACAGACAACAAC 3713  
AAV-2 .....T.....C..C.....A..A.CA..G...TCTG.G..T..... 3690  
AAV-6 .....C..... 3698

AAV-1 AACAGCAATTTTACCTGGACTGGTGCTTCAAAATATAACCTCAATGGGCGTGAATCCATC 3773  
AAV-2 .....TG.A.ACT.G.....A...A.C..G..CC.....CA.A..C..TC.G 3750  
AAV-6 .....C.....T.....T..A 3758

AAV-1 ATCAACCCTGGCACTGCTATGGCCTCACACAAAGACGACGAAGACAAGTTCTTTCCCATG 3833  
AAV-2 G.G..T..G..GC.C..C.....AAGC.....G.....T.....A.....T.....TCA. 3810  
AAV-6 .....A..... 3818

AAV-1 AGCGGTGTCATGATTTTTTGGAAGAGAGCGCCGGAGCTTCAAACACTGCATTGGACAAT 3893  
AAV-2 .....G..TC.C..C.....G..GC.AG..T.A.AGAAAA...TGTGAACA.T..A..G 3870  
AAV-6 .....G..... 3878

AAV-1 GTCATGATTACAGACGAAGAGGAAATTAAAGCCACTAACCCTGTGGCCACCGAAAGATTT 3953  
AAV-2 .....CGG.A.A..C..T..C.....T..G..GCAG.A. 3930  
AAV-6 .....C.....C.....C..... 3938

AAV-1 GGGACCGTGGCAGTCAATTTCCAGAGCAGCAGCACAGACCCTGCGACCGGAGATGTGCAT 4013  
AAV-2 ..TT.T..AT.TAC...CC.....AG...A..G.C.AG.A..T...C.....CA.C 3990  
AAV-6 .....T.....C..... 3998

AAV-1 GCTATGGGAGCATTACCTGGCATGGTGTGGCAAGATAGAGACGTGTACCTGCAGGGTCCC 4073  
AAV-2 A.ACAA..C.TTC.T..A.....C.....G..C.....T.....T.....G... 4050  
AAV-6 T.....C.....A.....C.....A.....T 4058

6/13

FIG 1F

AAV-1 ATTTGGGCCAAAATTCCTCACACAGATGGACACTTTCACCCGTCTCCTCTTATGGGCGGC 4133  
AAV-2 ..C.....A..G.....A.....G..C.....T.....C.....C..C.....T..A 4110  
AAV-6 .....G.....C..... 4118

AAV-1 TTTGGACTCAAGAACCCGCCTCCTCAGATCCTCATCAAAAACACGCCTGTTCTGCGAAT 4193  
AAV-2 ..C.....T..AC....T.....A.....T.....G.....C..G..A..... 4170  
AAV-6 .....T...C..... 4178

AAV-1 CCTCCGGCGGAGTTTTCAGCTACAAAGTTTGCTTCATTCATCACCCAATACTCCACAGGA 4253  
AAV-2 ...T..A.CACC..CAGT..GG.....C.....A..G.....G... 4230  
AAV-6 .....A.....G.....G..T..... 4238

AAV-1 CA-AGTGAGTGTGGAAATTGAATGGGAGCTGCAGAAAGAAAACAGCAAGCGCTGGAATCC 4312  
AAV-2 ..CG..C..C.....G..C..G.....G.....A..... 4290  
AAV-6 ..-.....C.....G.....A..... 4297

AAV-1 CGAAGTGCAGTACACATCCAATTATGCAAAATCTGCCAA-CGTTGATTTTACTGTGGACA 4371  
AAV-2 ....A.T.....T.....C..CAAC..G....TT..T..G..C.....C.....T. 4350  
AAV-6 .....T.....T..C.....-.....C..... 4356

AAV-1 ACAATGGACTTTTATACTGAGCCTCGCCCCATTGGCACCCGTTACCTTACCCGTCCCCTGT 4431  
AAV-2 CT.....CG.G...T.A.....A.A.....G..T...AAT.... 4410  
AAV-6 .....C..... 4416

VP1-3 stop PolyA signal

AAV-1 AATTACGTGTTAATCAATAAACCGGTTGATTCGTTTCAGTTGAACTTTGGTCTCCTGTCC 4491  
AAV-2 ....G.T.....T..A.....TGCCTA 4470  
AAV-6 ....GT.....A.....G.....A....G 4476

AAV-1 TTCTTATCTTATC-GGTTACCATGGTTAT-AGCTTACACATTA--ACTGCTTGGTTGCGC 4547  
AAV-2 ..TC.T.....TA...T.....C..CGTAGA..AGT.GC.TGG.G.G..AA.CATTA 4530  
AAV-6 ..A.....T...C.....A.CA.C-C.G.....--.....A..... 4533

AAV-1 TTCGCGATAAAAGACTTACGTCATCGGGGttacccctagtgatggagttgcccactccctc 4607  
AAV-2 ACTA.A.gg.a-----g..... 4570  
AAV-6 .....at.----- 4572

AAV-1 tctgcgcgctcgctcgctcggtggggccggcagagcagagctctgccgtctgcggacctt 4667  
AAV-2 .c.....ac..a.....gc..c..a..g..gc...a.gc.c.gg... 4630  
AAV-6 .a.....g..... 4632

AAV-1 tgggtccgcaggccccaccgagcgagcgagcgcgagagaggagtgaggcaa 4718  
AAV-2 ..cc.g.gc....t..gt.....c... 4681  
AAV-6 .....t..... 4683

AAV-1 TR

A A A  
G C  
G C  
T A  
C G  
gC Gc  
cG Cg  
C G  
aA Tg a ca  
G CCGGGTGGCTCGCTCGCTCGCGGTCTCTCCCTCACCCTT  
A C GGCCCCACCGAGCGAGCGCGCAGAGAGGGAGTGGGCACTCCATCACTAGGGGTAA  
G C t gt  
cG Cg  
C G  
cA Tg  
G C  
gA Tc  
G C  
C G  
T T  
C  
t

a

---aav-1 itr  
---aav-2 itr  
---AAV-1 ITR

tcct

FIG 2




FIG. 3A






FIG. 3B



10/13




FIG. 4A




FIG. 4B

FIG. 5A




FIG. 5B




FIG. 5C





FIG. 5D



Group	1	2	3	4	5	6
Vector1- $\alpha$ 1AT	AAV2	AAV1	PBS	PBS	AAV2	AAV1
Vector2-EPO	AAV2	AAV1	AAV2	AAV1	AAV1	AAV2

13/13

FIG. 6A




FIG. 6B




FIG. 6C





FIG. 6D




Group	1	2	3	4	5	6
Vector1- $\alpha$ 1AT	AAV2	AAV1	PBS	PBS	AAV2	AAV1
Vector2-EPO	AAV2	AAV1	AAV2	AAV1	AAV1	AAV2



00270

PATENT TRADEMARK OFFICE



# DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME, the specification of which

(check one)                      is attached hereto  
    X                      was filed on April 17, 2001 as Application No. 09/807,802 and  
                         was amended on April 17, 2001. (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Not Claimed	Certified Copy Attached?	
_____ (Number)	_____ (Country)	_____ (MM/DD/YYYY)	_____	_____ Yes	_____ No

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

60/107,114  
(Application Number)

November 5, 1998  
(Filing Date, MM/DD/YYYY)

I hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

STANLEY B. KITA, Registration No. 24,561; GEORGE A. SMITH, JR., Registration No. 24,442; MARY E. BAK, Registration No. 31,215, CATHY A. KODROFF, Registration Number 33,980, WILLIAM BAK, Registration Number 37,277, HENRY HANSEN, Registration No. 19,612, and TRACY U. PALOVICH, Registration No. 47,840.

Address all telephone calls to Cathy A. Kodroff at telephone no. (215) 540-9210.  
Address all correspondence to HOWSON AND HOWSON, Spring House Corporate Center, P. O. Box 457, Spring House, Pennsylvania 19477.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: James M. Wilson

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Gladwyne, Pennsylvania 19035

Citizenship: United States of America

Post Office Address: 1350 N. Avignon Drive, Gladwyne, Pennsylvania 19035

2-00  
Full name of first inventor: Weidong Xiao

Inventor's signature Weidong Xiao Date 11/27/01

Residence: Fort Washington, Pennsylvania 19034

Citizenship: China CNX

Post Office Address: 1604 Conquest Way, Fort Washington, Pennsylvania 19034

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: STANLEY B. KITA, Registration No. 24,561; GEORGE A. SMITH, JR., Registration No. 24,442; WILSON OBERDORFER, Registration No. 17,379; MARY E. BAK, Registration No. 31,215; CATHY A. KODROFF, Registration Number 33,980; HENRY HANSEN, Registration No. 19,612, and WILLIAM BAK, Registration Number 37,277.

Address all telephone calls to Cathy A. Kodroff at telephone no. (215) 540-9210. Address all correspondence to HOWSON AND HOWSON, Spring House Corporate Center, P. O. Box 457, Spring House, Pennsylvania 19477.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: James M. Wilson

Inventor's signature [Signature] Date 3-16-01

Residence: Gladwyne, Pennsylvania 19035

Citizenship: United States of America USX

Post Office Address: 1350 N. Avignon Drive, Gladwyne, Pennsylvania 19035

Full name of first inventor: Weidong Xiao

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: Jenkintown, Pennsylvania 19046

Citizenship: China

Post Office Address: 155 Washington Lane, Apt. P4, Jenkintown, Pennsylvania 19046

WO 00/28061

PCT/US99/25694

SEQUENCE LISTING

<110> Wilson, James M.  
Xiao, Weidong  
The Trustees of the University of Pennsylvania

<120> Adeno-Associated Virus Serotype I Nucleic Acid  
Sequences, Vectors and Host Cells Containing Same

<130> GNVPN.031PCT

<140>

<141>

<150> 60/107,114

<151> 1998-11-05

<160> 20

<170> PatentIn Ver. 2.0

<210> 1

<211> 4718

<212> DNA

<213> AAV-1

<220>

<221> CDS

<222> (335) .. (2206)

<220>

<221> CDS

<222> (2223) .. (4430)

<400> 1

ttgccactc cctctctgcg cgctcgctcg ctgggtgggg cctgcggacc aaaggtccgc 60  
agacggcaga gctctgctct gccggcccca ccgagcgagc gagcgcgag agagggagtg 120  
ggcaactcca tcactagggg taatcgcgaa gcgcctccca cgctgccgcg tcagcgctga 180  
cgtaaattac gtcatagggg agtggtcctg tattagctgt cacgtgagtg cttttgcgac 240  
attttgcgac accacgtggc catttagggg atatatggcc gagtgagcga gcaggatctc 300  
cattttgacc gcgaaatttg aacgagcagc agcc atg ccg ggc ttc tac gag atc 355  
Met Pro Gly Phe Tyr Glu Ile

1

5





WO 00/28061

PCT/US99/25694

cag gag cag aac aag gag aat ctg aac ccc aat tct gac gcg cct gtc	979
Gln Glu Gln Asn Lys Glu Asn Leu Asn Pro Asn Ser Asp Ala Pro Val	
200 205 210 215	
atc cgg tca aaa acc tcc gcg cgc tac atg gag ctg gtc ggg tgg ctg	1027
Ile Arg Ser Lys Thr Ser Ala Arg Tyr Met Glu Leu Val Gly Trp Leu	
220 225 230	
gtg gac cgg ggc atc acc tcc gag aag cag tgg atc cag gag gac cag	1075
Val Asp Arg Gly Ile Thr Ser Glu Lys Gln Trp Ile Gln Glu Asp Gln	
235 240 245	
gcc tcg tac atc tcc ttc aac gcc gct tcc aac tcg cgg tcc cag atc	1123
Ala Ser Tyr Ile Ser Phe Asn Ala Ala Ser Asn Ser Arg Ser Gln Ile	
250 255 260	
aag gcc gct ctg gac aat gcc ggc aag atc atg gcg ctg acc aaa tcc	1171
Lys Ala Ala Leu Asp Asn Ala Gly Lys Ile Met Ala Leu Thr Lys Ser	
265 270 275	
gcg ccc gac tac ctg gta ggc ccc gct ccg ccc gcg gac att aaa acc	1219
Ala Pro Asp Tyr Leu Val Gly Pro Ala Pro Pro Ala Asp Ile Lys Thr	
280 285 290 295	
aac cgc atc tac cgc atc ctg gag ctg aac ggc tac gaa cct gcc tac	1267
Asn Arg Ile Tyr Arg Ile Leu Glu Leu Asn Gly Tyr Glu Pro Ala Tyr	
300 305 310	
gcc ggc tcc gtc ttt ctc ggc tgg gcc cag aaa agg ttc ggg aag cgc	1315
Ala Gly Ser Val Phe Leu Gly Trp Ala Gln Lys Arg Phe Gly Lys Arg	
315 320 325	
aac acc atc tgg ctg ttt ggg ccg gcc acc acg ggc aag acc aac atc	1363
Asn Thr Ile Trp Leu Phe Gly Pro Ala Thr Thr Gly Lys Thr Asn Ile	
330 335 340	
gcg gaa gcc atc gcc cac gcc gtg ccc ttc tac ggc tgc gtc aac tgg	1411
Ala Glu Ala Ile Ala His Ala Val Pro Phe Tyr Gly Cys Val Asn Trp	
345 350 355	
acc aat gag aac ttt ccc ttc aat gat tgc gtc gac aag atg gtg atc	1459
Thr Asn Glu Asn Phe Pro Phe Asn Asp Cys Val Asp Lys Met Val Ile	
360 365 370 375	
tgg tgg gag gag ggc aag atg acg gcc aag gtc gtg gag tcc gcc aag	1507
Trp Trp Glu Glu Gly Lys Met Thr Ala Lys Val Val Glu Ser Ala Lys	
380 385 390	

WO 00/28061

PCT/US99/25694

gcc att ctc ggc ggc agc aag gtg cgc gtg gac caa aag tgc aag tcg 1555  
Ala Ile Leu Gly Gly Ser Lys Val Arg Val Asp Gln Lys Cys Lys Ser  
395 400 405

tcc gcc cag atc gac ccc acc ccc gtg atc gtc acc tcc aac acc aac 1603  
Ser Ala Gln Ile Asp Pro Thr Pro Val Ile Val Thr Ser Asn Thr Asn  
410 415 420

atg tgc gcc gtg att gac ggg aac agc acc acc ttc gag cac cag cag 1651  
Met Cys Ala Val Ile Asp Gly Asn Ser Thr Thr Phe Glu His Gln Gln  
425 430 435

ccg ttg cag gac cgg atg ttc aaa ttt gaa ctc acc cgc cgt ctg gag 1699  
Pro Leu Gln Asp Arg Met Phe Lys Phe Glu Leu Thr Arg Arg Leu Glu  
440 445 450 455

cat gac ttt ggc aag gtg aca aag cag gaa gtc aaa gag ttc ttc cgc 1747  
His Asp Phe Gly Lys Val Thr Lys Gln Glu Val Lys Glu Phe Phe Arg  
460 465 470

tgg gcg cag gat cac gtg acc gag gtg gcg cat gag ttc tac gtc aga 1795  
Trp Ala Gln Asp His Val Thr Glu Val Ala His Glu Phe Tyr Val Arg  
475 480 485

aag ggt gga gcc aac aaa aga ccc gcc ccc gat gac gcg gat aaa agc 1843  
Lys Gly Gly Ala Asn Lys Arg Pro Ala Pro Asp Asp Ala Asp Lys Ser  
490 495 500

gag ccc aag cgg gcc tgc ccc tca gtc gcg gat cca tgc acg tca gac 1891  
Glu Pro Lys Arg Ala Cys Pro Ser Val Ala Asp Pro Ser Thr Ser Asp  
505 510 515

gcg gaa gga gct ccg gtg gac ttt gcc gac agg tac caa aac aaa tgt 1939  
Ala Glu Gly Ala Pro Val Asp Phe Ala Asp Arg Tyr Gln Asn Lys Cys  
520 525 530 535

tct cgt cac gcg ggc atg ctt cag atg ctg ttt ccc tgc aag aca tgc 1987  
Ser Arg His Ala Gly Met Leu Gln Met Leu Phe Pro Cys Lys Thr Cys  
540 545 550

gag aga atg aat cag aat ttc aac att tgc ttc acg cac ggg acg aga 2035  
Glu Arg Met Asn Gln Asn Phe Asn Ile Cys Phe Thr His Gly Thr Arg  
555 560 565

gac tgt tca gag tgc ttc ccc ggc gtg tca gaa tct caa ccg gtc gtc 2083  
Asp Cys Ser Glu Cys Phe Pro Gly Val Ser Glu Ser Gln Pro Val Val  
570 575 580

WO 00/28061

PCT/US99/25694

aga aag agg acg tat cgg aaa ctc tgt gcc att cat cat ctg ctg ggg	2131
Arg Lys Arg Thr Tyr Arg Lys Leu Cys Ala Ile His His Leu Leu Gly	
585 590 595	
cgg gct ccc gag att gct tgc tcg gcc tgc gat ctg gtc aac gtg gac	2179
Arg Ala Pro Glu Ile Ala Cys Ser Ala Cys Asp Leu Val Asn Val Asp	
600 605 610 615	
ctg gat gac tgt gtt tct gag caa taa atgacttaaa ccaggt atg gct gcc	2231
Leu Asp Asp Cys Val Ser Glu Gln Met Ala Ala	
620 625	
gat ggt tat ctt cca gat tgg ctc gag gac aac ctc tct gag ggc att	2279
Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser Glu Gly Ile	
630 635 640	
cgc gag tgg tgg gac ttg aaa cct gga gcc ccg aag ccc aaa gcc aac	2327
Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro Lys Ala Asn	
645 650 655	
cag caa aag cag gac gac ggc cgg ggt ctg gtg ctt cct ggc tac aag	2375
Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro Gly Tyr Lys	
660 665 670 675	
tac ctc gga ccc ttc aac gga ctc gac aag ggg gag ccc gtc aac gcg	2423
Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro Val Asn Ala	
680 685 690	
gcg gac gca gcg gcc ctc gag cac gac aag gcc tac gac cag cag ctc	2471
Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln Gln Leu	
695 700 705	
aaa gcg ggt gac aat ccg tac ctg cgg tat aac cac gcc gac gcc gag	2519
Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala Asp Ala Glu	
710 715 720	
ttt cag gag cgt ctg caa gaa gat acg tct ttt ggg ggc aac ctc ggg	2567
Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly Asn Leu Gly	
725 730 735	
cga gca gtc ttc cag gcc aag aag cgg gtt ctc gaa cct ctc ggt ctg	2615
Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu Gly Leu	
740 745 750 755	
gtt gag gaa ggc gct aag acg gct cct gga aag aaa cgt ccg gta gag	2663
Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro Val Glu	
760 765 770	



WO 00/28061

PCT/US99/25694

acg gtt caa gtc ttc tcg gac tcg gag tac cag ctt ccg tac gtc ctc 3287  
 Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu  
 965 970 975

ggc tct gcg cac cag ggc tgc ctc cct ccg ttc ccg gcg gac gtg ttc 3335  
 Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe  
 980 985 990 995

atg att ccg caa tac ggc tac ctg acg ctc aac aat ggc agc caa gcc 3383  
 Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala  
 1000 1005 1010

gtg gga cgt tca tcc ttt tac tgc ctg gaa tat ttc cct tct cag atg 3431  
 Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met  
 1015 1020 1025

ctg aga acg ggc aac aac ttt acc ttc agc tac acc ttt gag gaa gtg 3479  
 Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu Glu Val  
 1030 1035 1040

cct ttc cac agc agc tac gcg cac agc cag agc ctg gac cgg ctg atg 3527  
 Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met  
 1045 1050 1055

aat cct ctc atc gac caa tac ctg tat tac ctg aac aga act caa aat 3575  
 Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg Thr Gln Asn  
 1060 1065 1070 1075

cag tcc gga agt gcc caa aac aag gac ttg ctg ttt agc cgt ggg tct 3623  
 Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser Arg Gly Ser  
 1080 1085 1090

cca gct ggc atg tct gtt cag ccc aaa aac tgg cta cct gga ccc tgt 3671  
 Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro Gly Pro Cys  
 1095 1100 1105

tat cgg cag cag cgc gtt tct aaa aca aaa aca gac aac aac aac agc 3719  
 Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn Asn Asn Ser  
 1110 1115 1120

aat ttt acc tgg act ggt gct tca aaa tat aac ctc aat ggg cgt gaa 3767  
 Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn Gly Arg Glu  
 1125 1130 1135

tcc atc atc aac cct ggc act gct atg gcc tca cac aaa gac gac gaa 3815  
 Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys Asp Asp Glu  
 1140 1145 1150 1155

WO 00/28061

PCT/US99/25694

gac aag ttc ttt ccc atg agc ggt gtc atg att ttt gga aaa gag agc 3863  
 Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly Lys Glu Ser  
 1160 1165 1170

gcc gga gct tca aac act gca ttg gac aat gtc atg att aca gac gaa 3911  
 Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile Thr Asp Glu  
 1175 1180 1185

gag gaa att aaa gcc act aac cct gtg gcc acc gaa aga ttt ggg acc 3959  
 Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg Phe Gly Thr  
 1190 1195 1200

gtg gca gtc aat ttc cag agc agc agc aca gac cct gcg acc gga gat 4007  
 Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp  
 1205 1210 1215

gtg cat gct atg gga gca tta cct ggc atg gtg tgg caa gat aga gac 4055  
 Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln Asp Arg Asp  
 1220 1225 1230 1235

gtg tac ctg cag ggt ccc att tgg gcc aaa att cct cac aca gat gga 4103  
 Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly  
 1240 1245 1250

cac ttt cac ccg tct cct ctt atg ggc gcc ttt gga ctc aag aac ccg 4151  
 His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys Asn Pro  
 1255 1260 1265

cct cct cag atc ctc atc aaa aac acg cct gtt cct gcg aat cct ccg 4199  
 Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro  
 1270 1275 1280

gcg gag ttt tca gct aca aag ttt gct tca ttc atc acc caa tac tcc 4247  
 Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser  
 1285 1290 1295

aca gga caa gtg agt gtg gaa att gaa tgg gag ctg cag aaa gaa aac 4295  
 Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn  
 1300 1305 1310 1315

agc aag cgc tgg aat ccc gaa gtg cag tac aca tcc aat tat gca aaa 4343  
 Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn Tyr Ala Lys  
 1320 1325 1330

tct gcc aac gtt gat ttt act gtg gac aac aat gga ctt tat act gag 4391  
 Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu Tyr Thr Glu  
 1335 1340 1345

WO 00/28061

PCT/US99/25694

cct cgc ccc att ggc acc cgt tac ctt acc cgt ccc ctg taattacgtg 4440  
Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu  
1350 1355 1360

ttaatcaata aaccggttga ttcgtttcag ttgaactttg gtctctctgtc cttcttatct 4500  
tatcggttac catggttata gcttacacat taactgcttg gttgcgcttc gcgataaaaag 4560  
acttacgtca tcgggttacc cctagtgatg gagttgccc ctcctctctc gcgcgctcgc 4620  
tcgctcggtg gggcctgcgg accaaaggtc cgcagacggc agagctctgc tctgccggcc 4680  
ccaccgagcg agcgagcgcg cagagaggga gtgggcaa 4718

<210> 2  
<211> 623  
<212> PRT  
<213> AAV-1

<400> 2  
Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp  
1 5 10 15  
Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu  
20 25 30  
Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile  
35 40 45  
Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu  
50 55 60  
Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val  
65 70 75 80  
Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu  
85 90 95  
Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile  
100 105 110  
Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu  
115 120 125  
Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly  
130 135 140





**WO 00/28061**

**PCT/US99/25694**

Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val
				405					410					415	
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser
			420					425					430		
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe
		435					440					445			
Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln
	450					455					460				
Glu	Val	Lys	Glu	Phe	Phe	Arg	Trp	Ala	Gln	Asp	His	Val	Thr	Glu	Val
465					470					475					480
Ala	His	Glu	Phe	Tyr	Val	Arg	Lys	Gly	Gly	Ala	Asn	Lys	Arg	Pro	Ala
			485					490						495	
Pro	Asp	Asp	Ala	Asp	Lys	Ser	Glu	Pro	Lys	Arg	Ala	Cys	Pro	Ser	Val
			500				505						510		
Ala	Asp	Pro	Ser	Thr	Ser	Asp	Ala	Glu	Gly	Ala	Pro	Val	Asp	Phe	Ala
		515				520						525			
Asp	Arg	Tyr	Gln	Asn	Lys	Cys	Ser	Arg	His	Ala	Gly	Met	Leu	Gln	Met
	530				535						540				
Leu	Phe	Pro	Cys	Lys	Thr	Cys	Glu	Arg	Met	Asn	Gln	Asn	Phe	Asn	Ile
545					550					555					560
Cys	Phe	Thr	His	Gly	Thr	Arg	Asp	Cys	Ser	Glu	Cys	Phe	Pro	Gly	Val
			565					570						575	
Ser	Glu	Ser	Gln	Pro	Val	Val	Arg	Lys	Arg	Thr	Tyr	Arg	Lys	Leu	Cys
			580				585						590		
Ala	Ile	His	His	Leu	Leu	Gly	Arg	Ala	Pro	Glu	Ile	Ala	Cys	Ser	Ala
		595				600						605			
Cys	Asp	Leu	Val	Asn	Val	Asp	Leu	Asp	Asp	Cys	Val	Ser	Glu	Gln	
	610					615					620				

<210> 3  
<211> 736  
<212> PRT  
<213> AAV-1



WO 00/28061

PCT/US99/25694

				245					250					255		
Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His	
			260					265					270			
Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	
		275					280					285				
His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	
	290					295					300					
Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln	
305					310					315					320	
Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn	
				325					330					335		
Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro	
			340					345					350			
Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala	
		355					360					365				
Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly	
	370					375					380					
Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	
385					390					395					400	
Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	
				405					410					415		
Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	
			420					425					430			
Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg	
		435					440					445				
Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser	
	450					455					460					
Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro	
465					470					475					480	
Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn	
				485					490					495		
Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn	

WO 00/28061

PCT/US99/25694

	500		505		510
Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys	515		520		525
Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly	530		535		540
Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile	545		550		555
Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg		565		570	575
Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala		580		585	590
Thr Gly Asp Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln		595		600	605
Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His		610		615	620
Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu		625		630	635
Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala		645		650	655
Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr		660		665	670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln		675		680	685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn		690		695	700
Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu		705		710	715
Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu		725		730	735

<210> 4

<211> 1872

<212> DNA



WO 00/28061

PCT/US99/25694

Thr	Gln	Pro	Glu	Leu	Gln	Trp	Ala	Trp	Thr	Asn	Met	Glu	Glu	Tyr	Ile	
				165					170					175		
agc	gcc	tgt	ttg	aac	ctg	gcc	gag	cgc	aaa	cgg	ctc	gtg	gcg	cag	cac	576
Ser	Ala	Cys	Leu	Asn	Leu	Ala	Glu	Arg	Lys	Arg	Leu	Val	Ala	Gln	His	
			180					185					190			
ctg	acc	cac	gtc	agc	cag	acc	cag	gag	cag	aac	aag	gag	aat	ctg	aac	624
Leu	Thr	His	Val	Ser	Gln	Thr	Gln	Glu	Gln	Asn	Lys	Glu	Asn	Leu	Asn	
		195					200					205				
ccc	aat	tct	gac	gcg	cct	gtc	atc	cgg	tca	aaa	acc	tcc	gcg	cgc	tac	672
Pro	Asn	Ser	Asp	Ala	Pro	Val	Ile	Arg	Ser	Lys	Thr	Ser	Ala	Arg	Tyr	
	210					215					220					
atg	gag	ctg	gtc	ggg	tgg	ctg	gtg	gac	cgg	ggc	atc	acc	tcc	gag	aag	720
Met	Glu	Leu	Val	Gly	Trp	Leu	Val	Asp	Arg	Gly	Ile	Thr	Ser	Glu	Lys	
225					230					235					240	
cag	tgg	atc	cag	gag	gac	cag	gcc	tcg	tac	atc	tcc	ttc	aac	gcc	gct	768
Gln	Trp	Ile	Gln	Glu	Asp	Gln	Ala	Ser	Tyr	Ile	Ser	Phe	Asn	Ala	Ala	
			245						250					255		
tcc	aac	tcg	cgg	tcc	cag	atc	aag	gcc	gct	ctg	gac	aat	gcc	ggc	aag	816
Ser	Asn	Ser	Arg	Ser	Gln	Ile	Lys	Ala	Ala	Leu	Asp	Asn	Ala	Gly	Lys	
			260					265					270			
atc	atg	gcg	ctg	acc	aaa	tcc	gcg	ccc	gac	tac	ctg	gta	ggc	ccc	gct	864
Ile	Met	Ala	Leu	Thr	Lys	Ser	Ala	Pro	Asp	Tyr	Leu	Val	Gly	Pro	Ala	
		275					280					285				
ccg	ccc	gcg	gac	att	aaa	acc	aac	cgc	atc	tac	cgc	atc	ctg	gag	ctg	912
Pro	Pro	Ala	Asp	Ile	Lys	Thr	Asn	Arg	Ile	Tyr	Arg	Ile	Leu	Glu	Leu	
	290					295					300					
aac	ggc	tac	gaa	cct	gcc	tac	gcc	ggc	tcc	gtc	ttt	ctc	ggc	tgg	gcc	960
Asn	Gly	Tyr	Glu	Pro	Ala	Tyr	Ala	Gly	Ser	Val	Phe	Leu	Gly	Trp	Ala	
305					310					315					320	
cag	aaa	agg	ttc	ggg	aag	cgc	aac	acc	atc	tgg	ctg	ttt	ggg	ccg	gcc	1008
Gln	Lys	Arg	Phe	Gly	Lys	Arg	Asn	Thr	Ile	Trp	Leu	Phe	Gly	Pro	Ala	
			325					330					335			
acc	acg	ggc	aag	acc	aac	atc	gcg	gaa	gcc	atc	gcc	cac	gcc	gtg	ccc	1056
Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Ala	Val	Pro	
			340					345				350				
ttc	tac	ggc	tgc	gtc	aac	tgg	acc	aat	gag	aac	ttt	ccc	ttc	aat	gat	1104

WO 00/28061

PCT/US99/25694

Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp	
		355					360					365				
tgc	gtc	gac	aag	atg	gtg	atc	tgg	tgg	gag	gag	ggc	aag	atg	acg	gcc	1152
Cys	Val	Asp	Lys	Met	Val	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Ala	
	370					375					380					
aag	gtc	gtg	gag	tcc	gcc	aag	gcc	att	ctc	ggc	ggc	agc	aag	gtg	cgc	1200
Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg	
385					390					395					400	
gtg	gac	caa	aag	tgc	aag	tcg	tcc	gcc	cag	atc	gac	ccc	acc	ccc	gtg	1248
Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val	
			405						410					415		
atc	gtc	acc	tcc	aac	acc	aac	atg	tgc	gcc	gtg	att	gac	ggg	aac	agc	1296
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser	
			420					425					430			
acc	acc	ttc	gag	cac	cag	cag	ccg	ttg	cag	gac	cgg	atg	ttc	aaa	ttt	1344
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe	
		435					440					445				
gaa	ctc	acc	cgc	cgt	ctg	gag	cat	gac	ttt	ggc	aag	gtg	aca	aag	cag	1392
Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln	
	450					455					460					
gaa	gtc	aaa	gag	ttc	ttc	cgc	tgg	gcg	cag	gat	cac	gtg	acc	gag	gtg	1440
Glu	Val	Lys	Glu	Phe	Phe	Arg	Trp	Ala	Gln	Asp	His	Val	Thr	Glu	Val	
465					470					475					480	
gcg	cat	gag	ttc	tac	gtc	aga	aag	ggt	gga	gcc	aac	aaa	aga	ccc	gcc	1488
Ala	His	Glu	Phe	Tyr	Val	Arg	Lys	Gly	Gly	Ala	Asn	Lys	Arg	Pro	Ala	
			485						490					495		
ccc	gat	gac	gcg	gat	aaa	agc	gag	ccc	aag	cgg	gcc	tgc	ccc	tca	gtc	1536
Pro	Asp	Asp	Ala	Asp	Lys	Ser	Glu	Pro	Lys	Arg	Ala	Cys	Pro	Ser	Val	
			500					505					510			
gcg	gat	cca	tcg	acg	tca	gac	gcg	gaa	gga	gct	ccg	gtg	gac	ttt	gcc	1584
Ala	Asp	Pro	Ser	Thr	Ser	Asp	Ala	Glu	Gly	Ala	Pro	Val	Asp	Phe	Ala	
		515					520					525				
gac	agg	tac	caa	aac	aaa	tgt	tct	cgt	cac	gcg	ggc	atg	ctt	cag	atg	1632
Asp	Arg	Tyr	Gln	Asn	Lys	Cys	Ser	Arg	His	Ala	Gly	Met	Leu	Gln	Met	
	530					535					540					
ctg	ttt	ccc	tgc	aag	aca	tgc	gag	aga	atg	aat	cag	aat	ttc	aac	att	1680



WO 00/28061

PCT/US99/25694

Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile  
545 550 555 560

tgc ttc acg cac ggg acg aga gac tgt tca gag tgc ttc ccc ggc gtg 1728  
Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val  
565 570 575

tca gaa tct caa ccg gtc gtc aga aag agg acg tat cgg aaa ctc tgt 1776  
Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys  
580 585 590

gcc att cat cat ctg ctg ggg cgg gct ccc gag att gct tgc tcg gcc 1824  
Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala  
595 600 605

tgc gat ctg gtc aac gtg gac ctg gat gac tgt gtt tct gag caa taa 1872  
Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln  
610 615 620

<210> 5

<211> 623

<212> PRT

<213> AAV-1

<400> 5

Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp  
1 5 10 15

Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu  
20 25 30

Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile  
35 40 45

Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu  
50 55 60

Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val  
65 70 75 80

Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu  
85 90 95

Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile  
100 105 110

Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu

WO 00/28061

PCT/US99/25694

115	120	125
Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly		
130	135	140
Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys		
145	150	155
Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile		
165	170	175
Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His		
180	185	190
Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn		
195	200	205
Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr		
210	215	220
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys		
225	230	235
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala		
245	250	255
Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys		
260	265	270
Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala		
275	280	285
Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu		
290	295	300
Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala		
305	310	315
Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala		
325	330	335
Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro		
340	345	350
Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp		
355	360	365
Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala		

WO 00/28061

PCT/US99/25694

370	375	380
Lys Val Val Glu Ser Ala	Lys Ala Ile Leu Gly Gly Ser Lys Val Arg	
385	390	395 400
Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val		
	405	410 415
Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser		
	420	425 430
Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe		
	435	440 445
Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln		
	450	455 460
Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val		
	465	470 475 480
Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala		
	485	490 495
Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val		
	500	505 510
Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala		
	515	520 525
Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met		
	530	535 540
Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile		
	545	550 555 560
Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val		
	565	570 575
Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys		
	580	585 590
Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala		
	595	600 605
Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln		
	610	615 620

WO 00/28061

PCT/US99/25694

<210> 6

<211> 1641

<212> DNA

<213> AAV-1

<220>

<221> CDS

<222> (1) .. (1638)

<400> 6

```

atg ccg ggc ttc tac gag atc gtg atc aag gtg ccg agc gac ctg gac      48
Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
  1             5             10             15

gag cac ctg ccg ggc att tct gac tcg ttt gtg agc tgg gtg gcc gag      96
Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu
          20             25             30

aag gaa tgg gag ctg ccc ccg gat tct gac atg gat ctg aat ctg att      144
Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile
          35             40             45

gag cag gca ccc ctg acc gtg gcc gag aag ctg cag cgc gac ttc ctg      192
Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu
          50             55             60

gtc caa tgg cgc cgc gtg agt aag gcc ccg gag gcc ctc ttc ttt gtt      240
Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val
          65             70             75             80

cag ttc gag aag ggc gag tcc tac ttc cac ctc cat att ctg gtg gag      288
Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu
          85             90             95

acc acg ggg gtc aaa tcc atg gtg ctg ggc cgc ttc ctg agt cag att      336
Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile
          100             105             110

agg gac aag ctg gtg cag acc atc tac cgc ggg atc gag ccg acc ctg      384
Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu
          115             120             125

ccc aac tgg ttc gcg gtg acc aag acg cgt aat ggc gcc gga ggg ggg      432
Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly
          130             135             140

aac aag gtg gtg gac gag tgc tac atc ccc aac tac ctc ctg ccc aag      480
Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys

```

22

**PCT/US99/25694**

			340					345					350				
ttc	tac	ggc	tgc	gtc	aac	tgg	acc	aat	gag	aac	ttt	ccc	ttc	aat	gat		1104
Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp		
		355					360					365					
tgc	gtc	gac	aag	atg	gtg	atc	tgg	tgg	gag	gag	ggc	aag	atg	acg	gcc		1152
Cys	Val	Asp	Lys	Met	Val	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Ala		
	370					375					380						
aag	gtc	gtg	gag	tcc	gcc	aag	gcc	att	ctc	ggc	ggc	agc	aag	gtg	cgc		1200
Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg		
385					390					395					400		
gtg	gac	caa	aag	tgc	aag	tcg	tcc	gcc	cag	atc	gac	ccc	acc	ccc	gtg		1248
Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val		
				405					410					415			
atc	gtc	acc	tcc	aac	acc	aac	atg	tgc	gcc	gtg	att	gac	ggg	aac	agc		1296
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser		
			420					425					430				
acc	acc	ttc	gag	cac	cag	cag	ccg	ttg	cag	gac	cgg	atg	ttc	aaa	ttt		1344
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe		
		435					440					445					
gaa	ctc	acc	cgc	cgt	ctg	gag	cat	gac	ttt	ggc	aag	gtg	aca	aag	cag		1392
Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln		
	450					455					460						
gaa	gtc	aaa	gag	ttc	ttc	cgc	tgg	gcg	cag	gat	cac	gtg	acc	gag	gtg		1440
Glu	Val	Lys	Glu	Phe	Phe	Arg	Trp	Ala	Gln	Asp	His	Val	Thr	Glu	Val		
465					470					475					480		
gcg	cat	gag	ttc	tac	gtc	aga	aag	ggt	gga	gcc	aac	aaa	aga	ccc	gcc		1488
Ala	His	Glu	Phe	Tyr	Val	Arg	Lys	Gly	Gly	Ala	Asn	Lys	Arg	Pro	Ala		
				485					490					495			
ccc	gat	gac	gcg	gat	aaa	agc	gag	ccc	aag	cgg	gcc	tgc	ccc	tca	gtc		1536
Pro	Asp	Asp	Ala	Asp	Lys	Ser	Glu	Pro	Lys	Arg	Ala	Cys	Pro	Ser	Val		
			500					505					510				
gcg	gat	cca	tcg	acg	tca	gac	gcg	gaa	gga	gct	ccg	gtg	gac	ttt	gcc		1584
Ala	Asp	Pro	Ser	Thr	Ser	Asp	Ala	Glu	Gly	Ala	Pro	Val	Asp	Phe	Ala		
		515					520					525					
gac	agg	tat	ggc	tgc	cga	tgg	tta	tct	tcc	aga	ttg	gct	cga	gga	caa		1632
Asp	Arg	Tyr	Gly	Cys	Arg	Trp	Leu	Ser	Ser	Arg	Leu	Ala	Arg	Gly	Gln		

**WO 00/28061**

**PCT/US99/25694**

530

535

540

cct ctc tga  
Pro Leu  
545

1641

```
<210> 7
<211> 546
<212> PRT
<213> AAV-1
```

<400> 7

Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp  
1 5 10 15

Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu  
20 25 30

Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile  
35 40 45

Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu  
50 55 60

Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val  
65 70 75 80

Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu  
85 90 95

Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile  
100 105 110

Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu  
115 120 125

Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly  
130 135 140

Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys  
145 150 155 160

Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile  
165 170 175

Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His  
180 185 190





WO 00/28061

PCT/US99/25694

Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln  
 450 455 460

Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val  
 465 470 475 480

Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala  
 485 490 495

Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val  
 500 505 510

Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
 515 520 525

Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln  
 530 535 540

Pro Leu  
 545

<210> 8  
 <211> 1200  
 <212> DNA  
 <213> AAV-1

<220>  
 <221> CDS  
 <222> (1)..(1197)

<400> 8  
 atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag 48  
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
 1 5 10 15

cag tgg atc cag gag gac cag gcc tcg tac atc tcc ttc aac gcc gct 96  
 Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
 20 25 30

tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag 144  
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
 35 40 45

atc atg gcg ctg acc aaa tcc gcg ccc gac tac ctg gta ggc ccc gct 192  
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala  
 50 55 60



WO 00/28061

PCT/US99/25694

gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc 816  
Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala  
260 265 270

ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc 864  
Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val  
275 280 285

gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc 912  
Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
290 295 300

gac agg tac caa aac aaa tgt tct cgt cac gcg ggc atg ctt cag atg 960  
Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met  
305 310 315 320

ctg ttt ccc tgc aag aca tgc gag aga atg aat cag aat ttc aac att 1008  
Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile  
325 330 335

tgc ttc acg cac ggg acg aga gac tgt tca gag tgc ttc ccc ggc gtg 1056  
Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val  
340 345 350

tca gaa tct caa ccg gtc gtc aga aag agg acg tat cgg aaa ctc tgt 1104  
Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys  
355 360 365

gcc att cat cat ctg ctg ggg cgg gct ccc gag att gct tgc tcg gcc 1152  
Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala  
370 375 380

tgc gat ctg gtc aac gtg gac ctg gat gac tgt gtt tct gag caa taa 1200  
Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln  
385 390 395

<210> 9

<211> 399

<212> PRT

<213> AAV-1

<400> 9

Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
1 5 10 15

Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala

WO 00/28061

PCT/US99/25694

20	25	30
Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys		
35	40	45
Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala		
50	55	60
Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu		
65	70	75
Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala		
85	90	95
Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala		
100	105	110
Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro		
115	120	125
Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp		
130	135	140
Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala		
145	150	155
Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg		
165	170	175
Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val		
180	185	190
Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser		
195	200	205
Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe		
210	215	220
Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln		
225	230	235
Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val		
245	250	255
Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala		
260	265	270
Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val		

WO 00/28061

PCT/US99/25694

275	280	285
Ala Asp Pro Ser Thr Ser Asp	Ala Glu Gly Ala Pro Val Asp Phe Ala	
290	295	300
Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met		
305	310	315
Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile		
325	330	335
Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val		
340	345	350
Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys		
355	360	365
Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala		
370	375	380
Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln		
385	390	395

<210> 10  
 <211> 969  
 <212> DNA  
 <213> AAV-1

<220>  
 <221> CDS  
 <222> (1)..(966)

<220>  
 <221> misc\_feature  
 <222> (943)..(944)  
 <223> minor splice site

<400> 10															
atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag	48														
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys															
1                      5                      10                      15															
cag tgg atc cag gag gac cag gcc tcg tac atc tcc ttc aac gcc gct	96														
Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala															
20                      25                      30															
tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag	144														

WO 00/28061

PCT/US99/25694

Ser	Asn	Ser	Arg	Ser	Gln	Ile	Lys	Ala	Ala	Leu	Asp	Asn	Ala	Gly	Lys	
	35						40					45				
atc	atg	gcg	ctg	acc	aaa	tcc	gcg	ccc	gac	tac	ctg	gta	ggc	ccc	gct	192
Ile	Met	Ala	Leu	Thr	Lys	Ser	Ala	Pro	Asp	Tyr	Leu	Val	Gly	Pro	Ala	
	50					55					60					
ccg	ccc	gcg	gac	att	aaa	acc	aac	cgc	atc	tac	cgc	atc	ctg	gag	ctg	240
Pro	Pro	Ala	Asp	Ile	Lys	Thr	Asn	Arg	Ile	Tyr	Arg	Ile	Leu	Glu	Leu	
	65				70					75					80	
aac	ggc	tac	gaa	cct	gcc	tac	gcc	ggc	tcc	gtc	ttt	ctc	ggc	tgg	gcc	288
Asn	Gly	Tyr	Glu	Pro	Ala	Tyr	Ala	Gly	Ser	Val	Phe	Leu	Gly	Trp	Ala	
				85					90					95		
cag	aaa	agg	ttc	ggg	aag	cgc	aac	acc	atc	tgg	ctg	ttt	ggg	ccg	gcc	336
Gln	Lys	Arg	Phe	Gly	Lys	Arg	Asn	Thr	Ile	Trp	Leu	Phe	Gly	Pro	Ala	
			100					105					110			
acc	acg	ggc	aag	acc	aac	atc	gcg	gaa	gcc	atc	gcc	cac	gcc	gtg	ccc	384
Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Ala	Val	Pro	
		115					120					125				
ttc	tac	ggc	tgc	gtc	aac	tgg	acc	aat	gag	aac	ttt	ccc	ttc	aat	gat	432
Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp	
	130					135					140					
tgc	gtc	gac	aag	atg	gtg	atc	tgg	tgg	gag	gag	ggc	aag	atg	acg	gcc	480
Cys	Val	Asp	Lys	Met	Val	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Ala	
	145				150					155					160	
aag	gtc	gtg	gag	tcc	gcc	aag	gcc	att	ctc	ggc	ggc	agc	aag	gtg	cgc	528
Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg	
				165					170					175		
gtg	gac	caa	aag	tgc	aag	tcg	tcc	gcc	cag	atc	gac	ccc	acc	ccc	gtg	576
Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val	
			180					185					190			
atc	gtc	acc	tcc	aac	acc	aac	atg	tgc	gcc	gtg	att	gac	ggg	aac	agc	624
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser	
		195					200					205				
acc	acc	ttc	gag	cac	cag	cag	ccg	ttg	cag	gac	cgg	atg	ttc	aaa	ttt	672
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe	
		210				215					220					
gaa	ctc	acc	cgc	cgt	ctg	gag	cat	gac	ttt	ggc	aag	gtg	aca	aag	cag	720

WO 00/28061

PCT/US99/25694

Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln  
 225 230 235 240

gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg 768  
 Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val  
 245 250 255

gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc 816  
 Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala  
 260 265 270

ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc 864  
 Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val  
 275 280 285

gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc 912  
 Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
 290 295 300

gac agg tat ggc tgc cga tgg tta tct tcc aga ttg gct cga gga caa 960  
 Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln  
 305 310 315 320

cct ctc tga 969  
 Pro Leu

<210> 11  
 <211> 322  
 <212> PRT  
 <213> AAV-1

<400> 11  
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
 1 5 10 15

Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
 20 25 30

Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
 35 40 45

Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala  
 50 55 60

Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu  
 65 70 75 80





WO 00/28061

PCT/US99/25694

<210> 12  
<211> 2211  
<212> DNA  
<213> AAV-1

<220>  
<221> CDS  
<222> (1)..(2208)

<400> 12

```

atg gct gcc gat ggt tat ctt cca gat tgg ctc gag gac aac ctc tct 48
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
  1           5           10           15

gag ggc att cgc gag tgg tgg gac ttg aaa cct gga gcc ccg aag ccc 96
Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
          20           25           30

aaa gcc aac cag caa aag cag gac gac ggc cgg ggt ctg gtg ctt cct 144
Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
          35           40           45

ggc tac aag tac ctc gga ccc ttc aac gga ctc gac aag ggg gag ccc 192
Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
          50           55           60

gtc aac gcg gcg gac gca gcg gcc ctc gag cac gac aag gcc tac gac 240
Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
          65           70           75           80

cag cag ctc aaa gcg ggt gac aat ccg tac ctg cgg tat aac cac gcc 288
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
          85           90           95

gac gcc gag ttt cag gag cgt ctg caa gaa gat acg tct ttt ggg ggc 336
Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
          100          105          110

aac ctc ggg cga gca gtc ttc cag gcc aag aag cgg gtt ctc gaa cct 384
Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
          115          120          125

ctc ggt ctg gtt gag gaa ggc gct aag acg gct cct gga aag aaa cgt 432
Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
          130          135          140

ccg gta gag cag tcg cca caa gag cca gac tcc tcc tcg ggc atc ggc 480

```

WO 00/28061

PCT/US99/25694

Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly	
145					150					155					160	
aag	aca	ggc	cag	cag	ccc	gct	aaa	aag	aga	ctc	aat	ttt	ggt	cag	act	528
Lys	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr	
				165					170					175		
ggc	gac	tca	gag	tca	gtc	ccc	gat	cca	caa	cct	ctc	gga	gaa	cct	cca	576
Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro	
			180					185					190			
gca	acc	ccc	gct	gct	gtg	gga	cct	act	aca	atg	gct	tca	ggc	ggt	ggc	624
Ala	Thr	Pro	Ala	Ala	Val	Gly	Pro	Thr	Thr	Met	Ala	Ser	Gly	Gly	Gly	
		195					200					205				
gca	cca	atg	gca	gac	aat	aac	gaa	ggc	gcc	gac	gga	gtg	ggt	aat	gcc	672
Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ala	
	210					215					220					
tca	gga	aat	tgg	cat	tgc	gat	tcc	aca	tgg	ctg	ggc	gac	aga	gtc	atc	720
Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	Ile	
225					230					235					240	
acc	acc	agc	acc	cgc	acc	tgg	gcc	ttg	ccc	acc	tac	aat	aac	cac	ctc	768
Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu	
				245					250					255		
tac	aag	caa	atc	tcc	agt	gct	tca	acg	ggg	gcc	agc	aac	gac	aac	cac	816
Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His	
		260						265					270			
tac	ttc	ggc	tac	agc	acc	ccc	tgg	ggg	tat	ttt	gat	ttc	aac	aga	ttc	864
Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	
		275					280					285				
cac	tgc	cac	ttt	tca	cca	cgt	gac	tgg	cag	cga	ctc	atc	aac	aac	aat	912
His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	
	290					295					300					
tgg	gga	ttc	cgg	ccc	aag	aga	ctc	aac	ttc	aaa	ctc	ttc	aac	atc	caa	960
Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln	
305					310					315				320		
gtc	aag	gag	gtc	acg	acg	aat	gat	ggc	gtc	aca	acc	atc	gct	aat	aac	1008
Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn	
				325					330				335			
ctt	acc	agc	acg	ggt	caa	gtc	ttc	tcg	gac	tcg	gag	tac	cag	ctt	ccg	1056

WO 00/28061

PCT/US99/25694

Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro	
340 345 350	
tac gtc ctc ggc tct gcg cac cag ggc tgc ctc cct ccg ttc ccg gcg	1104
Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala	
355 360 365	
gac gtg ttc atg att ccg caa tac ggc tac ctg acg ctc aac aat ggc	1152
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly	
370 375 380	
agc caa gcc gtg gga cgt tca tcc ttt tac tgc ctg gaa tat ttc cct	1200
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro	
385 390 395 400	
tct cag atg ctg aga acg ggc aac aac ttt acc ttc agc tac acc ttt	1248
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe	
405 410 415	
gag gaa gtg cct ttc cac agc agc tac gcg cac agc cag agc ctg gac	1296
Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp	
420 425 430	
cgg ctg atg aat cct ctc atc gac caa tac ctg tat tac ctg aac aga	1344
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg	
435 440 445	
act caa aat cag tcc gga agt gcc caa aac aag gac ttg ctg ttt agc	1392
Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser	
450 455 460	
cgt ggg tct cca gct ggc atg tct gtt cag ccc aaa aac tgg cta cct	1440
Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro	
465 470 475 480	
gga ccc tgt tat cgg cag cag cgc gtt tct aaa aca aaa aca gac aac	1488
Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn	
485 490 495	
aac aac agc aat ttt acc tgg act ggt gct tca aaa tat aac ctc aat	1536
Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn	
500 505 510	
ggg cgt gaa tcc atc atc aac cct ggc act gct atg gcc tca cac aaa	1584
Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys	
515 520 525	
gac gac gaa gac aag ttc ttt ccc atg agc ggt gtc atg att ttt gga	1632

WO 00/28061

PCT/US99/25694

Asp	Asp	Glu	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly	
530							535					540				
aaa	gag	agc	gcc	gga	gct	tca	aac	act	gca	ttg	gac	aat	gtc	atg	att	1680
Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile	
545					550					555					560	
aca	gac	gaa	gag	gaa	att	aaa	gcc	act	aac	cct	gtg	gcc	acc	gaa	aga	1728
Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg	
				565					570					575		
ttt	ggg	acc	gtg	gca	gtc	aat	ttc	cag	agc	agc	agc	aca	gac	cct	gcg	1776
Phe	Gly	Thr	Val	Ala	Val	Asn	Phe	Gln	Ser	Ser	Ser	Thr	Asp	Pro	Ala	
			580					585						590		
acc	gga	gat	gtg	cat	gct	atg	gga	gca	tta	cct	ggc	atg	gtg	tgg	caa	1824
Thr	Gly	Asp	Val	His	Ala	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	
		595					600					605				
gat	aga	gac	gtg	tac	ctg	cag	ggc	ccc	att	tgg	gcc	aaa	att	cct	cac	1872
Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	
	610					615					620					
aca	gat	gga	cac	ttt	cac	ccg	tct	cct	ctt	atg	ggc	ggc	ttt	gga	ctc	1920
Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	
625					630					635					640	
aag	aac	ccg	cct	cct	cag	atc	ctc	atc	aaa	aac	acg	cct	gtt	cct	gcg	1968
Lys	Asn	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	
			645						650					655		
aat	cct	ccg	gcg	gag	ttt	tca	gct	aca	aag	ttt	gct	tca	ttc	atc	acc	2016
Asn	Pro	Pro	Ala	Glu	Phe	Ser	Ala	Thr	Lys	Phe	Ala	Ser	Phe	Ile	Thr	
			660					665					670			
caa	tac	tcc	aca	gga	caa	gtg	agt	gtg	gaa	att	gaa	tgg	gag	ctg	cag	2064
Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	
			675				680					685				
aaa	gaa	aac	agc	aag	cgc	tgg	aat	ccc	gaa	gtg	cag	tac	aca	tcc	aat	2112
Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Val	Gln	Tyr	Thr	Ser	Asn	
	690					695					700					
tat	gca	aaa	tct	gcc	aac	gtt	gat	ttt	act	gtg	gac	aac	aat	gga	ctt	2160
Tyr	Ala	Lys	Ser	Ala	Asn	Val	Asp	Phe	Thr	Val	Asp	Asn	Asn	Gly	Leu	
705					710					715					720	
tat	act	gag	cct	cgc	ccc	att	ggc	acc	cgt	tac	ctt	acc	cgt	ccc	ctg	2208

WO 00/28061

PCT/US99/25694

Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu  
725 730 735

taa

2211

<210> 13

<211> 736

<212> PRT

<213> AAV-1

<400> 13

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
145 150 155 160

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
180 185 190

WO 00/28061

PCT/US99/25694

Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly		
195	200	205
Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala		
210	215	220
Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile		
225	230	235 240
Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu		
	245	250 255
Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His		
	260	265 270
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe		
	275	280 285
His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn		
	290	295 300
Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln		
305	310	315 320
Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn		
	325	330 335
Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro		
	340	345 350
Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala		
	355	360 365
Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly		
	370	375 380
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro		
385	390	395 400
Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe		
	405	410 415
Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp		
	420	425 430
Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg		
	435	440 445

$$\frac{1}{\Gamma(\alpha)} \int_0^t (t-\tau)^{\alpha-1} f(\tau) d\tau = I^\alpha f(t), \quad t \geq 0, \quad f(0) = 0.$$

**WO 00/28061**

**PCT/US99/25694**

Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser  
450 455 460

Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro  
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn  
485 490 495

Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn Leu Asn  
500 505 510

Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala Ser His Lys  
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Met Ile Phe Gly  
530 535 540

Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu Asp Asn Val Met Ile  
545 550 555 560

Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Arg  
565 570 575

Phe Gly Thr Val Ala Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala  
580 585 590

Thr Gly Asp Val His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln  
595 600 605

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His  
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu  
625 630 635 640

Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala  
645 650 655

Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr  
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln  
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn  
690 695 700

WO 00/28061

PCT/US99/25694

Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu  
705 710 715 720

Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu  
725 730 735

<210> 14

<211> 1800

<212> DNA

<213> AAV-1

<220>

<221> CDS

<222> (1)..(1797)

<400> 14

acg gct cct gga aag aaa cgt ccg gta gag cag tcg cca caa gag cca 48  
Thr Ala Pro Gly Lys Lys Arg Pro Val Glu Gln Ser Pro Gln Glu Pro  
1 5 10 15

gac tcc tcc tcg ggc atc ggc aag aca ggc cag cag ccc gct aaa aag 96  
Asp Ser Ser Ser Gly Ile Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys  
20 25 30

aga ctc aat ttt ggt cag act ggc gac tca gag tca gtc ccc gat cca 144  
Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu Ser Val Pro Asp Pro  
35 40 45

caa cct ctc gga gaa cct cca gca acc ccc gct gct gtg gga cct act 192  
Gln Pro Leu Gly Glu Pro Pro Ala Thr Pro Ala Ala Val Gly Pro Thr  
50 55 60

aca atg gct tca ggc ggt ggc gca cca atg gca gac aat aac gaa ggc 240  
Thr Met Ala Ser Gly Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly  
65 70 75 80

gcc gac gga gtg ggt aat gcc tca gga aat tgg cat tgc gat tcc aca 288  
Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr  
85 90 95

tgg ctg ggc gac aga gtc atc acc acc agc acc cgc acc tgg gcc ttg 336  
Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu  
100 105 110

ccc acc tac aat aac cac ctc tac aag caa atc tcc agt gct tca acg 384  
Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr  
115 120 125



WO 00/28061

PCT/US99/25694

ggg gcc agc aac gac aac cac tac ttc ggc tac agc acc ccc tgg ggg	432
Gly Ala Ser Asn Asp Asn His Tyr Phe Gly Tyr Ser Thr Pro Trp Gly	
130 135 140	
tat ttt gat ttc aac aga ttc cac tgc cac ttt tca cca cgt gac tgg	480
Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp	
145 150 155 160	
cag cga ctc atc aac aac aat tgg gga ttc cgg ccc aag aga ctc aac	528
Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn	
165 170 175	
ttc aaa ctc ttc aac atc caa gtc aag gag gtc acg acg aat gat ggc	576
Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Thr Asn Asp Gly	
180 185 190	
gtc aca acc atc gct aat aac ctt acc agc acg gtt caa gtc ttc tcg	624
Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Ser	
195 200 205	
gac tcg gag tac cag ctt ccg tac gtc ctc ggc tct gcg cac cag ggc	672
Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly	
210 215 220	
tgc ctc cct ccg ttc ccg gcg gac gtg ttc atg att ccg caa tac ggc	720
Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly	
225 230 235 240	
tac ctg acg ctc aac aat ggc agc caa gcc gtg gga cgt tca tcc ttt	768
Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe	
245 250 255	
tac tgc ctg gaa tat ttc cct tct cag atg ctg aga acg ggc aac aac	816
Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn	
260 265 270	
ttt acc ttc agc tac acc ttt gag gaa gtg cct ttc cac agc agc tac	864
Phe Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr	
275 280 285	
gcg cac agc cag agc ctg gac cgg ctg atg aat cct ctc atc gac caa	912
Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln	
290 295 300	
tac ctg tat tac ctg aac aga act caa aat cag tcc gga agt gcc caa	960
Tyr Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln	
305 310 315 320	

WO 00/28061

PCT/US99/25694

aac aag gac ttg ctg ttt agc cgt ggg tct cca gct ggc atg tct gtt	1008
Asn Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val	
325 330 335	
cag ccc aaa aac tgg cta cct gga ccc tgt tat cgg cag cag cgc gtt	1056
Gln Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val	
340 345 350	
tct aaa aca aaa aca gac aac aac aac agc aat ttt acc tgg act ggt	1104
Ser Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly	
355 360 365	
gct tca aaa tat aac ctc aat ggg cgt gaa tcc atc atc aac cct ggc	1152
Ala Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly	
370 375 380	
act gct atg gcc tca cac aaa gac gac gaa gac aag ttc ttt ccc atg	1200
Thr Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met	
385 390 395 400	
agc ggt gtc atg att ttt gga aaa gag agc gcc gga gct tca aac act	1248
Ser Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr	
405 410 415	
gca ttg gac aat gtc atg att aca gac gaa gag gaa att aaa gcc act	1296
Ala Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr	
420 425 430	
aac cct gtg gcc acc gaa aga ttt ggg acc gtg gca gtc aat ttc cag	1344
Asn Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln	
435 440 445	
agc agc agc aca gac cct gcg acc gga gat gtg cat gct atg gga gca	1392
Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala	
450 455 460	
tta cct ggc atg gtg tgg caa gat aga gac gtg tac ctg cag ggt ccc	1440
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro	
465 470 475 480	
att tgg gcc aaa att cct cac aca gat gga cac ttt cac ccg tct cct	1488
Ile Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro	
485 490 495	
ctt atg ggc ggc ttt gga ctc aag aac ccg cct cct cag atc ctc atc	1536
Leu Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile	
500 505 510	

WO 00/28061

PCT/US99/25694

aaa aac acg cct gtt cct gcg aat cct ccg gcg gag ttt tca gct aca 1584  
Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr  
515 520 525

aag ttt gct tca ttc atc acc caa tac tcc aca gga caa gtg agt gtg 1632  
Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val  
530 535 540

gaa att gaa tgg gag ctg cag aaa gaa aac agc aag cgc tgg aat ccc 1680  
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro  
545 550 555 560

gaa gtg cag tac aca tcc aat tat gca aaa tct gcc aac gtt gat ttt 1728  
Glu Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe  
565 570 575

act gtg gac aac aat gga ctt tat act gag cct cgc ccc att ggc acc 1776  
Thr Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr  
580 585 590

cgt tac ctt acc cgt ccc ctg taa 1800  
Arg Tyr Leu Thr Arg Pro Leu  
595

<210> 15  
<211> 599  
<212> PRT  
<213> AAV-1

<400> 15  
Thr Ala Pro Gly Lys Lys Arg Pro Val Glu Gln Ser Pro Gln Glu Pro  
1 5 10 15

Asp Ser Ser Ser Gly Ile Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys  
20 25 30

Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu Ser Val Pro Asp Pro  
35 40 45

Gln Pro Leu Gly Glu Pro Pro Ala Thr Pro Ala Ala Val Gly Pro Thr  
50 55 60

Thr Met Ala Ser Gly Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly  
65 70 75 80

Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr



WO 00/28061

PCT/US99/25694

340	345	350
Ser Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly		
355	360	365
Ala Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly		
370	375	380
Thr Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met		
385	390	395
Ser Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr		
405	410	415
Ala Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr		
420	425	430
Asn Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln		
435	440	445
Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala		
450	455	460
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro		
465	470	475
Ile Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro		
485	490	495
Leu Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile		
500	505	510
Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr		
515	520	525
Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val		
530	535	540
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro		
545	550	555
Glu Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe		
565	570	575
Thr Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr		
580	585	590
Arg Tyr Leu Thr Arg Pro Leu		



WO 00/28061

PCT/US99/25694

tcg gag tac cag ctt ccg tac gtc ctc ggc tct gcg cac cag ggc tgc	480
Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys	
145 150 155 160	
ctc cct ccg ttc ccg gcg gac gtg ttc atg att ccg caa tac ggc tac	528
Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr	
165 170 175	
ctg acg ctc aac aat ggc agc caa gcc gtg gga cgt tca tcc ttt tac	576
Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr	
180 185 190	
tgc ctg gaa tat ttc cct tct cag atg ctg aga acg ggc aac aac ttt	624
Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe	
195 200 205	
acc ttc agc tac acc ttt gag gaa gtg cct ttc cac agc agc tac gcg	672
Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala	
210 215 220	
cac agc cag agc ctg gac cgg ctg atg aat cct ctc atc gac caa tac	720
His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr	
225 230 235 240	
ctg tat tac ctg aac aga act caa aat cag tcc gga agt gcc caa aac	768
Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn	
245 250 255	
aag gac ttg ctg ttt agc cgt ggg tct cca gct ggc atg tct gtt cag	816
Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val Gln	
260 265 270	
ccc aaa aac tgg cta cct gga ccc tgt tat cgg cag cag cgc gtt tct	864
Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser	
275 280 285	
aaa aca aaa aca gac aac aac aac agc aat ttt acc tgg act ggt gct	912
Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala	
290 295 300	
tca aaa tat aac ctc aat ggg cgt gaa tcc atc atc aac cct ggc act	960
Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr	
305 310 315 320	
gct atg gcc tca cac aaa gac gac gaa gac aag ttc ttt ccc atg agc	1008
Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met Ser	
325 330 335	

WO 00/28061

PCT/US99/25694

ggt gtc atg att ttt gga aaa gag agc gcc gga gct tca aac act gca	1056
Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala	
340 345 350	
ttg gac aat gtc atg att aca gac gaa gag gaa att aaa gcc act aac	1104
Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn	
355 360 365	
cct gtg gcc acc gaa aga ttt ggg acc gtg gca gtc aat ttc cag agc	1152
Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln Ser	
370 375 380	
agc agc aca gac cct gcg acc gga gat gtg cat gct atg gga gca tta	1200
Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala Leu	
385 390 395 400	
cct ggc atg gtg tgg caa gat aga gac gtg tac ctg cag ggt ccc att	1248
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile	
405 410 415	
tgg gcc aaa att cct cac aca gat gga cac ttt cac ccg tct cct ctt	1296
Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu	
420 425 430	
atg ggc ggc ttt gga ctc aag aac ccg cct cct cag atc ctc atc aaa	1344
Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys	
435 440 445	
aac acg cct gtt cct gcg aat cct ccg gcg gag ttt tca gct aca aag	1392
Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys	
450 455 460	
ttt gct tca ttc atc acc caa tac tcc aca gga caa gtg agt gtg gaa	1440
Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu	
465 470 475 480	
att gaa tgg gag ctg cag aaa gaa aac agc aag cgc tgg aat ccc gaa	1488
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu	
485 490 495	
gtg cag tac aca tcc aat tat gca aaa tct gcc aac gtt gat ttt act	1536
Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr	
500 505 510	
gtg gac aac aat gga ctt tat act gag cct cgc ccc att ggc acc cgt	1584
Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg	
515 520 525	



WO 00/28061

PCT/US99/25694

tac ctt acc cgt ccc ctg taa  
Tyr Leu Thr Arg Pro Leu  
530

1605

<210> 17  
<211> 534  
<212> PRT  
<213> AAV-1

<400> 17

Met Ala Ser Gly Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala  
1 5 10 15

Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp  
20 25 30

Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro  
35 40 45

Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly  
50 55 60

Ala Ser Asn Asp Asn His Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr  
65 70 75 80

Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln  
85 90 95

Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe  
100 105 110

Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Thr Asn Asp Gly Val  
115 120 125

Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Ser Asp  
130 135 140

Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys  
145 150 155 160

Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr  
165 170 175

Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr  
180 185 190

WO 00/28061

PCT/US99/25694

Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe  
195 200 205

Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala  
210 215 220

His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr  
225 230 235 240

Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn  
245 250 255

Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val Gln  
260 265 270

Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser  
275 280 285

Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala  
290 295 300

Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr  
305 310 315 320

Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met Ser  
325 330 335

Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala  
340 345 350

Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn  
355 360 365

Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln Ser  
370 375 380

Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala Leu  
385 390 395 400

Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile  
405 410 415

Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu  
420 425 430

Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys  
435 440 445

WO 00/28061

PCT/US99/25694

Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys  
450 455 460

Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu  
465 470 475 480

Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu  
485 490 495

Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr  
500 505 510

Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg  
515 520 525

Tyr Leu Thr Arg Pro Leu  
530

<210> 18  
<211> 4681  
<212> DNA  
<213> aav-2

<400> 18  
ttggccaactc cctctctgcg cgcctcgcgcg ctcactgagg ccggggcgacc aaaggctcgcc 60  
cgacgcccgg gctttgcccc ggccggcctca gtgagcgagc gagcgcgagc agaggggagtg 120  
gccaactcca tcactagggg ttccctggagg ggtggagtcg tgacgtgaat tacgtcatag 180  
ggttagggag gtccctgtatt agaggctcacg tgagtgtttt gcgacatttt gcgacaccat 240  
gtggtcacgc tgggtattta agcccagagt agcacgcagg gtctccattt tgaagcggga 300  
ggtttgaacg cgcagccgcc atgccgggggt ttacgagat tgtgattaag gtccccagcg 360  
accttgacgg gcatctgcc ggcatctctg acagctttgt gaactgggtg gccgagaagg 420  
aatgggagtt gccgccagat tctgacatgg atctgaatct gattgagcag gcaccctga 480  
ccgtggccga gaagctgcag cgcgactttc tgacggaatg gcgccgtgtg agtaaggccc 540  
cggaggccct tttctttgtg caatttgaga agggagagag ctacttccac atgcacgtgc 600  
tcgtggaaac caccgggggtg aaatccatgg ttttgggacg ttccctgagt cagattcgcg 660  
aaaaactgat tcagagaatt taccgcggga tcgagccgac tttgccaaac tggttcgcg 720

WO 00/28061

PCT/US99/25694

tcacaaagac cagaaatggc gccggaggcg ggaacaaggt ggtggatgag tgctacatcc 780  
ccaattactt gctccccaaa acccagcctg agctccagtg ggcgtggact aatatggaac 840  
agtattttaag cgectgtttg aatctcacgg agcgtaaacg gttggtggcg cagcatctga 900  
cgcacgtgtc gcagacgcag gagcagaaca aagagaatca gaatcccaat tctgatgcgc 960  
cggatgatcag atcaaaaact tcagccaggt acatggagct ggtcgggtgg ctctgtggaca 1020  
aggggattac ctgggagaag cagtggatcc aggaggacca ggctcctac atctccttca 1080  
atgcggcctc caactcgcgg tcccaaatca aggctgcctt ggacaatgcg ggaaagatta 1140  
tgagcctgac taaaaccgcc cccgactacc tgggtgggcca gcagcccgctg gaggacattt 1200  
ccagcaatcg gatattataaa attttggaac taaacgggta cgatccccaa tatgcggctt 1260  
ccgtctttct gggatgggcc acgaaaaagt tcggcaagag gaacaccatc tggctgtttg 1320  
ggcctgcaac taccgggaag accaaccatc cgagggccat agcccacact gtgcccttct 1380  
acgggtgcgt aaactggacc aatgagaact ttccttcaa cgactgtgtc gacaagatgg 1440  
tgatctggtg ggaggagggg aagatgaccg ccaaggctcg ggagtcggcc aaagccattc 1500  
tcggaggaag caaggtgcgc gtggaccaga aatgcaagtc ctgggccag atagaccga 1560  
ctcccgatg cgtcacctcc aacaccaaca tgtgcgccgt gattgacggg aactcaacga 1620  
ccttcgaaca ccagcagccg ttgcaagacc ggatgttcaa atttgaactc acccgccgtc 1680  
tgatcatga ctttgggaag gtcaccaagc aggaagtcaa agactttttc cgggtgggcaa 1740  
aggatcacgt ggttgagggt gagcatgaat tctacgtcaa aaaggggtga gccaaagaaa 1800  
gacccgcccc cagtgcgcga gatataagt agcccaaacg ggtgcgcgag tcagttgcgc 1860  
agccatcgac gtcagacgcg gaagcttcga tcaactacgc agacaggtag caaaacaaat 1920  
gttctcgtca cgtgggcatg aatctgatgc tgtttccctg cagacaatgc gagagaatga 1980  
atcagaattc aaatatctgc ttcactcacg gacagaaaga ctgttttagag tgctttcccg 2040  
tgtcagaatc tcaaccggtt tctgtcgtca aaaaggcgta tcagaaactg tgctacattc 2100  
atcatatcat gggaaaggtg ccagacgctt gcactgcctg cgatctggtc aatgtggatt 2160

WO 00/28061

PCT/US99/25694

tggatgactg catctttgaa caataaatga tttaaatacag gtatggctgc cgatgggttat 2220  
 cttccagatt ggctcgagga cactctctct gaaggaataa gacagtgggtg gaagctcaaa 2280  
 cctggccac caccaccaa gcccgagag cggcataagg acgacagcag gggctctgtg 2340  
 cttcctgggt acaagtacct cggaccttc aacggactcg acaagggaga gccggtcaac 2400  
 gaggcagacg ccgcggccct cgagcacgac aaagcctacg accggcagct cgacagcggg 2460  
 gacaaccctg acctcaagta caaccacgcc gacgcggagt ttcaggagcg ccttaaagaa 2520  
 gatacgtctt ttgggggcaa cctcggacga gcagtcttcc aggcgaaaaa gagggttctt 2580  
 gaacctctcg gcctgggtga ggaacctgtt aagacggctc cgggaaaaaa gaggccggta 2640  
 gagcactctc ctgtggagcc agactcctcc tcgggaaccg gaaagccggg ccagcagcct 2700  
 gcaagaaaaa gattgaattt tggtcagact ggagacgcag actcagtacc tgacccccag 2760  
 cctctcggac agccaccagc agccccctct ggtctgggaa ctaatacgat ggctacaggc 2820  
 agtggcgcac caatggcaga caataacgag ggcgccgacg gagtgggtaa ttcctccgga 2880  
 aattggcatt gcgattccac atggatgggc gacagagtca tcaccaccag caccogaacc 2940  
 tgggccctgc ccacctaaa caaccacctc tacaacaaa ttccagcca atcaggagcc 3000  
 tcgaacgaca atcactactt tggctacagc accccttggg ggtattttga cttcaacaga 3060  
 ttccactgcc acttttcacc acgtgactgg caaagactca tcaacaacaa ctggggattc 3120  
 cgacccaaga gactcaactt caacctcttt aacattcaag tcaaagaggt cagcagaat 3180  
 gacggtagca cgacgattgc caataacctt accagcacgg ttcagggtgt tactgactcg 3240  
 gagtaccagc tcccgtacgt cctcggctcg gcgcataag gatgcctccc gccgttccca 3300  
 gcagacgtct tcatgggtgc acagtatgga tacctcacc tgaacaacgg gagtcaggca 3360  
 gtaggacgct cttcatttta ctgcctggag tactttcctt ctcagatgct gcgtaccgga 3420  
 aacaacttta ccttcagcta cacttttgag gacgttcctt tccacagcag ctacgtcac 3480  
 agccagagtc tggaccgtct catgaatcct ctcacgacc agtacctgta ttacttgagc 3540  
 agaacaacaa ctccaagtgg aaccaccacg cagtcaaggc ttcagttttc tcaggcccca 3600

WO 00/28061

PCT/US99/25694

gccagtgaca ttccgggacca gtctaggaac tggcttcctg gaccctgtta ccgccagcag 3660  
 cgagtatgaa agacatctgc ggataacaac aacagtgaat actcgtggac tggagctacc 3720  
 aagtaccacc tcaatggcag agactctctg gtgaatccgg ggcccggccat ggcaagccac 3780  
 aaggacgatg aagaaaagtt ttttctcag agcgggggttc tcattcttgg gaagcaaggc 3840  
 tcagagaaaa caaatgtgaa cattgaaaag gtcattgatta cagacgaaga ggaaatccca 3900  
 acaaccaatc ccgtgggtac ggagcagtat ggttctgtat ctaccaacct ccagagaggc 3960  
 aacagacaag cagctaccgc agatgtcaac acacaaggcg ttcttccagg catgggtctg 4020  
 caggacagag atgtgtacct tcagggggccc atctgggcaa agattccaca cacggacgga 4080  
 cattttcacc cctctccctt catgggtgga ttccgactta aacaccctcc tccacagatt 4140  
 ctcatcaaga acaccccggt acctgcgaat ccttcgacca ccttcagtgc ggcaaagttt 4200  
 gcttccttca tcacacagta ctccacggga cacggtcagc gtggagatcg agtgggagct 4260  
 gcagaacgaa aacagcaaac gctggaatcc cgaaattcag tacacttcca actacaacaa 4320  
 gtctgttaat cgtggacttt accgtggata ctaatggcgt gtattcagag cctcgcccca 4380  
 ttggcaccag atacctgact cgtaatctgt aattgcttgt taatcaataa accgtttaat 4440  
 tcgtttcagt tgaactttgg tctctgcgta tttctttctt atctagtttc catggctacg 4500  
 tagataagta gcatggcggg ttaatcatta actacaagga acccctagtg atggagttag 4560  
 ccactccctc tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag gtcgcccgcg 4620  
 gcccggtt tgccccggcg gcctcagtga gcgagcgagc gcgagagag ggagtgggca 4680  
 a 4681

<210> 19

<211> 4683

<212> DNA

<213> aav-6

<400> 19

ttggccactc cctctctgcg cgctcgctcg ctactgagg ccgggcgacc aaaggtcgcc 60

WO 00/28061

PCT/US99/25694

cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgagc agagggagtg 120  
gccaactcca tcactagggg ttectggagg ggtggagtcg tgacgtgaat tacgtcatag 180  
ggttagggag gtectgtatt agaggtcacg tgagtgtttt gcgacatttt gcgacaccat 240  
gtggtcacgc tgggtattta agcccagagt agcacgcagg gtctccattt tgaagcggga 300  
ggtttgaacg cgcagcgcca tgccgggggt ttacgagatt gtgattaagg tcccagcgga 360  
ccttgacgag catctgcccg gcatttctga cagctttgtg aactgggttg ccgagaagga 420  
atgggagttg ccgccagatt ctgacatgga tctgaatctg attgagcagg caccctgac 480  
cgtggccgag aagctgcagc gcgacttctt ggtccactgg cggcgctga gtaaggcccc 540  
ggaggccctc ttctttgttc agttcgagaa gggcgagtcc tacttccacc tccatattct 600  
ggtggagacc acgggggtca aatccatggt gctgggcccg ttectgagtc agattagcga 660  
caagctggtg cagaccatct accgcgggat cgagccgacc ctgcccactt ggttcgcggt 720  
gaccaagacg cgtaatggcg ccggaggggg gaacaagggt gtggacgagt gctacatccc 780  
caactacctc ctgcccaga ctcagccoga gctgcagtgg gcgtggacta acatggagga 840  
gtatataagc gcgtgtttta acctggccga gcgcaaacgg ctgctggcgc acgacctgac 900  
ccacgtcagc cagaccagag agcagaacaa ggagaatctg aaccccaatt ctgacgcgcc 960  
tgtcatccgg tcaaaaacct ccgcacgcta catggagctg gtcgggtggc tgggtggaccg 1020  
gggcatcacc tccgagaagc agtggatcca ggaggaccag gcctcgtaaa tctccttcaa 1080  
cgccgcctcc aactcgcggt ccagatcaa ggcgctctg gacaatgccg gcaagatcat 1140  
ggcgctgacc aaatccgcgc ccgactacct ggtaggcccc gctccgcccg ccgacattaa 1200  
aaccaaccgc atttaccgca tectggagct gaacggctac gacctgcct acgccggctc 1260  
cgtctttctc ggctgggccc agaaaagggt cggaaaacgc aacaccatct ggtgttttgg 1320  
gccggccacc acgggcaaga ccaacatcgc ggaagccatc gccacgccg tgcccttcta 1380  
cggctgcgtc aactggacca atgagaactt tcccttcaac gattgcgtcg acaagatggt 1440  
gatctgggtg gaggagggca agatgacggc caaggctcgt gagtccgcca aggccattct 1500

WO 00/28061

PCT/US99/25694

cggcggcagc aaggtgcgcg tggaccaaaa gtgcaagtcg tccgcccaga tcgatccac 1560  
 ccccgatgac gtcacctcca acaccaacat gtgcgcgcgtg attgacggga acagcaccac 1620  
 cttegagcac cagcagccgt tgcaggaccg gatgttcaaa tttgaactca cccgccgtct 1680  
 ggagcatgac tttggcaagg tgacaaagca ggaagtcaaa gagttcttcc gctgggagca 1740  
 ggatcacgtg accgaggtgg cgcattgagtt ctacgtcaga aagggtggag ccaacaacag 1800  
 acccgcccc gatgacgcgg ataaaagcga gcccaagcgg gcctgcccct cagtcgcgga 1860  
 tccatcgacg tcagacgcgg aaggagctcc ggtggacttt gccgacaggt accaaaacaa 1920  
 atgttctcgt cagcggggca tgcttcagat gctgtttccc tgcaaacat gcgagagaat 1980  
 gaatcagaat ttcaacattt gcttcacgca cgggaccaga gactgttcag aatgtttccc 2040  
 cggcgtgtca gaatctcaac cggtcgtcag aaagaggacg tateggaaac tctgtgccat 2100  
 tcatcatctg ctggggcggg ctcccagat tgcttgctcg gcctgcgac tggtcaacgt 2160  
 ggatctggat gactgtgttt ctgagcaata aatgacttaa accaggtatg gctgccgatg 2220  
 gttatcttcc agattggctc gaggacaacc tctctgaggg cattcggcag tgggtgggact 2280  
 tgaaacctgg agccccgaaa cccaaagcca accagcaaaa gcaggacgac ggccgggggtc 2340  
 tgggtgcttcc tggctacaag tacctcggac ccttcaacgg actcgacaag ggggagccccg 2400  
 tcaacgcggc ggatgcagcg gccctcgagc acgacaaggc ctacgaccag cagctcaaag 2460  
 cgggtgacaa tccgtacctg cggataaacc acgccgacgc cgagtttcag gagegtctgc 2520  
 aagaagatac gtcttttggg ggcaacctcg ggcgagcagt ctccaggcc aagaagaggg 2580  
 ttctcgaacc ttttgggtctg gttgaggaag gtgctaagac ggctcctgga aagaaacgtc 2640  
 cggtagagca gtcgccacaa gagccagact cctcctcggg cattggcaag acaggccagc 2700  
 agcccgttaa aaagagactc aattttggtc agactggcga ctacagagtca gtccccgacc 2760  
 cacaacctct cggagaacct ccagcaacct ccgctgctgt gggacctact acaatggctt 2820  
 caggcggtgg cgcaccaatg gcagacaata acgaaggcgc cgacggagtg ggtaatgcct 2880  
 caggaaattg gcattgcgat tccacatggc tgggcgacag agtcaccacc accagcacc 2940



WO 00/28061

PCT/US99/25694

gaacatgggc cttgcccacc tataacaacc acctctacaa gcaaattctcc agtgcttcaa 3000  
 cggggggccag caacgacaac cactacttcg gctacagcac cccttggggg tatttttgatt 3060  
 tcaacagatt ccactgccat ttctcaccac gtgactggca gcgactcatc aacaacaatt 3120  
 ggggattccg gcccaagaga ctcaacttca agctcttcaa catccaagtc aaggagggtca 3180  
 cgacgaatga tggcgtcacg accatcgcta ataaccttac cagcacgggt caagtcttgt 3240  
 cggactcgga gtaccagttc ccgtacgtcc tgggtctctgc gcaccagggc tgcctccctc 3300  
 cgttcccggc ggacgtgttc atgattccgc agtacggcta cctaacgctc aacaatggca 3360  
 gccaggcagt gggacgctca tccttttact gcctggaata tttcccatcg cagatgctga 3420  
 gaacgggcaa taactttacc ttcagctaca ctttcgagga cgtgcctttc cacagcagct 3480  
 acgcgcacag ccagagcctg gaccgggtga tgaatcctct catcgaccag tacctgtatt 3540  
 acctgaacag aactcacaat cagtccggaa gtgccccaaa caaggacttg ctgttttagcc 3600  
 gtgggtctcc agctggcatg tctgttcagc ccaaaaactg gctacctgga ccctgttacc 3660  
 ggcagcagcg cgttttctaaa acaaaaacag acaacaacaa cagcaacttt acctggactg 3720  
 gtgcttcaaa atataacctt aatgggcgtg aatctataat caaccctggc actgctatgg 3780  
 cctcacacaa agacgacaaa gacaagttct tcccatgag cgggtgtcatg atttttggaa 3840  
 aggagagcgc cggagcttca aacactgcat tggacaatgt catgatcaca gacgaagagg 3900  
 aatcaaagc cactaacccc gtggccaccg aaagatttgg gactgtggca gtcaatctcc 3960  
 agagcagcag cacagaccct gcgaccggag atgtgcatgt tatgggagcc ttacctggaa 4020  
 tgggtgtggca agacagagac gtatacctgc agggtcctat ttgggccaaa attcctcaca 4080  
 cggatggaca ctttcacccg tctcctctca tgggcggctt tggacttaag caccgcctc 4140  
 ctcagatcct catcaaaaac acgcctgttc ctgcgaatcc tccggcagag ttttcggcta 4200  
 caaagtttgc ttcattcatc acccagtatt ccacaggaca agtgagcgtg gagattgaat 4260  
 gggagctgca gaaagaaaac agcaaacgct ggaatccga agtgacgtat acatctaact 4320  
 atgcaaaatc tgccaacggt gatttcactg tggacaacaa tggactttat actgagcctc 4380





gat tct gac atg gat ctg aat ctg att gag cag gca ccc ctg acc gtg Asp Ser Asp Met Asp Leu Asn Leu Ile Glu Gln Ala Pro Leu Thr Val 40 45 50 55	499
gcc gag aag ctg cag cgc gac ttc ctg gtc caa tgg cgc cgc gtg agt Ala Glu Lys Leu Gln Arg Asp Phe Leu Val Gln Trp Arg Arg Val Ser 60 65 70	547
aag gcc ccg gag gcc ctc ttc ttt gtt cag ttc gag aag ggc gag tcc Lys Ala Pro Glu Ala Leu Phe Phe Val Gln Phe Glu Lys Gly Glu Ser 75 80 85	595
tac ttc cac ctc cat att ctg gtg gag acc acg ggg gtc aaa tcc atg Tyr Phe His Leu His Ile Leu Val Glu Thr Thr Gly Val Lys Ser Met 90 95 100	643
gtg ctg ggc cgc ttc ctg agt cag att agg gac aag ctg gtg cag acc Val Leu Gly Arg Phe Leu Ser Gln Ile Arg Asp Lys Leu Val Gln Thr 105 110 115	691
atc tac cgc ggg atc gag ccg acc ctg ccc aac tgg ttc gcg gtg acc Ile Tyr Arg Gly Ile Glu Pro Thr Leu Pro Asn Trp Phe Ala Val Thr 120 125 130 135	739
aag acg cgt aat ggc gcc gga ggg ggg aac aag gtg gtg gac gag tgc Lys Thr Arg Asn Gly Ala Gly Gly Asn Lys Val Val Asp Glu Cys 140 145 150	787
tac atc ccc aac tac ctc ctg ccc aag act cag ccc gag ctg cag tgg Tyr Ile Pro Asn Tyr Leu Leu Pro Lys Thr Gln Pro Glu Leu Gln Trp 155 160 165	835
gcg tgg act aac atg gag gag tat ata agc gcc tgt ttg aac ctg gcc Ala Trp Thr Asn Met Glu Glu Tyr Ile Ser Ala Cys Leu Asn Leu Ala 170 175 180	883
gag cgc aaa cgg ctc gtg gcg cag cac ctg acc cac gtc agc cag acc Glu Arg Lys Arg Leu Val Ala Gln His Leu Thr His Val Ser Gln Thr 185 190 195	931
cag gag cag aac aag gag aat ctg aac ccc aat tct gac gcg cct gtc Gln Glu Gln Asn Lys Glu Asn Leu Asn Pro Asn Ser Asp Ala Pro Val 200 205 210 215	979
atc cgg tca aaa acc tcc gcg cgc tac atg gag ctg gtc ggg tgg ctg Ile Arg Ser Lys Thr Ser Ala Arg Tyr Met Glu Leu Val Gly Trp Leu 220 225 230	1027
gtg gac cgg ggc atc acc tcc gag aag cag tgg atc cag gag gac cag Val Asp Arg Gly Ile Thr Ser Glu Lys Gln Trp Ile Gln Glu Asp Gln 235 240 245	1075
gcc tcg tac atc tcc ttc aac gcc gct tcc aac tcg cgg tcc cag atc Ala Ser Tyr Ile Ser Phe Asn Ala Ala Ser Asn Ser Arg Ser Gln Ile 250 255 260	1123
aag gcc gct ctg gac aat gcc ggc aag atc atg gcg ctg acc aaa tcc Lys Ala Ala Leu Asp Asn Ala Gly Lys Ile Met Ala Leu Thr Lys Ser 265 270 275	1171

gcg Ala 280	ccc Pro	gac Asp	tac Tyr	ctg Leu	gta Val 285	ggc Gly	ccc Pro	gct Ala	ccg Pro	ccc Pro 290	gcg Ala	gac Asp	att Ile	aaa Lys	acc Thr 295	1219
aac Asn	cgc Arg	atc Ile	tac Tyr	cgc Arg 300	atc Ile	ctg Leu	gag Glu	ctg Leu	aac Asn 305	ggc Gly	tac Tyr	gaa Glu	cct Pro	gcc Ala 310	tac Tyr	1267
gcc Ala	ggc Gly	tcc Ser	gtc Val 315	ttt Phe	ctc Leu	ggc Gly	tgg Trp	gcc Ala 320	cag Gln	aaa Lys	agg Arg	ttc Phe	ggg Gly 325	aag Lys	cgc Arg	1315
aac Asn	acc Thr	atc Ile 330	tgg Trp	ctg Leu	ttt Phe	ggg Gly	ccg Pro 335	gcc Ala	acc Thr	acg Thr	ggc Gly	aag Lys 340	acc Thr	aac Asn	atc Ile	1363
gcg Ala 345	gaa Glu	gcc Ala	atc Ile	gcc Ala	cac His	gcc Ala 350	gtg Val	ccc Pro	ttc Phe	tac Tyr	ggc Gly 355	tgc Cys	gtc Val	aac Asn	tgg Trp	1411
acc Thr 360	aat Asn	gag Glu	aac Asn	ttt Phe	ccc Pro 365	ttc Phe	aat Asn	gat Asp	tgc Cys	gtc Val 370	gac Asp	aag Lys	atg Met	gtg Val	atc Ile 375	1459
tgg Trp	tgg Trp	gag Glu	gag Glu	ggc Gly 380	aag Lys	atg Met	acg Thr	gcc Ala	aag Lys 385	gtc Val	gtg Val	gag Glu	tcc Ser	gcc Ala 390	aag Lys	1507
gcc Ala	att Ile	ctc Leu	ggc Gly 395	ggc Gly	agc Ser	aag Lys	gtg Val	cgc Arg 400	gtg Val	gac Asp	caa Gln	aag Lys	tgc Cys 405	aag Lys	tcg Ser	1555
tcc Ser	gcc Ala	cag Gln 410	atc Ile	gac Asp	ccc Pro	acc Thr	ccc Pro 415	gtg Val	atc Ile	gtc Val	acc Thr	tcc Ser 420	aac Asn	acc Thr	aac Asn	1603
atg Met	tgc Cys 425	gcc Ala	gtg Val	att Ile	gac Asp	ggg Gly 430	aac Asn	agc Ser	acc Thr	acc Thr	ttc Phe 435	gag Glu	cac His	cag Gln	cag Gln	1651
ccg Pro 440	ttg Leu	cag Gln	gac Asp	cgg Arg	atg Met 445	ttc Phe	aaa Lys	ttt Phe	gaa Glu	ctc Leu 450	acc Thr	cgc Arg	cgt Arg	ctg Leu	gag Glu 455	1699
cat His	gac Asp	ttt Phe	ggc Gly	aag Lys 460	gtg Val	aca Thr	aag Lys	cag Gln	gaa Glu 465	gtc Val	aaa Lys	gag Glu	ttc Phe	ttc Phe 470	cgc Arg	1747
tgg Trp	gcg Ala	cag Gln	gat Asp 475	cac His	gtg Val	acc Thr	gag Glu	gtg Val 480	gcg Ala	cat His	gag Glu	ttc Phe	tac Tyr 485	gtc Val	aga Arg	1795
aag Lys	ggt Gly	gga Gly 490	gcc Ala	aac Asn	aaa Lys	aga Arg	ccc Pro 495	gcc Ala	ccc Pro	gat Asp	gac Asp	gcg Ala 500	gat Asp	aaa Lys	agc Ser	1843
gag Glu	ccc Pro 505	aag Lys	cgg Arg	gcc Ala	tgc Cys	ccc Pro 510	tca Ser	gtc Val	gcg Ala	gat Asp	cca Pro 515	tcg Ser	acg Thr	tca Ser	gac Asp	1891

gcg gaa gga gct ccg gtg gac ttt gcc gac agg tac caa aac aaa tgt Ala Glu Gly Ala Pro Val Asp Phe Ala Asp Arg Tyr Gln Asn Lys Cys 520 525 530 535	1939
tct cgt cac gcg ggc atg ctt cag atg ctg ttt ccc tgc aag aca tgc Ser Arg His Ala Gly Met Leu Gln Met Leu Phe Pro Cys Lys Thr Cys 540 545 550	1987
gag aga atg aat cag aat ttc aac att tgc ttc acg cac ggg acg aga Glu Arg Met Asn Gln Asn Phe Asn Ile Cys Phe Thr His Gly Thr Arg 555 560 565	2035
gac tgt tca gag tgc ttc ccc ggc gtg tca gaa tct caa ccg gtc gtc Asp Cys Ser Glu Cys Phe Pro Gly Val Ser Glu Ser Gln Pro Val Val 570 575 580	2083
aga aag agg acg tat cgg aaa ctc tgt gcc att cat cat ctg ctg ggg Arg Lys Arg Thr Tyr Arg Lys Leu Cys Ala Ile His His Leu Leu Gly 585 590 595	2131
cgg gct ccc gag att gct tgc tcg gcc tgc gat ctg gtc aac gtg gac Arg Ala Pro Glu Ile Ala Cys Ser Ala Cys Asp Leu Val Asn Val Asp 600 605 610 615	2179
ctg gat gac tgt gtt tct gag caa taa atgacttaaa ccagggt atg gct gcc Leu Asp Asp Cys Val Ser Glu Gln Met Ala Ala 620 625	2231
gat ggt tat ctt cca gat tgg ctc gag gac aac ctc tct gag ggc att Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser Glu Gly Ile 630 635 640	2279
cgc gag tgg tgg gac ttg aaa cct gga gcc ccg aag ccc aaa gcc aac Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro Lys Ala Asn 645 650 655	2327
cag caa aag cag gac gac ggc cgg ggt ctg gtg ctt cct ggc tac aag Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro Gly Tyr Lys 660 665 670	2375
tac ctc gga ccc ttc aac gga ctc gac aag ggg gag ccc gtc aac gcg Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro Val Asn Ala 675 680 685 690	2423
gcg gac gca gcg gcc ctc gag cac gac aag gcc tac gac cag cag ctc Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp Gln Gln Leu 695 700 705	2471
aaa gcg ggt gac aat ccg tac ctg cgg tat aac cac gcc gac gcc gag Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala Asp Ala Glu 710 715 720	2519
ttt cag gag cgt ctg caa gaa gat acg tct ttt ggg ggc aac ctc ggg Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly Asn Leu Gly 725 730 735	2567
cga gca gtc ttc cag gcc aag aag cgg gtt ctc gaa cct ctc ggt ctg Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Leu Gly Leu 740 745 750	2615

gtt gag gaa ggc gct aag acg gct cct gga aag aaa cgt ccg gta gag Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg Pro Val Glu 755 760 765 770	2663
cag tcg cca caa gag cca gac tcc tcc tcg ggc atc ggc aag aca ggc Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly Lys Thr Gly 775 780 785	2711
cag cag ccc gct aaa aag aga ctc aat ttt ggt cag act ggc gac tca Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser 790 795 800	2759
gag tca gtc ccc gat cca caa cct ctc gga gaa cct cca gca acc ccc Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Thr Pro 805 810 815	2807
gct gct gtg gga cct act aca atg gct tca ggc ggt ggc gca cca atg Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly Ala Pro Met 820 825 830	2855
gca gac aat aac gaa ggc gcc gac gga gtg ggt aat gcc tca gga aat Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn 835 840 845 850	2903
tgg cat tgc gat tcc aca tgg ctg ggc gac aga gtc atc acc acc agc Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser 855 860 865	2951
acc cgc acc tgg gcc ttg ccc acc tac aat aac cac ctc tac aag caa Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln 870 875 880	2999
atc tcc agt gct tca acg ggg gcc agc aac gac aac cac tac ttc ggc Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His Tyr Phe Gly 885 890 895	3047
tac agc acc ccc tgg ggg tat ttt gat ttc aac aga ttc cac tgc cac Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His 900 905 910	3095
ttt tca cca cgt gac tgg cag cga ctc atc aac aac aat tgg gga ttc Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe 915 920 925 930	3143
cgg ccc aag aga ctc aac ttc aaa ctc ttc aac atc caa gtc aag gag Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu 935 940 945	3191
gtc acg acg aat gat ggc gtc aca acc atc gct aat aac ctt acc agc Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser 950 955 960	3239
acg gtt caa gtc ttc tcg gac tcg gag tac cag ctt ccg tac gtc ctc Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu 965 970 975	3287
ggc tct gcg cac cag ggc tgc ctc cct ccg ttc ccg gcg gac gtg ttc Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe 980 985 990	3335

atg att ccg caa tac ggc	tac ctg acg ctc aac	aat ggc agc caa	3380
Met Ile Pro Gln Tyr Gly	Tyr Leu Thr Leu Asn	Asn Gly Ser Gln	
995	1000	1005	
gcc gtg gga cgt tca tcc	ttt tac tgc ctg gaa	tat ttc cct tct	3425
Ala Val Gly Arg Ser Ser	Phe Tyr Cys Leu Glu	Tyr Phe Pro Ser	
1010	1015	1020	
cag atg ctg aga acg ggc	aac aac ttt acc ttc	agc tac acc ttt	3470
Gln Met Leu Arg Thr Gly	Asn Asn Phe Thr Phe	Ser Tyr Thr Phe	
1025	1030	1035	
gag gaa gtg cct ttc cac	agc agc tac gcg cac	agc cag agc ctg	3515
Glu Glu Val Pro Phe His	Ser Ser Tyr Ala His	Ser Gln Ser Leu	
1040	1045	1050	
gac cgg ctg atg aat cct	ctc atc gac caa tac	ctg tat tac ctg	3560
Asp Arg Leu Met Asn Pro	Leu Ile Asp Gln Tyr	Leu Tyr Tyr Leu	
1055	1060	1065	
aac aga act caa aat cag	tcc gga agt gcc caa	aac aag gac ttg	3605
Asn Arg Thr Gln Asn Gln	Ser Gly Ser Ala Gln	Asn Lys Asp Leu	
1070	1075	1080	
ctg ttt agc cgt ggg tct	cca gct ggc atg tct	gtt cag ccc aaa	3650
Leu Phe Ser Arg Gly Ser	Pro Ala Gly Met Ser	Val Gln Pro Lys	
1085	1090	1095	
aac tgg cta cct gga ccc	tgt tat cgg cag cag	cgc gtt tct aaa	3695
Asn Trp Leu Pro Gly Pro	Cys Tyr Arg Gln Gln	Arg Val Ser Lys	
1100	1105	1110	
aca aaa aca gac aac aac	aac agc aat ttt acc	tgg act ggt gct	3740
Thr Lys Thr Asp Asn Asn	Asn Ser Asn Phe Thr	Trp Thr Gly Ala	
1115	1120	1125	
tca aaa tat aac ctc aat	ggg cgt gaa tcc atc	atc aac cct ggc	3785
Ser Lys Tyr Asn Leu Asn	Gly Arg Glu Ser Ile	Ile Asn Pro Gly	
1130	1135	1140	
act gct atg gcc tca cac	aaa gac gac gaa gac	aag ttc ttt ccc	3830
Thr Ala Met Ala Ser His	Lys Asp Asp Glu Asp	Lys Phe Phe Pro	
1145	1150	1155	
atg agc ggt gtc atg att	ttt gga aaa gag agc	gcc gga gct tca	3875
Met Ser Gly Val Met Ile	Phe Gly Lys Glu Ser	Ala Gly Ala Ser	
1160	1165	1170	
aac act gca ttg gac aat	gtc atg att aca gac	gaa gag gaa att	3920
Asn Thr Ala Leu Asp Asn	Val Met Ile Thr Asp	Glu Glu Glu Ile	
1175	1180	1185	
aaa gcc act aac cct gtg	gcc acc gaa aga ttt	ggg acc gtg gca	3965
Lys Ala Thr Asn Pro Val	Ala Thr Glu Arg Phe	Gly Thr Val Ala	
1190	1195	1200	
gtc aat ttc cag agc agc	agc aca gac cct gcg	acc gga gat gtg	4010
Val Asn Phe Gln Ser Ser	Ser Thr Asp Pro Ala	Thr Gly Asp Val	
1205	1210	1215	



cat	gct	atg	gga	gca	tta	cct	ggc	atg	gtg	tgg	caa	gat	aga	gac	4055
His	Ala	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	Asp	Arg	Asp	
1220					1225					1230					
gtg	tac	ctg	cag	ggt	ccc	att	tgg	gcc	aaa	att	cct	cac	aca	gat	4100
Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	Thr	Asp	
1235					1240					1245					
gga	cac	ttt	cac	ccg	tct	cct	ctt	atg	ggc	ggc	ttt	gga	ctc	aag	4145
Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	Lys	
1250					1255					1260					
aac	ccg	cct	cct	cag	atc	ctc	atc	aaa	aac	acg	cct	gtt	cct	gcg	4190
Asn	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	
1265					1270					1275					
aat	cct	ccg	gcg	gag	ttt	tca	gct	aca	aag	ttt	gct	tca	ttc	atc	4235
Asn	Pro	Pro	Ala	Glu	Phe	Ser	Ala	Thr	Lys	Phe	Ala	Ser	Phe	Ile	
1280					1285					1290					
acc	caa	tac	tcc	aca	gga	caa	gtg	agt	gtg	gaa	att	gaa	tgg	gag	4280
Thr	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	
1295					1300					1305					
ctg	cag	aaa	gaa	aac	agc	aag	cgc	tgg	aat	ccc	gaa	gtg	cag	tac	4325
Leu	Gln	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Val	Gln	Tyr	
1310					1315					1320					
aca	tcc	aat	tat	gca	aaa	tct	gcc	aac	gtt	gat	ttt	act	gtg	gac	4370
Thr	Ser	Asn	Tyr	Ala	Lys	Ser	Ala	Asn	Val	Asp	Phe	Thr	Val	Asp	
1325					1330					1335					
aac	aat	gga	ctt	tat	act	gag	cct	cgc	ccc	att	ggc	acc	cgt	tac	4415
Asn	Asn	Gly	Leu	Tyr	Thr	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	
1340					1345					1350					
ctt	acc	cgt	ccc	ctg	taattacgtg	ttaatcaata	aaccggttga	ttcgtttcag							4470
Leu	Thr	Arg	Pro	Leu											
1355															
ttgaactttg	gtctcctgtc	cttcttatct	tatcggttac	catggttata	gcttacacat										4530
taactgcttg	gttgcgcttc	gcgataaaag	acttacgtca	tcgggttacc	cctagtgatg										4590
gagttgcca	ctccctctct	gcgcgctcgc	tcgctcggtg	gggcctgcgg	accaaaggtc										4650
cgcagacggc	agagctctgc	tctgccggcc	ccaccgagcg	agcgagcgcg	cagagaggga										4710
gtgggcaa															4718

<210> 2  
 <211> 623  
 <212> PRT  
 <213> AAV-1

<400> 2  
 Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp  
 1 5 10 15

Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu  
 20 25 30  
 Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile  
 35 40 45  
 Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu  
 50 55 60  
 Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val  
 65 70 75 80  
 Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu  
 85 90 95  
 Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile  
 100 105 110  
 Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu  
 115 120 125  
 Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly  
 130 135 140  
 Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys  
 145 150 155 160  
 Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile  
 165 170 175  
 Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His  
 180 185 190  
 Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn  
 195 200 205  
 Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr  
 210 215 220  
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
 225 230 235 240  
 Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
 245 250 255  
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
 260 265 270  
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala  
 275 280 285  
 Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu  
 290 295 300  
 Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala  
 305 310 315 320  
 Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala  
 325 330 335

1977-78	1978-79	1979-80	1980-81	1981-82	1982-83	1983-84	1984-85	1985-86	1986-87	1987-88	1988-89	1989-90	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00	2000-01	2001-02	2002-03	2003-04	2004-05	2005-06	2006-07	2007-08	2008-09	2009-10	2010-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26	2026-27	2027-28	2028-29	2029-30	2030-31	2031-32	2032-33	2033-34	2034-35	2035-36	2036-37	2037-38	2038-39	2039-40	2040-41	2041-42	2042-43	2043-44	2044-45	2045-46	2046-47	2047-48	2048-49	2049-50	2050-51	2051-52	2052-53	2053-54	2054-55	2055-56	2056-57	2057-58	2058-59	2059-60	2060-61	2061-62	2062-63	2063-64	2064-65	2065-66	2066-67	2067-68	2068-69	2069-70	2070-71	2071-72	2072-73	2073-74	2074-75	2075-76	2076-77	2077-78	2078-79	2079-80	2080-81	2081-82	2082-83	2083-84	2084-85	2085-86	2086-87	2087-88	2088-89	2089-90	2090-91	2091-92	2092-93	2093-94	2094-95	2095-96	2096-97	2097-98	2098-99	2099-00	2100-01	2101-02	2102-03	2103-04	2104-05	2105-06	2106-07	2107-08	2108-09	2109-10	2110-11	2111-12	2112-13	2113-14	2114-15	2115-16	2116-17	2117-18	2118-19	2119-20	2120-21	2121-22	2122-23	2123-24	2124-25	2125-26	2126-27	2127-28	2128-29	2129-30	2130-31	2131-32	2132-33	2133-34	2134-35	2135-36	2136-37	2137-38	2138-39	2139-40	2140-41	2141-42	2142-43	2143-44	2144-45	2145-46	2146-47	2147-48	2148-49	2149-50	2150-51	2151-52	2152-53	2153-54	2154-55	2155-56	2156-57	2157-58	2158-59	2159-60	2160-61	2161-62	2162-63	2163-64	2164-65	2165-66	2166-67	2167-68	2168-69	2169-70	2170-71	2171-72	2172-73	2173-74	2174-75	2175-76	2176-77	2177-78	2178-79	2179-80	2180-81	2181-82	2182-83	2183-84	2184-85	2185-86	2186-87	2187-88	2188-89	2189-90	2190-91	2191-92	2192-93	2193-94	2194-95	2195-96	2196-97	2197-98	2198-99	2199-00	2200-01	2201-02	2202-03	2203-04	2204-05	2205-06	2206-07	2207-08	2208-09	2209-10	2210-11	2211-12	2212-13	2213-14	2214-15	2215-16	2216-17	2217-18	2218-19	2219-20	2220-21	2221-22	2222-23	2223-24	2224-25	2225-26	2226-27	2227-28	2228-29	2229-30	2230-31	2231-32	2232-33	2233-34	2234-35	2235-36	2236-37	2237-38	2238-39	2239-40	2240-41	2241-42	2242-43	2243-44	2244-45	2245-46	2246-47	2247-48	2248-49	2249-50	2250-51	2251-52	2252-53	2253-54	2254-55	2255-56	2256-57	2257-58	2258-59	2259-60	2260-61	2261-62	2262-63	2263-64	2264-65	2265-66	2266-67	2267-68	2268-69	2269-70	2270-71	2271-72	2272-73	2273-74	2274-75	2275-76	2276-77	2277-78	2278-79	2279-80	2280-81	2281-82	2282-83	2283-84	2284-85	2285-86	2286-87	2287-88	2288-89	2289-90	2290-91	229
---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	---------	-----

Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Ala	Val	Pro
			340					345					350		
Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp
		355					360					365			
Cys	Val	Asp	Lys	Met	Val	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Ala
	370					375					380				
Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg
385					390					395					400
Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val
				405					410					415	
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser
			420					425					430		
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe
		435					440					445			
Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln
	450					455					460				
Glu	Val	Lys	Glu	Phe	Phe	Arg	Trp	Ala	Gln	Asp	His	Val	Thr	Glu	Val
465					470					475					480
Ala	His	Glu	Phe	Tyr	Val	Arg	Lys	Gly	Gly	Ala	Asn	Lys	Arg	Pro	Ala
				485					490					495	
Pro	Asp	Asp	Ala	Asp	Lys	Ser	Glu	Pro	Lys	Arg	Ala	Cys	Pro	Ser	Val
			500					505					510		
Ala	Asp	Pro	Ser	Thr	Ser	Asp	Ala	Glu	Gly	Ala	Pro	Val	Asp	Phe	Ala
		515					520					525			
Asp	Arg	Tyr	Gln	Asn	Lys	Cys	Ser	Arg	His	Ala	Gly	Met	Leu	Gln	Met
	530					535					540				
Leu	Phe	Pro	Cys	Lys	Thr	Cys	Glu	Arg	Met	Asn	Gln	Asn	Phe	Asn	Ile
545					550					555					560
Cys	Phe	Thr	His	Gly	Thr	Arg	Asp	Cys	Ser	Glu	Cys	Phe	Pro	Gly	Val
				565					570					575	
Ser	Glu	Ser	Gln	Pro	Val	Val	Arg	Lys	Arg	Thr	Tyr	Arg	Lys	Leu	Cys
			580					585					590		
Ala	Ile	His	His	Leu	Leu	Gly	Arg	Ala	Pro	Glu	Ile	Ala	Cys	Ser	Ala
		595					600					605			
Cys	Asp	Leu	Val	Asn	Val	Asp	Leu	Asp	Asp	Cys	Val	Ser	Glu	Gln	
	610					615					620				

<210>	3
<211>	736
<212>	PRT
<213>	AAV-1

[illegible]

<400> 1	3 Met	Ala	Ala	Asp	5 Gly	Tyr	Leu	Pro	Asp	10 Trp	Leu	Glu	Asp	Asn	15 Leu	Ser
	Glu	Gly	Ile	20 Arg	Glu	Trp	Trp	Asp	25 Leu	Lys	Pro	Gly	Ala	30 Pro	Lys	Pro
	Lys	Ala	Asn	35 Gln	Gln	Lys	Gln	Asp	40 Asp	Gly	Arg	Gly	Leu	45 Val	Leu	Pro
	Gly	Tyr	Lys	50 Tyr	Leu	Gly	Pro	55 Phe	Asn	Gly	Leu	60 Asp	Lys	Gly	Glu	Pro
65	Val	Asn	Ala	Ala	Asp	70 Ala	Ala	Ala	Leu	Glu	75 His	Asp	Lys	Ala	Tyr	80 Asp
	Gln	Gln	Leu	Lys	85 Ala	Gly	Asp	Asn	Pro	Tyr	90 Leu	Arg	Tyr	Asn	95 His	Ala
	Asp	Ala	Glu	Phe	100 Gln	Glu	Arg	Leu	Gln	105 Glu	Asp	Thr	Ser	Phe	110 Gly	Gly
	Asn	Leu	Gly	Arg	115 Ala	Val	Phe	Gln	120 Ala	Lys	Lys	Arg	125 Val	Leu	Glu	Pro
	Leu	Gly	Leu	Val	Glu	Glu	Gly	135 Ala	Lys	Thr	Ala	140 Pro	Gly	Lys	Lys	Arg
145	Pro	Val	Glu	Gln	Ser	150 Pro	Gln	Glu	Pro	Asp	155 Ser	Ser	Ser	Gly	Ile	160 Gly
	Lys	Thr	Gly	Gln	Gln	165 Pro	Ala	Lys	Lys	Arg	170 Leu	Asn	Phe	Gly	Gln	175 Thr
	Gly	Asp	Ser	Glu	Ser	180 Val	Pro	Asp	185 Pro	Gln	Pro	Leu	Gly	Glu	190 Pro	Pro
	Ala	Thr	Pro	Ala	Ala	Val	Gly	200 Pro	Thr	Thr	Met	Ala	205 Ser	Gly	Gly	Gly
	Ala	Pro	Met	Ala	Asp	Asn	215 Asn	Glu	Gly	Ala	Asp	Gly	220 Val	Gly	Asn	Ala
225	Ser	Gly	Asn	Trp	His	230 Cys	Asp	Ser	Thr	Trp	Leu	Gly	235 Asp	Arg	Val	240 Ile
	Thr	Thr	Ser	Thr	Arg	245 Thr	Trp	Ala	Leu	250 Pro	Thr	Tyr	Asn	Asn	255 His	Leu
	Tyr	Lys	Gln	Ile	Ser	260 Ser	Ala	Ser	Thr	265 Gly	Ala	Ser	Asn	270 Asp	Asn	His
	Tyr	Phe	Gly	Tyr	Ser	275 Thr	Pro	Trp	Gly	280 Tyr	Phe	Asp	285 Phe	Asn	Arg	Phe
	His	Cys	His	Phe	Ser	290 Pro	Arg	295 Asp	Trp	Gln	Arg	Leu	300 Ile	Asn	Asn	Asn
	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln

305					310					315					320
Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn
				325					330					335	
Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro
			340					345					350		
Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala
		355					360					365			
Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly
	370					375					380				
Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro
385					390					395					400
Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe
				405					410					415	
Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp
			420					425					430		
Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg
		435					440					445			
Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser
	450					455					460				
Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro
465					470					475					480
Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn
				485					490					495	
Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn
			500					505					510		
Gly	Arg	Glu	Ser	Ile	Ile	Asn	Pro	Gly	Thr	Ala	Met	Ala	Ser	His	Lys
		515					520					525			
Asp	Asp	Glu	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly
	530					535					540				
Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile
545					550					555					560
Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg
				565					570					575	
Phe	Gly	Thr	Val	Ala	Val	Asn	Phe	Gln	Ser	Ser	Ser	Thr	Asp	Pro	Ala
			580					585					590		
Thr	Gly	Asp	Val	His	Ala	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln
		595					600					605			
Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His
	610					615					620				
Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu

625		630		635		640
Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala						
		645		650		655
Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr						
		660		665		670
Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln						
		675		680		685
Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn						
		690		695		700
Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu						
		705		710		715
Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu						
		725		730		735

<210> 4  
 <211> 1872  
 <212> DNA  
 <213> AAV-1

<220>  
 <221> CDS  
 <222> (1)..(1869)  
 <223>

<400> 4	
atg ccg ggc ttc tac gag atc gtg atc aag gtg ccg agc gac ctg gac	48
Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp	
1 5 10 15	
gag cac ctg ccg ggc att tct gac tcg ttt gtg agc tgg gtg gcc gag	96
Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu	
20 25 30	
aag gaa tgg gag ctg ccc ccg gat tct gac atg gat ctg aat ctg att	144
Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile	
35 40 45	
gag cag gca ccc ctg acc gtg gcc gag aag ctg cag cgc gac ttc ctg	192
Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu	
50 55 60	
gtc caa tgg cgc cgc gtg agt aag gcc ccg gag gcc ctc ttc ttt gtt	240
Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val	
65 70 75 80	
cag ttc gag aag ggc gag tcc tac ttc cac ctc cat att ctg gtg gag	288
Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu	
85 90 95	
acc acg ggg gtc aaa tcc atg gtg ctg ggc cgc ttc ctg agt cag att	336
Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile	
100 105 110	



ttc tac ggc tgc gtc aac tgg acc aat gag aac ttt ccc ttc aat gat	1104
Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp	
355 360 365	
tgc gtc gac aag atg gtg atc tgg tgg gag gag ggc aag atg acg gcc	1152
Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala	
370 375 380	
aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc agc aag gtg cgc	1200
Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg	
385 390 395 400	
gtg gac caa aag tgc aag tcg tcc gcc cag atc gac ccc acc ccc gtg	1248
Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val	
405 410 415	
atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac agc	1296
Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser	
420 425 430	
acc acc ttc gag cac cag cag ccg ttg cag gac cgg atg ttc aaa ttt	1344
Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe	
435 440 445	
gaa ctc acc cgc cgt ctg gag cat gac ttt ggc aag gtg aca aag cag	1392
Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln	
450 455 460	
gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg	1440
Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val	
465 470 475 480	
gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc	1488
Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala	
485 490 495	
ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc	1536
Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val	
500 505 510	
gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc	1584
Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala	
515 520 525	
gac agg tac caa aac aaa tgt tct cgt cac gcg ggc atg ctt cag atg	1632
Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met	
530 535 540	
ctg ttt ccc tgc aag aca tgc gag aga atg aat cag aat ttc aac att	1680
Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile	
545 550 555 560	
tgc ttc acg cac ggg acg aga gac tgt tca gag tgc ttc ccc ggc gtg	1728
Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val	
565 570 575	
tca gaa tct caa ccg gtc gtc aga aag agg acg tat cgg aaa ctc tgt	1776
Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys	
580 585 590	



gcc att cat cat ctg ctg ggg cgg gct ccc gag att gct tgc tcg gcc 1824  
Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala  
595 600 605

tgc	gat	ctg	gtc	aac	gtg	gac	ctg	gat	gac	tgt	gtt	tct	gag	caa	taa	1872
Cys	Asp	Leu	Val	Asn	Val	Asp	Leu	Asp	Asp	Cys	Val	Ser	Glu	Gln		
	610					615					620					

<210>	5
<211>	623
<212>	PRT
<213>	AAV-1

```
<400> 5
Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp
1          5          10          15
```

Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu  
20 25 30

Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile  
35 40 45

Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg Asp Phe Leu  
50 55 60

Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu Phe Phe Val  
65 70 75 80

Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His Ile Leu Val Glu  
85 90 95

Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe Leu Ser Gln Ile  
100 105 110

Arg Asp Lys Leu Val Gln Thr Ile Tyr Arg Gly Ile Glu Pro Thr Leu  
115 120 125

Pro Asn Trp Phe Ala Val Thr Lys Thr Arg Asn Gly Ala Gly Gly Gly  
130 135 140

Asn Lys Val Val Asp Glu Cys Tyr Ile Pro Asn Tyr Leu Leu Pro Lys  
145 150 155 160

Thr Gln Pro Glu Leu Gln Trp Ala Trp Thr Asn Met Glu Glu Tyr Ile  
165 170 175

Ser Ala Cys Leu Asn Leu Ala Glu Arg Lys Arg Leu Val Ala Gln His  
180 185 190

Leu Thr His Val Ser Gln Thr Gln Glu Gln Asn Lys Glu Asn Leu Asn  
195 200 205

Pro Asn Ser Asp Ala Pro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr  
210 215 220

Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
225 230 235 240

Gln	Trp	Ile	Gln	Glu	Asp	Gln	Ala	Ser	Tyr	Ile	Ser	Phe	Asn	Ala	Ala
				245					250					255	
Ser	Asn	Ser	Arg	Ser	Gln	Ile	Lys	Ala	Ala	Leu	Asp	Asn	Ala	Gly	Lys
			260					265					270		
Ile	Met	Ala	Leu	Thr	Lys	Ser	Ala	Pro	Asp	Tyr	Leu	Val	Gly	Pro	Ala
		275					280					285			
Pro	Pro	Ala	Asp	Ile	Lys	Thr	Asn	Arg	Ile	Tyr	Arg	Ile	Leu	Glu	Leu
	290					295					300				
Asn	Gly	Tyr	Glu	Pro	Ala	Tyr	Ala	Gly	Ser	Val	Phe	Leu	Gly	Trp	Ala
305					310					315					320
Gln	Lys	Arg	Phe	Gly	Lys	Arg	Asn	Thr	Ile	Trp	Leu	Phe	Gly	Pro	Ala
				325					330					335	
Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Ala	Val	Pro
			340					345					350		
Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp
		355					360					365			
Cys	Val	Asp	Lys	Met	Val	Ile	Trp	Trp	Glu	Glu	Gly	Lys	Met	Thr	Ala
	370					375					380				
Lys	Val	Val	Glu	Ser	Ala	Lys	Ala	Ile	Leu	Gly	Gly	Ser	Lys	Val	Arg
385					390					395					400
Val	Asp	Gln	Lys	Cys	Lys	Ser	Ser	Ala	Gln	Ile	Asp	Pro	Thr	Pro	Val
				405					410					415	
Ile	Val	Thr	Ser	Asn	Thr	Asn	Met	Cys	Ala	Val	Ile	Asp	Gly	Asn	Ser
			420					425					430		
Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe
		435					440					445			
Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln
	450					455					460				
Glu	Val	Lys	Glu	Phe	Phe	Arg	Trp	Ala	Gln	Asp	His	Val	Thr	Glu	Val
465					470					475					480
Ala	His	Glu	Phe	Tyr	Val	Arg	Lys	Gly	Gly	Ala	Asn	Lys	Arg	Pro	Ala
				485					490					495	
Pro	Asp	Asp	Ala	Asp	Lys	Ser	Glu	Pro	Lys	Arg	Ala	Cys	Pro	Ser	Val
			500					505					510		
Ala	Asp	Pro	Ser	Thr	Ser	Asp	Ala	Glu	Gly	Ala	Pro	Val	Asp	Phe	Ala
		515					520					525			
Asp	Arg	Tyr	Gln	Asn	Lys	Cys	Ser	Arg	His	Ala	Gly	Met	Leu	Gln	Met
	530					535					540				
Leu	Phe	Pro	Cys	Lys	Thr	Cys	Glu	Arg	Met	Asn	Gln	Asn	Phe	Asn	Ile
545					550					555					560

$$\frac{1}{\Gamma(\alpha)} \int_0^t (t-\tau)^{\alpha-1} f(\tau) d\tau = I^\alpha f(t), \quad t \in [0, T],$$

Cys	Phe	Thr	His	Gly 565	Thr	Arg	Asp	Cys	Ser 570	Glu	Cys	Phe	Pro	Gly 575	Val
Ser	Glu	Ser	Gln 580	Pro	Val	Val	Arg	Lys 585	Arg	Thr	Tyr	Arg	Lys 590	Leu	Cys
Ala	Ile	His 595	His	Leu	Leu	Gly	Arg 600	Ala	Pro	Glu	Ile	Ala 605	Cys	Ser	Ala
Cys	Asp 610	Leu	Val	Asn	Val	Asp 615	Leu	Asp	Asp	Cys	Val 620	Ser	Glu	Gln	

```

<210>      6
<211>    1641
<212>      DNA
<213>    AAV-1

<220>
<221>      CDS
<222>    (1)..(1638)
<223>

```

<400>																
atg	ccg	ggc	ttc	tac	gag	atc	gtg	atc	aag	gtg	ccg	agc	gac	ctg	gac	48
Met	Pro	Gly	Phe	Tyr	Glu	Ile	Val	Ile	Lys	Val	Pro	Ser	Asp	Leu	Asp	
1				5					10					15		
<hr/>																
gag	cac	ctg	ccg	ggc	att	tct	gac	tcg	ttt	gtg	agc	tgg	gtg	gcc	gag	96
Glu	His	Leu	Pro	Gly	Ile	Ser	Asp	Ser	Phe	Val	Ser	Trp	Val	Ala	Glu	
			20					25					30			
<hr/>																
aag	gaa	tgg	gag	ctg	ccc	ccg	gat	tct	gac	atg	gat	ctg	aat	ctg	att	144
Lys	Glu	Trp	Glu	Leu	Pro	Pro	Asp	Ser	Asp	Met	Asp	Leu	Asn	Leu	Ile	
		35					40					45				
<hr/>																
gag	cag	gca	ccc	ctg	acc	gtg	gcc	gag	aag	ctg	cag	cgc	gac	ttc	ctg	192
Glu	Gln	Ala	Pro	Leu	Thr	Val	Ala	Glu	Lys	Leu	Gln	Arg	Asp	Phe	Leu	
	50					55					60					
<hr/>																
gtc	caa	tgg	cgc	cgc	gtg	agt	aag	gcc	ccg	gag	gcc	ctc	ttc	ttt	gtt	240
Val	Gln	Trp	Arg	Arg	Val	Ser	Lys	Ala	Pro	Glu	Ala	Leu	Phe	Phe	Val	
65					70					75					80	
<hr/>																
cag	ttc	gag	aag	ggc	gag	tcc	tac	ttc	cac	ctc	cat	att	ctg	gtg	gag	288
Gln	Phe	Glu	Lys	Gly	Glu	Ser	Tyr	Phe	His	Leu	His	Ile	Leu	Val	Glu	
				85					90					95		
<hr/>																
acc	acg	ggg	gtc	aaa	tcc	atg	gtg	ctg	ggc	cgc	ttc	ctg	agt	cag	att	336
Thr	Thr	Gly	Val	Lys	Ser	Met	Val	Leu	Gly	Arg	Phe	Leu	Ser	Gln	Ile	
			100					105					110			
<hr/>																
agg	gac	aag	ctg	gtg	cag	acc	atc	tac	cgc	ggg	atc	gag	ccg	acc	ctg	384
Arg	Asp	Lys	Leu	Val	Gln	Thr	Ile	Tyr	Arg	Gly	Ile	Glu	Pro	Thr	Leu	
		115					120					125				
<hr/>																
ccc	aac	tgg	ttc	gcg	gtg	acc	aag	acg	cgt	aat	ggc	gcc	gga	ggg	ggg	432
Pro	Asn	Trp	Phe	Ala	Val	Thr	Lys	Thr	Arg	Asn	Gly	Ala	Gly	Gly	Gly	
	130					135					140					

aac Asn 145	aag Lys	gtg Val	gtg Val	gac Asp	gag Glu 150	tgc Cys	tac Tyr	atc Ile	ccc Pro	aac Asn 155	tac Tyr	ctc Leu	ctg Leu	ccc Pro	aag Lys 160	480
act Thr	cag Gln	ccc Pro	gag Glu 165	ctg Leu 165	cag Gln	tgg Trp	gcg Ala	tgg Trp	act Thr 170	aac Asn	atg Met	gag Glu	gag Glu	tat Tyr 175	ata Ile	528
agc Ser	gcc Ala	tgt Cys	ttg Leu 180	aac Asn	ctg Leu	gcc Ala	gag Glu	cgc Arg 185	aaa Lys	cgg Arg	ctc Leu	gtg Val	gcg Ala 190	cag Gln	cac His	576
ctg Leu	acc Thr	cac His 195	gtc Val	agc Ser	cag Gln	acc Thr	cag Gln 200	gag Glu	cag Gln	aac Asn	aag Lys	gag Glu 205	aat Asn	ctg Leu	aac Asn	624
ccc Pro	aat Asn 210	tct Ser	gac Asp	gcg Ala	cct Pro	gtc Val 215	atc Ile	cgg Arg	tca Ser	aaa Lys	acc Thr 220	tcc Ser	gcg Ala	cgc Arg	tac Tyr	672
atg Met 225	gag Glu	ctg Leu	gtc Val	ggg Gly	tgg Trp 230	ctg Leu	gtg Val	gac Asp	cgg Arg	ggc Gly 235	atc Ile	acc Thr	tcc Ser	gag Glu	aag Lys 240	720
cag Gln	tgg Trp	atc Ile	cag Gln	gag Glu 245	gac Asp	cag Gln	gcc Ala	tgc Ser	tac Tyr 250	atc Ile	tcc Ser	ttc Phe	aac Asn	gcc Ala 255	gct Ala	768
tcc Ser	aac Asn	tcg Ser	cgg Arg 260	tcc Ser	cag Gln	atc Ile	aag Lys	gcc Ala 265	gct Ala	ctg Leu	gac Asp	aat Asn	gcc Ala 270	ggc Gly	aag Lys	816
atc Ile	atg Met	gcg Ala 275	ctg Leu	acc Thr	aaa Lys	tcc Ser	gcg Ala 280	ccc Pro	gac Asp	tac Tyr	ctg Leu	gta Val 285	ggc Gly	ccc Pro	gct Ala	864
ccg Pro	ccc Pro 290	gcg Ala	gac Asp	att Ile	aaa Lys	acc Thr 295	aac Asn	cgc Arg	atc Ile	tac Tyr	cgc Arg 300	atc Ile	ctg Leu	gag Glu	ctg Leu	912
aac Asn 305	ggc Gly	tac Tyr	gaa Glu	cct Pro	gcc Ala 310	tac Tyr	gcc Ala	ggc Gly	tcc Ser	gtc Val 315	ttt Phe	ctc Leu	ggc Gly	tgg Trp	gcc Ala 320	960
cag Gln	aaa Lys	agg Arg	ttc Phe	ggg Gly 325	aag Lys	cgc Arg	aac Asn	acc Thr	atc Ile 330	tgg Trp	ctg Leu	ttt Phe	ggg Gly	ccg Pro 335	gcc Ala	1008
acc Thr	acg Thr	ggc Gly	aag Lys 340	acc Thr	aac Asn	atc Ile	gcg Ala	gaa Glu 345	gcc Ala	atc Ile	gcc Ala	cac His	gcc Ala 350	gtg Val	ccc Pro	1056
ttc Phe	tac Tyr	ggc Gly 355	tgc Cys	gtc Val	aac Asn	tgg Trp	acc Thr 360	aat Asn	gag Glu	aac Asn	ttt Phe	ccc Pro 365	ttc Phe	aat Asn	gat Asp	1104
tgc Cys	gtc Val 370	gac Asp	aag Lys	atg Met	gtg Val	atc Ile 375	tgg Trp	tgg Trp	gag Glu	gag Glu	ggc Gly 380	aag Lys	atg Met	acg Thr	gcc Ala	1152

aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc agc aag gtg cgc 1200  
 Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg  
 385 390 395 400

gtg gac caa aag tgc aag tcg tcc gcc cag atc gac ccc acc ccc gtg 1248  
 Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val  
 405 410 415

atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac agc 1296  
 Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser  
 420 425 430

acc acc ttc gag cac cag cag ccg ttg cag gac cgg atg ttc aaa ttt 1344  
 Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe  
 435 440 445

gaa ctc acc cgc cgt ctg gag cat gac ttt ggc aag gtg aca aag cag 1392  
 Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln  
 450 455 460

gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg 1440  
 Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val  
 465 470 475 480

gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc 1488  
 Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala  
 485 490 495

ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc 1536  
 Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val  
 500 505 510

gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc 1584  
 Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
 515 520 525

gac agg tat ggc tgc cga tgg tta tct tcc aga ttg gct cga gga caa 1632  
 Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln  
 530 535 540

cct ctc tga 1641  
 Pro Leu  
 545

<210> 7  
 <211> 546  
 <212> PRT  
 <213> AAV-1

<400> 7  
 Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp Leu Asp  
 1 5 10 15

Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Ser Trp Val Ala Glu  
 20 25 30

Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu Asn Leu Ile  
 35 40 45

Glu	Gln	Ala	Pro	Leu	Thr	Val	Ala	Glu	Lys	Leu	Gln	Arg	Asp	Phe	Leu
50						55					60				
Val	Gln	Trp	Arg	Arg	Val	Ser	Lys	Ala	Pro	Glu	Ala	Leu	Phe	Phe	Val
65					70					75					80
Gln	Phe	Glu	Lys	Gly	Glu	Ser	Tyr	Phe	His	Leu	His	Ile	Leu	Val	Glu
				85					90					95	
Thr	Thr	Gly	Val	Lys	Ser	Met	Val	Leu	Gly	Arg	Phe	Leu	Ser	Gln	Ile
			100					105					110		
Arg	Asp	Lys	Leu	Val	Gln	Thr	Ile	Tyr	Arg	Gly	Ile	Glu	Pro	Thr	Leu
		115					120					125			
Pro	Asn	Trp	Phe	Ala	Val	Thr	Lys	Thr	Arg	Asn	Gly	Ala	Gly	Gly	Gly
	130					135					140				
Asn	Lys	Val	Val	Asp	Glu	Cys	Tyr	Ile	Pro	Asn	Tyr	Leu	Leu	Pro	Lys
145					150					155					160
Thr	Gln	Pro	Glu	Leu	Gln	Trp	Ala	Trp	Thr	Asn	Met	Glu	Glu	Tyr	Ile
				165					170					175	
Ser	Ala	Cys	Leu	Asn	Leu	Ala	Glu	Arg	Lys	Arg	Leu	Val	Ala	Gln	His
			180					185					190		
Leu	Thr	His	Val	Ser	Gln	Thr	Gln	Glu	Gln	Asn	Lys	Glu	Asn	Leu	Asn
		195					200					205			
Pro	Asn	Ser	Asp	Ala	Pro	Val	Ile	Arg	Ser	Lys	Thr	Ser	Ala	Arg	Tyr
	210					215					220				
Met	Glu	Leu	Val	Gly	Trp	Leu	Val	Asp	Arg	Gly	Ile	Thr	Ser	Glu	Lys
225					230					235					240
Gln	Trp	Ile	Gln	Glu	Asp	Gln	Ala	Ser	Tyr	Ile	Ser	Phe	Asn	Ala	Ala
				245					250					255	
Ser	Asn	Ser	Arg	Ser	Gln	Ile	Lys	Ala	Ala	Leu	Asp	Asn	Ala	Gly	Lys
			260					265					270		
Ile	Met	Ala	Leu	Thr	Lys	Ser	Ala	Pro	Asp	Tyr	Leu	Val	Gly	Pro	Ala
		275					280					285			
Pro	Pro	Ala	Asp	Ile	Lys	Thr	Asn	Arg	Ile	Tyr	Arg	Ile	Leu	Glu	Leu
	290					295					300				
Asn	Gly	Tyr	Glu	Pro	Ala	Tyr	Ala	Gly	Ser	Val	Phe	Leu	Gly	Trp	Ala
305					310					315					320
Gln	Lys	Arg	Phe	Gly	Lys	Arg	Asn	Thr	Ile	Trp	Leu	Phe	Gly	Pro	Ala
				325					330					335	
Thr	Thr	Gly	Lys	Thr	Asn	Ile	Ala	Glu	Ala	Ile	Ala	His	Ala	Val	Pro
			340					345					350		
Phe	Tyr	Gly	Cys	Val	Asn	Trp	Thr	Asn	Glu	Asn	Phe	Pro	Phe	Asn	Asp
		355					360					365			

Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala  
 370 375 380

Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg  
 385 390 395 400

Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val  
 405 410 415

Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser  
 420 425 430

Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe  
 435 440 445

Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln  
 450 455 460

Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val  
 465 470 475 480

Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala  
 485 490 495

Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val  
 500 505 510

Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
 515 520 525

Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln  
 530 535 540

Pro Leu  
 545

<210> 8  
 <211> 1200  
 <212> DNA  
 <213> AAV-1

<220>  
 <221> CDS  
 <222> (1)..(1197)  
 <223>

<400> 8  
 atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag 48  
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
 1 5 10 15

cag tgg atc cag gag gac cag gcc tcg tac atc tcc ttc aac gcc gct 96  
 Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
 20 25 30

tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag 144  
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
 35 40 45

atc atg gcg ctg acc aaa tcc gcg ccc gac tac ctg gta ggc ccc gct Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala 50 55 60	192
ccg ccc gcg gac att aaa acc aac cgc atc tac cgc atc ctg gag ctg Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu 65 70 75 80	240
aac ggc tac gaa cct gcc tac gcc ggc tcc gtc ttt ctc ggc tgg gcc Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala 85 90 95	288
cag aaa agg ttc ggg aag cgc aac acc atc tgg ctg ttt ggg ccg gcc Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala 100 105 110	336
acc acg ggc aag acc aac atc gcg gaa gcc atc gcc cac gcc gtg ccc Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro 115 120 125	384
ttc tac ggc tgc gtc aac tgg acc aat gag aac ttt ccc ttc aat gat Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp 130 135 140	432
tgc gtc gac aag atg gtg atc tgg tgg gag gag ggc aag atg acg gcc Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala 145 150 155 160	480
aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc agc aag gtg cgc Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg 165 170 175	528
gtg gac caa aag tgc aag tcg tcc gcc cag atc gac ccc acc ccc gtg Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val 180 185 190	576
atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac agc Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser 195 200 205	624
acc acc ttc gag cac cag cag ccg ttg cag gac cgg atg ttc aaa ttt Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe 210 215 220	672
gaa ctc acc cgc cgt ctg gag cat gac ttt ggc aag gtg aca aag cag Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln 225 230 235 240	720
gaa gtc aaa gag ttc ttc cgc tgg gcg cag gat cac gtg acc gag gtg Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val 245 250 255	768
gcg cat gag ttc tac gtc aga aag ggt gga gcc aac aaa aga ccc gcc Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala 260 265 270	816
ccc gat gac gcg gat aaa agc gag ccc aag cgg gcc tgc ccc tca gtc Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val 275 280 285	864



gcg gat cca tcg acg tca gac gcg gaa gga gct ccg gtg gac ttt gcc 912  
Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
290 295 300

gac agg tac caa aac aaa tgt tct cgt cac gcg ggc atg ctt cag atg 960  
Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Leu Gln Met  
305 310 315 320

ctg ttt ccc tgc aag aca tgc gag aga atg aat cag aat ttc aac att 1008  
Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile  
325 330 335

tgc ttc acg cac ggg acg aga gac tgt tca gag tgc ttc ccc ggc gtg 1056  
Cys Phe Thr His Gly Thr Arg Asp Cys Ser Glu Cys Phe Pro Gly Val  
340 345 350

tca gaa tct caa ccg gtc gtc aga aag agg acg tat cgg aaa ctc tgt 1104  
Ser Glu Ser Gln Pro Val Val Arg Lys Arg Thr Tyr Arg Lys Leu Cys  
355 360 365

gcc att cat cat ctg ctg ggg cgg gct ccc gag att gct tgc tcg gcc 1152  
Ala Ile His His Leu Leu Gly Arg Ala Pro Glu Ile Ala Cys Ser Ala  
370 375 380

tgc gat ctg gtc aac gtg gac ctg gat gac tgt gtt tct gag caa taa 1200  
Cys Asp Leu Val Asn Val Asp Leu Asp Asp Cys Val Ser Glu Gln  
385 390 395

<210> 9  
<211> 399  
<212> PRT  
<213> AAV-1

<400> 9  
Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
1 5 10 15

Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
20 25 30

Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
35 40 45

Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala  
50 55 60

Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu  
65 70 75 80

Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala  
85 90 95

Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala  
100 105 110

Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro  
115 120 125

Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp

130					135					140					
Cys 145	Val	Asp	Lys	Met	Val 150	Ile	Trp	Trp	Glu	Glu 155	Gly	Lys	Met	Thr	Ala 160
Lys	Val	Val	Glu	Ser 165	Ala	Lys	Ala	Ile	Leu 170	Gly	Gly	Ser	Lys	Val	Arg 175
Val	Asp	Gln	Lys 180	Cys	Lys	Ser	Ser	Ala 185	Gln	Ile	Asp	Pro	Thr	Pro	Val
Ile	Val	Thr 195	Ser	Asn	Thr	Asn	Met 200	Cys	Ala	Val	Ile	Asp 205	Gly	Asn	Ser
Thr 210	Thr	Phe	Glu	His	Gln	Gln 215	Pro	Leu	Gln	Asp	Arg 220	Met	Phe	Lys	Phe
Glu 225	Leu	Thr	Arg	Arg	Leu 230	Glu	His	Asp	Phe	Gly 235	Lys	Val	Thr	Lys	Gln 240
Glu	Val	Lys	Glu	Phe 245	Phe	Arg	Trp	Ala	Gln 250	Asp	His	Val	Thr	Glu	Val 255
Ala	His	Glu	Phe 260	Tyr	Val	Arg	Lys	Gly 265	Gly	Ala	Asn	Lys	Arg 270	Pro	Ala
Pro	Asp	Asp 275	Ala	Asp	Lys	Ser	Glu 280	Pro	Lys	Arg	Ala	Cys 285	Pro	Ser	Val
Ala 290	Asp	Pro	Ser	Thr	Ser	Asp 295	Ala	Glu	Gly	Ala	Pro 300	Val	Asp	Phe	Ala
Asp 305	Arg	Tyr	Gln	Asn	Lys 310	Cys	Ser	Arg	His	Ala 315	Gly	Met	Leu	Gln	Met 320
Leu	Phe	Pro	Cys	Lys 325	Thr	Cys	Glu	Arg	Met 330	Asn	Gln	Asn	Phe	Asn 335	Ile
Cys	Phe	Thr	His 340	Gly	Thr	Arg	Asp	Cys 345	Ser	Glu	Cys	Phe	Pro 350	Gly	Val
Ser	Glu	Ser 355	Gln	Pro	Val	Val	Arg 360	Lys	Arg	Thr	Tyr	Arg 365	Lys	Leu	Cys
Ala 370	Ile	His	His	Leu	Leu	Gly 375	Arg	Ala	Pro	Glu	Ile 380	Ala	Cys	Ser	Ala
Cys 385	Asp	Leu	Val	Asn	Val 390	Asp	Leu	Asp	Asp	Cys 395	Val	Ser	Glu	Gln	

<210> 10  
 <211> 969  
 <212> DNA  
 <213> AAV-1

<220>  
 <221> CDS  
 <222> (1)..(966)  
 <223>

<220>  
 <221> misc\_feature  
 <222> (943)..(944)  
 <223> minor splice site

<400> 10  
 atg gag ctg gtc ggg tgg ctg gtg gac cgg ggc atc acc tcc gag aag 48  
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
 1 5 10 15  
 cag tgg atc cag gag gac cag gcc tcg tac atc tcc ttc aac gcc gct 96  
 Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
 20 25 30  
 tcc aac tcg cgg tcc cag atc aag gcc gct ctg gac aat gcc ggc aag 144  
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
 35 40 45  
 atc atg gcg ctg acc aaa tcc gcg ccc gac tac ctg gta ggc ccc gct 192  
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala  
 50 55 60  
 ccg ccc gcg gac att aaa acc aac cgc atc tac cgc atc ctg gag ctg 240  
 Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu  
 65 70 75 80  
 aac ggc tac gaa cct gcc tac gcc ggc tcc gtc ttt ctc ggc tgg gcc 288  
 Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala  
 85 90 95  
 cag aaa agg ttc ggg aag cgc aac acc atc tgg ctg ttt ggg ccg gcc 336  
 Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala  
 100 105 110  
 acc acg ggc aag acc aac atc gcg gaa gcc atc gcc cac gcc gtg ccc 384  
 Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro  
 115 120 125  
 ttc tac ggc tgc gtc aac tgg acc aat gag aac ttt ccc ttc aat gat 432  
 Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp  
 130 135 140  
 tgc gtc gac aag atg gtg atc tgg tgg gag gag ggc aag atg acg gcc 480  
 Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala  
 145 150 155 160  
 aag gtc gtg gag tcc gcc aag gcc att ctc ggc ggc agc aag gtg cgc 528  
 Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg  
 165 170 175  
 gtg gac caa aag tgc aag tcg tcc gcc cag atc gac ccc acc ccc gtg 576  
 Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val  
 180 185 190  
 atc gtc acc tcc aac acc aac atg tgc gcc gtg att gac ggg aac agc 624  
 Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser  
 195 200 205  
 acc acc ttc gag cac cag cag ccg ttg cag gac cgg atg ttc aaa ttt 672

Thr	Thr	Phe	Glu	His	Gln	Gln	Pro	Leu	Gln	Asp	Arg	Met	Phe	Lys	Phe		
210						215					220						
gaa	ctc	acc	cgc	cgt	ctg	gag	cat	gac	ttt	ggc	aag	gtg	aca	aag	cag		720
Glu	Leu	Thr	Arg	Arg	Leu	Glu	His	Asp	Phe	Gly	Lys	Val	Thr	Lys	Gln		
225					230					235					240		
gaa	gtc	aaa	gag	ttc	ttc	cgc	tgg	gcg	cag	gat	cac	gtg	acc	gag	gtg		768
Glu	Val	Lys	Glu	Phe	Phe	Arg	Trp	Ala	Gln	Asp	His	Val	Thr	Glu	Val		
				245					250					255			
gcg	cat	gag	ttc	tac	gtc	aga	aag	ggt	gga	gcc	aac	aaa	aga	ccc	gcc		816
Ala	His	Glu	Phe	Tyr	Val	Arg	Lys	Gly	Gly	Ala	Asn	Lys	Arg	Pro	Ala		
			260					265					270				
ccc	gat	gac	gcg	gat	aaa	agc	gag	ccc	aag	cgg	gcc	tgc	ccc	tca	gtc		864
Pro	Asp	Asp	Ala	Asp	Lys	Ser	Glu	Pro	Lys	Arg	Ala	Cys	Pro	Ser	Val		
		275					280					285					
gcg	gat	cca	tcg	acg	tca	gac	gcg	gaa	gga	gct	ccg	gtg	gac	ttt	gcc		912
Ala	Asp	Pro	Ser	Thr	Ser	Asp	Ala	Glu	Gly	Ala	Pro	Val	Asp	Phe	Ala		
	290					295					300						
gac	agg	tat	ggc	tgc	cga	tgg	tta	tct	tcc	aga	ttg	gct	cga	gga	caa		960
Asp	Arg	Tyr	Gly	Cys	Arg	Trp	Leu	Ser	Ser	Arg	Leu	Ala	Arg	Gly	Gln		
305					310					315					320		
cct	ctc	tga															969
Pro	Leu																

<210> 11  
 <211> 322  
 <212> PRT  
 <213> AAV-1

<220>  
 <221> misc\_feature  
 <222> (943)..(944)  
 <223> minor splice site

<400> 11  
 Met Glu Leu Val Gly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys  
 1 5 10 15  
 Gln Trp Ile Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala  
 20 25 30  
 Ser Asn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys  
 35 40 45  
 Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ala  
 50 55 60  
 Pro Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu  
 65 70 75 80  
 Asn Gly Tyr Glu Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala  
 85 90 95

Gln Lys Arg Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe Gly Pro Ala  
 100 105 110  
 Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala His Ala Val Pro  
 115 120 125  
 Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn Phe Pro Phe Asn Asp  
 130 135 140  
 Cys Val Asp Lys Met Val Ile Trp Trp Glu Glu Gly Lys Met Thr Ala  
 145 150 155 160  
 Lys Val Val Glu Ser Ala Lys Ala Ile Leu Gly Gly Ser Lys Val Arg  
 165 170 175  
 Val Asp Gln Lys Cys Lys Ser Ser Ala Gln Ile Asp Pro Thr Pro Val  
 180 185 190  
 Ile Val Thr Ser Asn Thr Asn Met Cys Ala Val Ile Asp Gly Asn Ser  
 195 200 205  
 Thr Thr Phe Glu His Gln Gln Pro Leu Gln Asp Arg Met Phe Lys Phe  
 210 215 220  
 Glu Leu Thr Arg Arg Leu Glu His Asp Phe Gly Lys Val Thr Lys Gln  
 225 230 235 240  
 Glu Val Lys Glu Phe Phe Arg Trp Ala Gln Asp His Val Thr Glu Val  
 245 250 255  
 Ala His Glu Phe Tyr Val Arg Lys Gly Gly Ala Asn Lys Arg Pro Ala  
 260 265 270  
 Pro Asp Asp Ala Asp Lys Ser Glu Pro Lys Arg Ala Cys Pro Ser Val  
 275 280 285  
 Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala  
 290 295 300  
 Asp Arg Tyr Gly Cys Arg Trp Leu Ser Ser Arg Leu Ala Arg Gly Gln  
 305 310 315 320  
 Pro Leu

<210> 12  
 <211> 2211  
 <212> DNA  
 <213> AAV-1

<220>  
 <221> CDS  
 <222> (1)..(2208)  
 <223>

<400> 12  
 atg gct gcc gat ggt tat ctt cca gat tgg ctc gag gac aac ctc tct  
 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser

1					5					10					15		
gag	ggc	att	cgc	gag	tgg	tgg	gac	ttg	aaa	cct	gga	gcc	ccg	aag	ccc	96	
Glu	Gly	Ile	Arg	Glu	Trp	Trp	Asp	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro		
			20					25					30				
aaa	gcc	aac	cag	caa	aag	cag	gac	gac	ggc	cgg	ggt	ctg	gtg	ctt	cct	144	
Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro		
		35					40					45					
ggc	tac	aag	tac	ctc	gga	ccc	ttc	aac	gga	ctc	gac	aag	ggg	gag	ccc	192	
Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro		
	50					55					60						
gtc	aac	gcg	gcg	gac	gca	gcg	gcc	ctc	gag	cac	gac	aag	gcc	tac	gac	240	
Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp		
65					70					75					80		
cag	cag	ctc	aaa	gcg	ggt	gac	aat	ccg	tac	ctg	cgg	tat	aac	cac	gcc	288	
Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala		
				85					90					95			
gac	gcc	gag	ttt	cag	gag	cgt	ctg	caa	gaa	gat	acg	tct	ttt	ggg	ggc	336	
Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly		
			100					105					110				
aac	ctc	ggg	cga	gca	gtc	ttc	cag	gcc	aag	aag	cgg	gtt	ctc	gaa	cct	384	
Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro		
		115					120					125					
ctc	ggt	ctg	gtt	gag	gaa	ggc	gct	aag	acg	gct	cct	gga	aag	aaa	cgt	432	
Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg		
	130					135					140						
ccg	gta	gag	cag	tcg	cca	caa	gag	cca	gac	tcc	tcc	tcg	ggc	atc	ggc	480	
Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly		
145					150					155					160		
aag	aca	ggc	cag	cag	ccc	gct	aaa	aag	aga	ctc	aat	ttt	ggt	cag	act	528	
Lys	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr		
				165					170					175			
ggc	gac	tca	gag	tca	gtc	ccc	gat	cca	caa	cct	ctc	gga	gaa	cct	cca	576	
Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro		
			180					185					190				
gca	acc	ccc	gct	gct	gtg	gga	cct	act	aca	atg	gct	tca	ggc	ggt	ggc	624	
Ala	Thr	Pro	Ala	Ala	Val	Gly	Pro	Thr	Thr	Met	Ala	Ser	Gly	Gly	Gly		
		195					200					205					
gca	cca	atg	gca	gac	aat	aac	gaa	ggc	gcc	gac	gga	gtg	ggt	aat	gcc	672	
Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ala		
	210					215					220						
tca	gga	aat	tgg	cat	tgc	gat	tcc	aca	tgg	ctg	ggc	gac	aga	gtc	atc	720	
Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	Ile		
225					230					235					240		
acc	acc	agc	acc	cgc	acc	tgg	gcc	ttg	ccc	acc	tac	aat	aac	cac	ctc	768	
Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu		

245							250							255							
tac	aag	caa	atc	tcc	agt	gct	tca	acg	ggg	gcc	agc	aac	gac	aac	cac	816					
Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His						
			260				265						270								
tac	ttc	ggc	tac	agc	acc	ccc	tgg	ggg	tat	ttt	gat	ttc	aac	aga	ttc	864					
Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe						
			275				280				285										
cac	tgc	cac	ttt	tca	cca	cgt	gac	tgg	cag	cga	ctc	atc	aac	aac	aat	912					
His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn						
			290				295				300										
tgg	gga	ttc	cgg	ccc	aag	aga	ctc	aac	ttc	aaa	ctc	ttc	aac	atc	caa	960					
Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln						
			305				310				315				320						
gtc	aag	gag	gtc	acg	acg	aat	gat	ggc	gtc	aca	acc	atc	gct	aat	aac	1008					
Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn						
			325							330				335							
ctt	acc	agc	acg	gtt	caa	gtc	ttc	tcg	gac	tcg	gag	tac	cag	ctt	ccg	1056					
Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro						
			340				345						350								
tac	gtc	ctc	ggc	tct	gcg	cac	cag	ggc	tgc	ctc	cct	ccg	ttc	ccg	gcg	1104					
Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala						
			355				360				365										
gac	gtg	ttc	atg	att	ccg	caa	tac	ggc	tac	ctg	acg	ctc	aac	aat	ggc	1152					
Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly						
			370				375				380										
agc	caa	gcc	gtg	gga	cgt	tca	tcc	ttt	tac	tgc	ctg	gaa	tat	ttc	cct	1200					
Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro						
			385				390				395				400						
tct	cag	atg	ctg	aga	acg	ggc	aac	aac	ttt	acc	ttc	agc	tac	acc	ttt	1248					
Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe						
			405							410				415							
gag	gaa	gtg	cct	ttc	cac	agc	agc	tac	gcg	cac	agc	cag	agc	ctg	gac	1296					
Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp						
			420				425						430								
cgg	ctg	atg	aat	cct	ctc	atc	gac	caa	tac	ctg	tat	tac	ctg	aac	aga	1344					
Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg						
			435				440						445								
act	caa	aat	cag	tcc	gga	agt	gcc	caa	aac	aag	gac	ttg	ctg	ttt	agc	1392					
Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser						
			450				455				460										
cgt	ggg	tct	cca	gct	ggc	atg	tct	gtt	cag	ccc	aaa	aac	tgg	cta	cct	1440					
Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro						
			465				470				475					480					
gga	ccc	tgt	tat	cgg	cag	cag	cgc	gtt	tct	aaa	aca	aaa	aca	gac	aac	1488					
Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn						

			485					490					495						
aac Asn	aac Asn	agc Ser	aat Asn 500	ttt Phe	acc Thr	tgg Trp	act Thr	ggt Gly 505	gct Ala	tca Ser	aaa Lys	tat Tyr	aac Asn 510	ctc Leu	aat Asn	1536			
ggg Gly	cgt Arg	gaa Glu 515	tcc Ser	atc Ile	atc Ile	aac Asn	cct Pro 520	ggc Gly	act Thr	gct Ala	atg Met	gcc Ala 525	tca Ser	cac His	aaa Lys	1584			
gac Asp	gac Asp 530	gaa Glu	gac Asp	aag Lys	ttc Phe	ttt Phe 535	ccc Pro	atg Met	agc Ser	ggt Gly	gtc Val 540	atg Met	att Ile	ttt Phe	gga Gly	1632			
aaa Lys 545	gag Glu	agc Ser	gcc Ala	gga Gly	gct Ala 550	tca Ser	aac Asn	act Thr	gca Ala 555	ttg Leu	gac Asp	aat Asn	gtc Val	atg Met	att Ile 560	1680			
aca Thr	gac Asp	gaa Glu	gag Glu	gaa Glu 565	att Ile	aaa Lys	gcc Ala	act Thr	aac Asn 570	cct Pro	gtg Val	gcc Ala	acc Thr	gaa Glu 575	aga Arg	1728			
ttt Phe	ggg Gly	acc Thr	gtg Val 580	gca Ala	gtc Val	aat Asn	ttc Phe	cag Gln 585	agc Ser	agc Ser	agc Ser	aca Thr	gac Asp 590	cct Pro	gcg Ala	1776			
acc Thr	gga Gly	gat Asp 595	gtg Val	cat His	gct Ala	atg Met	gga Gly 600	gca Ala	tta Leu	cct Pro	ggc Gly	atg Met 605	gtg Val	tgg Trp	caa Gln	1824			
gat Asp	aga Arg 610	gac Asp	gtg Val	tac Tyr	ctg Leu	cag Gln 615	ggt Gly	ccc Pro	att Ile	tgg Trp	gcc Ala 620	aaa Lys	att Ile	cct Pro	cac His	1872			
aca Thr 625	gat Asp	gga Gly	cac His	ttt Phe	cac His 630	ccg Pro	tct Ser	cct Pro	ctt Leu	atg Met 635	ggc Gly	ggc Gly	ttt Phe	gga Gly	ctc Leu 640	1920			
aag Lys	aac Asn	ccg Pro	cct Pro	cct Pro 645	cag Gln	atc Ile	ctc Leu	atc Ile	aaa Lys 650	aac Asn	acg Thr	cct Pro	gtt Val	cct Pro 655	gcg Ala	1968			
aat Asn	cct Pro	ccg Pro	gcg Ala 660	gag Glu	ttt Phe	tca Ser	gct Ala	aca Thr 665	aag Lys	ttt Phe	gct Ala	tca Ser	ttc Phe 670	atc Ile	acc Thr	2016			
caa Gln	tac Tyr	tcc Ser 675	aca Thr	gga Gly	caa Gln	gtg Val	agt Ser 680	gtg Val	gaa Glu	att Ile	gaa Glu	tgg Trp 685	gag Glu	ctg Leu	cag Gln	2064			
aaa Lys	gaa Glu 690	aac Asn	agc Ser	aag Lys	cgc Arg	tgg Trp 695	aat Asn	ccc Pro	gaa Glu	gtg Val	cag Gln 700	tac Tyr	aca Thr	tcc Ser	aat Asn	2112			
tat Tyr 705	gca Ala	aaa Lys	tct Ser	gcc Ala	aac Asn 710	gtt Val	gat Asp	ttt Phe	act Thr	gtg Val 715	gac Asp	aac Asn	aat Asn	gga Gly	ctt Leu 720	2160			
tat Tyr	act Thr	gag Glu	cct Pro	cgc Arg	ccc Pro	att Ile	ggc Gly	acc Thr	cgt Arg	tac Tyr	ctt Leu	acc Thr	cgt Arg	ccc Pro	ctg Leu	2208			



725

730

735

2211

taa

<210> 13  
 <211> 736  
 <212> PRT  
 <213> AAV-1

&lt;400&gt; 13

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser  
 1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro  
 20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro  
 35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro  
 50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp  
 65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala  
 85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly  
 100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro  
 115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg  
 130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly  
 145 150 155 160

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr  
 165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro  
 180 185 190

Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly  
 195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala  
 210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile  
 225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu  
 245 250 255

Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp Asn His

260					265					270					
Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe
		275					280					285			
His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn
	290					295					300				
Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln
305					310					315					320
Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn
				325					330					335	
Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro
			340					345					350		
Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala
		355					360					365			
Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly
	370					375					380				
Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro
385					390					395					400
Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe
				405					410					415	
Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp
			420					425					430		
Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg
		435					440					445			
Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser
	450					455					460				
Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro
465					470					475					480
Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn
				485					490					495	
Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn
			500					505					510		
Gly	Arg	Glu	Ser	Ile	Ile	Asn	Pro	Gly	Thr	Ala	Met	Ala	Ser	His	Lys
		515					520					525			
Asp	Asp	Glu	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly
	530				535						540				
Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile
545					550					555					560
Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg
				565					570					575	
Phe	Gly	Thr	Val	Ala	Val	Asn	Phe	Gln	Ser	Ser	Ser	Thr	Asp	Pro	Ala

580							585					590				
Thr	Gly	Asp	Val	His	Ala	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	
		595					600				605					
Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	
	610					615					620					
Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	
625					630					635					640	
Lys	Asn	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	
				645					650					655		
Asn	Pro	Pro	Ala	Glu	Phe	Ser	Ala	Thr	Lys	Phe	Ala	Ser	Phe	Ile	Thr	
			660				665						670			
Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	
		675					680					685				
Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Val	Gln	Tyr	Thr	Ser	Asn	
	690					695					700					
Tyr	Ala	Lys	Ser	Ala	Asn	Val	Asp	Phe	Thr	Val	Asp	Asn	Asn	Gly	Leu	
705					710					715					720	
Tyr	Thr	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Pro	Leu	
				725					730					735		

<210> 14  
 <211> 1800  
 <212> DNA  
 <213> AAV-1

<220>  
 <221> CDS  
 <222> (1)..(1797)  
 <223>

<400> 14																
acg	gct	cct	gga	aag	aaa	cgt	ccg	gta	gag	cag	tcg	cca	caa	gag	cca	48
Thr	Ala	Pro	Gly	Lys	Lys	Arg	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	
1				5					10					15		
gac	tcc	tcc	tcg	ggc	atc	ggc	aag	aca	ggc	cag	cag	ccc	gct	aaa	aag	96
Asp	Ser	Ser	Ser	Gly	Ile	Gly	Lys	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	
			20					25					30			
aga	ctc	aat	ttt	ggt	cag	act	ggc	gac	tca	gag	tca	gtc	ccc	gat	cca	144
Arg	Leu	Asn	Phe	Gly	Gln	Thr	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	
		35					40					45				
caa	cct	ctc	gga	gaa	cct	cca	gca	acc	ccc	gct	gct	gtg	gga	cct	act	192
Gln	Pro	Leu	Gly	Glu	Pro	Pro	Ala	Thr	Pro	Ala	Ala	Val	Gly	Pro	Thr	
	50					55				60						
aca	atg	gct	tca	ggc	ggt	ggc	gca	cca	atg	gca	gac	aat	aac	gaa	ggc	240
Thr	Met	Ala	Ser	Gly	Gly	Gly	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	
65					70					75				80		

gcc	gac	gga	gtg	ggt	aat	gcc	tca	gga	aat	tgg	cat	tgc	gat	tcc	aca	288
Ala	Asp	Gly	Val	Gly	Asn	Ala	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	
				85					90					95		
tgg	ctg	ggc	gac	aga	gtc	atc	acc	acc	agc	acc	cgc	acc	tgg	gcc	ttg	336
Trp	Leu	Gly	Asp	Arg	Val	Ile	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	
			100					105					110			
ccc	acc	tac	aat	aac	cac	ctc	tac	aag	caa	atc	tcc	agt	gct	tca	acg	384
Pro	Thr	Tyr	Asn	Asn	His	Leu	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	
		115					120					125				
ggg	gcc	agc	aac	gac	aac	cac	tac	ttc	ggc	tac	agc	acc	ccc	tgg	ggg	432
Gly	Ala	Ser	Asn	Asp	Asn	His	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	
	130					135					140					
tat	ttt	gat	ttc	aac	aga	ttc	cac	tgc	cac	ttt	tca	cca	cgt	gac	tgg	480
Tyr	Phe	Asp	Phe	Asn	Arg	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	
145					150					155					160	
cag	cga	ctc	atc	aac	aac	aat	tgg	gga	ttc	cgg	ccc	aag	aga	ctc	aac	528
Gln	Arg	Leu	Ile	Asn	Asn	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	
				165				170						175		
ttc	aaa	ctc	ttc	aac	atc	caa	gtc	aag	gag	gtc	acg	acg	aat	gat	ggc	576
Phe	Lys	Leu	Phe	Asn	Ile	Gln	Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	
			180					185					190			
gtc	aca	acc	atc	gct	aat	aac	ctt	acc	agc	acg	gtt	caa	gtc	ttc	tcg	624
Val	Thr	Thr	Ile	Ala	Asn	Asn	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	
		195					200					205				
gac	tcg	gag	tac	cag	ctt	ccg	tac	gtc	ctc	ggc	tct	gcg	cac	cag	ggc	672
Asp	Ser	Glu	Tyr	Gln	Leu	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	
	210					215					220					
tgc	ctc	cct	ccg	ttc	ccg	gcg	gac	gtg	ttc	atg	att	ccg	caa	tac	ggc	720
Cys	Leu	Pro	Pro	Phe	Pro	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	
225					230					235					240	
tac	ctg	acg	ctc	aac	aat	ggc	agc	caa	gcc	gtg	gga	cgt	tca	tcc	ttt	768
Tyr	Leu	Thr	Leu	Asn	Asn	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	
				245				250						255		
tac	tgc	ctg	gaa	tat	ttc	cct	tct	cag	atg	ctg	aga	acg	ggc	aac	aac	816
Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	
			260					265					270			
ttt	acc	ttc	agc	tac	acc	ttt	gag	gaa	gtg	cct	ttc	cac	agc	agc	tac	864
Phe	Thr	Phe	Ser	Tyr	Thr	Phe	Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	
		275					280					285				
gcg	cac	agc	cag	agc	ctg	gac	cgg	ctg	atg	aat	cct	ctc	atc	gac	caa	912
Ala	His	Ser	Gln	Ser	Leu	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	
	290					295					300					
tac	ctg	tat	tac	ctg	aac	aga	act	caa	aat	cag	tcc	gga	agt	gcc	caa	960
Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg	Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	
305					310					315					320	

aac aag gac ttg ctg ttt agc cgt ggg tct cca gct ggc atg tct gtt	1008
Asn Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val	
325 330 335	
cag ccc aaa aac tgg cta cct gga ccc tgt tat cgg cag cag cgc gtt	1056
Gln Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val	
340 345 350	
tct aaa aca aaa aca gac aac aac aac agc aat ttt acc tgg act ggt	1104
Ser Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly	
355 360 365	
gct tca aaa tat aac ctc aat ggg cgt gaa tcc atc atc aac cct ggc	1152
Ala Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly	
370 375 380	
act gct atg gcc tca cac aaa gac gac gaa gac aag ttc ttt ccc atg	1200
Thr Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met	
385 390 395 400	
agc ggt gtc atg att ttt gga aaa gag agc gcc gga gct tca aac act	1248
Ser Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr	
405 410 415	
gca ttg gac aat gtc atg att aca gac gaa gag gaa att aaa gcc act	1296
Ala Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr	
420 425 430	
aac cct gtg gcc acc gaa aga ttt ggg acc gtg gca gtc aat ttc cag	1344
Asn Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln	
435 440 445	
agc agc agc aca gac cct gcg acc gga gat gtg cat gct atg gga gca	1392
Ser Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala	
450 455 460	
tta cct ggc atg gtg tgg caa gat aga gac gtg tac ctg cag ggt ccc	1440
Leu Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro	
465 470 475 480	
att tgg gcc aaa att cct cac aca gat gga cac ttt cac ccg tct cct	1488
Ile Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro	
485 490 495	
ctt atg ggc ggc ttt gga ctc aag aac ccg cct cct cag atc ctc atc	1536
Leu Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile	
500 505 510	
aaa aac acg cct gtt cct gcg aat cct ccg gcg gag ttt tca gct aca	1584
Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr	
515 520 525	
aag ttt gct tca ttc atc acc caa tac tcc aca gga caa gtg agt gtg	1632
Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val	
530 535 540	
gaa att gaa tgg gag ctg cag aaa gaa aac agc aag cgc tgg aat ccc	1680
Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro	
545 550 555 560	

gaa gtg cag tac aca tcc aat tat gca aaa tct gcc aac gtt gat ttt 1728  
 Glu Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe  
                   565                  570                  575

act gtg gac aac aat gga ctt tat act gag cct cgc ccc att ggc acc 1776  
 Thr Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr  
                   580                  585                  590

cgt tac ctt acc cgt ccc ctg taa 1800  
 Arg Tyr Leu Thr Arg Pro Leu  
                   595

<210> 15  
 <211> 599  
 <212> PRT  
 <213> AAV-1

<400> 15  
 Thr Ala Pro Gly Lys Lys Arg Pro Val Glu Gln Ser Pro Gln Glu Pro  
 1                  5                  10                  15  
 Asp Ser Ser Ser Gly Ile Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys  
                   20                  25                  30  
 Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu Ser Val Pro Asp Pro  
                   35                  40                  45  
 Gln Pro Leu Gly Glu Pro Pro Ala Thr Pro Ala Ala Val Gly Pro Thr  
                   50                  55                  60  
 Thr Met Ala Ser Gly Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly  
 65                  70                  75                  80  
 Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr  
                   85                  90                  95  
 Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu  
                   100                  105                  110  
 Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr  
                   115                  120                  125  
 Gly Ala Ser Asn Asp Asn His Tyr Phe Gly Tyr Ser Thr Pro Trp Gly  
                   130                  135                  140  
 Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp  
 145                  150                  155                  160  
 Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn  
                   165                  170                  175  
 Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr Thr Asn Asp Gly  
                   180                  185                  190  
 Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Val Gln Val Phe Ser  
                   195                  200                  205  
 Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly

210	215	220
Cys 225	Leu Pro Pro Phe 230	Ala Asp Val Phe Met 235
Ile Pro Gln Tyr Gly 240		
Tyr 245	Leu Thr Leu Asn 245	Ala Val Gly Arg Ser Ser Phe 255
Tyr 260	Cys Leu Glu Tyr Phe Pro Ser 265	Met Leu Arg Thr Gly Asn Asn 270
Phe 275	Thr Phe Glu Glu Val Pro Phe 280	His Ser Ser Tyr 285
Ala 290	His Ser Gln Ser Leu Asp 295	Arg Leu Met Asn Pro Leu Ile Asp Gln 300
Tyr 305	Leu Tyr Tyr Leu Asn 310	Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln 315
Asn 325	Lys Asp Leu Leu Phe Ser Arg Gly 330	Ser Pro Ala Gly Met Ser Val 335
Gln 340	Pro Lys Asn Trp Leu Pro Gly 345	Pro Cys Tyr Arg Gln Gln Arg Val 350
Ser 355	Lys Thr Lys Thr Asp Asn 360	Asn Ser Asn Phe Thr Trp Thr Gly 365
Ala 370	Ser Lys Tyr Asn Leu Asn 375	Gly Arg Glu Ser Ile Ile Asn Pro Gly 380
Thr 385	Ala Met Ala Ser His 390	Lys Asp Asp Glu Asp Lys Phe Phe Pro Met 395
Ser 405	Gly Val Met Ile Phe Gly Lys Glu 410	Ser Ala Gly Ala Ser Asn Thr 415
Ala 420	Leu Asp Asn Val Met Ile Thr Asp 425	Glu Glu Glu Ile Lys Ala Thr 430
Asn 435	Pro Val Ala Thr Glu Arg Phe 440	Gly Thr Val Ala Val Asn Phe Gln 445
Ser 450	Ser Ser Thr Asp Pro Ala 455	Thr Gly Asp Val His Ala Met Gly Ala 460
Leu 465	Pro Gly Met Val Trp Gln Asp Arg Asp 470	Val Tyr Leu Gln Gly Pro 475
Ile 485	Trp Ala Lys Ile Pro His Thr Asp 490	Gly His Phe His Pro Ser Pro 495
Leu 500	Met Gly Gly Phe Gly Leu Lys 505	Asn Pro Pro Pro Gln Ile Leu Ile 510
Lys 515	Asn Thr Pro Val Pro Ala 520	Asn Pro Pro Ala Glu Phe Ser Ala Thr 525
Lys 530	Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly 535	Gln Val Ser Val 540





130	135	140	
tcg gag tac cag ctt ccg tac gtc ctc ggc tct gcg cac cag ggc tgc Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys 145 150 155 160			480
ctc cct ccg ttc ccg gcg gac gtg ttc atg att ccg caa tac ggc tac Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr 165 170 175			528
ctg acg ctc aac aat ggc agc caa gcc gtg gga cgt tca tcc ttt tac Leu Thr Leu Asn Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr 180 185 190			576
tgc ctg gaa tat ttc cct tct cag atg ctg aga acg ggc aac aac ttt Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe 195 200 205			624
acc ttc agc tac acc ttt gag gaa gtg cct ttc cac agc agc tac gcg Thr Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala 210 215 220			672
cac agc cag agc ctg gac cgg ctg atg aat cct ctc atc gac caa tac His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr 225 230 235 240			720
ctg tat tac ctg aac aga act caa aat cag tcc gga agt gcc caa aac Leu Tyr Tyr Leu Asn Arg Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn 245 250 255			768
aag gac ttg ctg ttt agc cgt ggg tct cca gct ggc atg tct gtt cag Lys Asp Leu Leu Phe Ser Arg Gly Ser Pro Ala Gly Met Ser Val Gln 260 265 270			816
ccc aaa aac tgg cta cct gga ccc tgt tat cgg cag cag cgc gtt tct Pro Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser 275 280 285			864
aaa aca aaa aca gac aac aac aac agc aat ttt acc tgg act ggt gct Lys Thr Lys Thr Asp Asn Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala 290 295 300			912
tca aaa tat aac ctc aat ggg cgt gaa tcc atc atc aac cct ggc act Ser Lys Tyr Asn Leu Asn Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr 305 310 315 320			960
gct atg gcc tca cac aaa gac gac gaa gac aag ttc ttt ccc atg agc Ala Met Ala Ser His Lys Asp Asp Glu Asp Lys Phe Phe Pro Met Ser 325 330 335			1008
ggt gtc atg att ttt gga aaa gag agc gcc gga gct tca aac act gca Gly Val Met Ile Phe Gly Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala 340 345 350			1056
ttg gac aat gtc atg att aca gac gaa gag gaa att aaa gcc act aac Leu Asp Asn Val Met Ile Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn 355 360 365			1104
cct gtg gcc acc gaa aga ttt ggg acc gtg gca gtc aat ttc cag agc Pro Val Ala Thr Glu Arg Phe Gly Thr Val Ala Val Asn Phe Gln Ser			1152

370	375	380	
agc agc aca gac cct gcg acc gga gat gtg cat gct atg gga gca tta			1200
Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala Leu			
385	390	395	400
cct ggc atg gtg tgg caa gat aga gac gtg tac ctg cag ggt ccc att			1248
Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile			
	405	410	415
tgg gcc aaa att cct cac aca gat gga cac ttt cac ccg tct cct ctt			1296
Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu			
	420	425	430
atg ggc ggc ttt gga ctc aag aac ccg cct cct cag atc ctc atc aaa			1344
Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys			
	435	440	445
aac acg cct gtt cct gcg aat cct ccg gcg gag ttt tca gct aca aag			1392
Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys			
	450	455	460
ttt gct tca ttc atc acc caa tac tcc aca gga caa gtg agt gtg gaa			1440
Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu			
	465	470	475
att gaa tgg gag ctg cag aaa gaa aac agc aag cgc tgg aat ccc gaa			1488
Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu			
	485	490	495
gtg cag tac aca tcc aat tat gca aaa tct gcc aac gtt gat ttt act			1536
Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr			
	500	505	510
gtg gac aac aat gga ctt tat act gag cct cgc ccc att ggc acc cgt			1584
Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg			
	515	520	525
tac ctt acc cgt ccc ctg taa			1605
Tyr Leu Thr Arg Pro Leu			
	530		

<210> 17  
 <211> 534  
 <212> PRT  
 <213> AAV-1

<400> 17  
 Met Ala Ser Gly Gly Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala  
 1 5 10 15  
 Asp Gly Val Gly Asn Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp  
 20 25 30  
 Leu Gly Asp Arg Val Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro  
 35 40 45  
 Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly  
 50 55 60

[illegible]

Ala 65	Ser	Asn	Asp	Asn	His 70	Tyr	Phe	Gly	Tyr	Ser 75	Thr	Pro	Trp	Gly	Tyr 80
Phe	Asp	Phe	Asn	Arg 85	Phe	His	Cys	His	Phe 90	Ser	Pro	Arg	Asp	Trp 95	Gln
Arg	Leu	Ile	Asn 100	Asn	Asn	Trp	Gly	Phe 105	Arg	Pro	Lys	Arg	Leu 110	Asn	Phe
Lys	Leu	Phe 115	Asn	Ile	Gln	Val	Lys 120	Glu	Val	Thr	Thr	Asn 125	Asp	Gly	Val
Thr	Thr 130	Ile	Ala	Asn	Asn	Leu 135	Thr	Ser	Thr	Val	Gln 140	Val	Phe	Ser	Asp
Ser 145	Glu	Tyr	Gln	Leu	Pro 150	Tyr	Val	Leu	Gly	Ser 155	Ala	His	Gln	Gly	Cys 160
Leu	Pro	Pro	Phe	Pro 165	Ala	Asp	Val	Phe	Met 170	Ile	Pro	Gln	Tyr	Gly 175	Tyr
Leu	Thr	Leu	Asn 180	Asn	Gly	Ser	Gln	Ala 185	Val	Gly	Arg	Ser	Ser 190	Phe	Tyr
Cys	Leu	Glu 195	Tyr	Phe	Pro	Ser	Gln 200	Met	Leu	Arg	Thr	Gly 205	Asn	Asn	Phe
Thr	Phe 210	Ser	Tyr	Thr	Phe	Glu 215	Glu	Val	Pro	Phe	His 220	Ser	Ser	Tyr	Ala
His 225	Ser	Gln	Ser	Leu	Asp 230	Arg	Leu	Met	Asn	Pro 235	Leu	Ile	Asp	Gln	Tyr 240
Leu	Tyr	Tyr	Leu	Asn 245	Arg	Thr	Gln	Asn	Gln 250	Ser	Gly	Ser	Ala	Gln 255	Asn
Lys	Asp	Leu	Leu 260	Phe	Ser	Arg	Gly	Ser 265	Pro	Ala	Gly	Met	Ser 270	Val	Gln
Pro	Lys	Asn 275	Trp	Leu	Pro	Gly	Pro 280	Cys	Tyr	Arg	Gln	Gln 285	Arg	Val	Ser
Lys	Thr 290	Lys	Thr	Asp	Asn 295	Asn	Asn	Ser	Asn	Phe	Thr 300	Trp	Thr	Gly	Ala
Ser 305	Lys	Tyr	Asn	Leu	Asn 310	Gly	Arg	Glu	Ser	Ile 315	Ile	Asn	Pro	Gly	Thr 320
Ala	Met	Ala	Ser	His 325	Lys	Asp	Asp	Glu	Asp 330	Lys	Phe	Phe	Pro	Met 335	Ser
Gly	Val	Met	Ile 340	Phe	Gly	Lys	Glu	Ser 345	Ala	Gly	Ala	Ser	Asn 350	Thr	Ala
Leu	Asp	Asn 355	Val	Met	Ile	Thr	Asp 360	Glu	Glu	Glu	Ile	Lys 365	Ala	Thr	Asn
Pro	Val 370	Ala	Thr	Glu	Arg	Phe 375	Gly	Thr	Val	Ala	Val 380	Asn	Phe	Gln	Ser

Ser Ser Thr Asp Pro Ala Thr Gly Asp Val His Ala Met Gly Ala Leu  
 385 390 395 400

Pro Gly Met Val Trp Gln Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile  
 405 410 415

Trp Ala Lys Ile Pro His Thr Asp Gly His Phe His Pro Ser Pro Leu  
 420 425 430

Met Gly Gly Phe Gly Leu Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys  
 435 440 445

Asn Thr Pro Val Pro Ala Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys  
 450 455 460

Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu  
 465 470 475 480

Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu  
 485 490 495

Val Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr  
 500 505 510

Val Asp Asn Asn Gly Leu Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg  
 515 520 525

Tyr Leu Thr Arg Pro Leu  
 530

<210> 18  
 <211> 4681  
 <212> DNA  
 <213> AAV-2

<400> 18  
 ttggccactc cctctctgcg cgctcgctcg ctactgagg ccgggcgacc aaaggctcgcc 60  
 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgag agagggagtg 120  
 gccaaactcca tctactagggg ttcctggagg ggtggagtcg tgacgtgaat tacgtcatag 180  
 ggtaggggag gtcctgtatt agaggtcacg tgagtgtttt gcgacatttt gcgacaccat 240  
 gtggtcacgc tgggtattta agcccagagt agcacgcagg gtctccattt tgaagcggga 300  
 ggtttgaacg cgcagccgcc atgccggggt ttacgagat tgtgattaag gtccccagcg 360  
 accttgacgg gcatctgccc ggcatttctg acagctttgt gaactgggtg gccgagaagg 420  
 aatgggagtt gccgccagat tctgacatgg atctgaatct gattgagcag gcacccctga 480  
 ccgtggccga gaagctgcag cgcgactttc tgacggaatg gcgccgtgtg agtaaggccc 540  
 cggaggccct tttctttgtg caatttgaga agggagagag ctacttccac atgcacgtgc 600  
 tcgtggaaac caccgggggtg aaatccatgg ttttgggacg tttcctgagt cagattcgcg 660

aaaaactgat tcagagaatt taccgcggga tcgagccgac tttgccaaac tggttcgcgg	720
tcacaaagac cagaaatggc gccggaggcg ggaacaaggt ggtggatgag tgctacatcc	780
ccaattactt gctccccaaa acccagcctg agctccagtg ggcgtggact aatatggaac	840
agtatttaag cgctgttttg aatctcacgg agcgtaaacg gttggtggcg cagcatctga	900
cgcacgtgtc gcagacgcag gagcagaaca aagagaatca gaatcccaat tctgatgcgc	960
cggatgatcag atcaaaaact tcagccaggt acatggagct ggtcgggtgg ctcgaggaca	1020
aggggattac ctcgagagaag cagtggatcc aggaggacca ggcctcatac atctccttca	1080
atgcggcctc caactcgcgg tcccaaatac aggcctgcctt ggacaatgcg ggaaagatta	1140
tgagcctgac taaaaccgcc cccgactacc tgggtgggcca gcagcccgtg gaggacattt	1200
ccagcaatcg gatttataaa attttggaac taaacgggta cgatcccaa tatgcggcctt	1260
ccgtctttct gggatgggcc acgaaaaagt tcggcaagag gaacaccatc tggctgtttg	1320
ggcctgcaac taccgggaag accaaccatc cgagggccat agcccacact gtgcccttct	1380
acgggtgcgt aaactggacc aatgagaact ttcccttcaa cgactgtgtc gacaagatgg	1440
tgatctggtg ggaggagggg aagatgaccg ccaaggctcg ggagtcggcc aaagccattc	1500
tcggaggaag caaggtgcgc gtggaccaga aatgcaagtc ctcggccag atagaccga	1560
ctcccgtgat cgtcacctcc aacaccaaca tgtgcgccgt gattgacggg aactcaacga	1620
ccttcgaaca ccagcagccg ttgcaagacc ggatgttcaa atttgaactc acccgccgtc	1680
tggatcatga ctttggaag gtcaccaagc aggaagtcaa agactttttc cgggtgggcaa	1740
aggatcacgt ggttgagggtg gagcatgaat tctacgtcaa aaaggggtgga gccaagaaaa	1800
gacccgcccc cagtgcgcga gatataagtg agcccaaacg ggtgcgcgag tcagttgcgc	1860
agccatcgac gtcagacgcg gaagcttcga tcaactacgc agacaggtag caaaacaaat	1920
gttctcgtca cgtgggcatg aatctgatgc tgtttccctg cagacaatgc gagagaatga	1980
atcagaattc aaatatctgc ttcactcacg gacagaaaga ctgttttagag tgctttcccg	2040
tgtcagaatc tcaaccggtt tctgtcgtca aaaaggcgta tcagaaactg tgctacattc	2100
atcatatcat gggaaagggtg ccagacgctt gcactgcctg cgatctgggtc aatgtggatt	2160
tggatgactg catctttgaa caataaatga tttaaatacag gtatggctgc cgatggttat	2220
cttccagatt ggctcgagga cactctctct gaaggaataa gacagtgggtg gaagctcaaa	2280
cctggcccac caccacaaa gcccgagag cggcataagg acgacagcag gggctctgtg	2340
cttcctgggt acaagtacct cggacccttc aacggactcg acaagggaga gccggtcaac	2400
gaggcagacg ccgcggccct cgagcacgac aaagcctacg accggcagct cgacagcgga	2460

gacaacccgt acctcaagta caaccacgcc gacgcggagt ttcaggagcg ccttaaagaa	2520
gatacgtctt ttgggggcaa cctcggacga gcagtcttcc aggcgaaaaa gagggttctt	2580
gaacctctcg gcctgggtga ggaacctgtt aagacggctc cgggaaaaaa gaggcgggta	2640
gagcactctc ctgtggagcc agactcctcc tcgggaaccg gaaagccggg ccagcagcct	2700
gcaagaaaaa gattgaattt tggtcagact ggagacgcag actcagtacc tgacccccag	2760
cctctcggac agccaccagc agccccctct ggtctgggaa ctaatacgat ggctacaggc	2820
agtggcgcac caatggcaga caataacgag ggcgcgcgacg gagtgggtaa ttctctccgga	2880
aattggcatt gcgattccac atggatgggc gacagagtca tcaccaccag caccggaacc	2940
tgggccctgc ccacctacaa caaccacctc tacaacaaa tttccagcca atcaggagcc	3000
tcgaacgaca atcactactt tggctacagc accccttggg ggtattttga cttcaacaga	3060
ttccactgcc acttttcacc acgtgactgg caaagactca tcaacaacaa ctgggggattc	3120
cgacccaaga gactcaactt caacctcttt aacattcaag tcaaagaggt cacgcagaat	3180
gacggtacga cgacgattgc caataacctt accagcacgg ttcagggtgtt tactgactcg	3240
gagtaccagc tcccgtacgt cctcggctcg gcgcatcaag gatgcctccc gccgttccca	3300
gcagacgtct tcatgggtgcc acagtatgga tacctcacc tgaacaacgg gagtcaggca	3360
gtaggacgct cttcatttta ctgcctggag tactttcctt ctcatatgct gcgtaccgga	3420
aacaacttta ccttcagcta cacttttgag gacgttcctt tccacagcag ctacgctcac	3480
agccagagtc tggaccgtct catgaatcct ctcatcgacc agtacctgta ttacttgagc	3540
agaacaaaca ctccaagtgg aaccaccacg cagtcaaggc ttcagttttc tcaggcccca	3600
gccagtgaca ttccgggacca gtctaggaac tggcttcctg gaccctgtta ccgccagcag	3660
cgagtatgaa agacatctgc ggataacaac aacagtgaat actcgtggac tggagctacc	3720
aagtaccacc tcaatggcag agactctctg gtgaatccgg ggcccgccat ggcaagccac	3780
aaggacgatg aagaaaagtt ttttcctcag agcgggggttc tcatctttgg gaagcaaggc	3840
tcagagaaaa caaatgtgaa cattgaaaag gtcattgatta cagacgaaga ggaaatccca	3900
acaaccaatc ccgtgggtac ggagcagtat ggttctgtat ctaccaacct ccagagaggc	3960
aacagacaag cagctaccgc agatgtcaac acacaaggcg ttcttccagg catggtctgg	4020
caggacagag atgtgtacct tcagggggccc atctgggcaa agattccaca cacggacgga	4080
catttttcacc cctctcccct catgggtgga ttcggactta aacaccctcc tccacagatt	4140
ctcatcaaga acaccccggt acctgcgaat ccttcgacca ccttcagtgc ggcaaagttt	4200
gcttcttca tcacacagta ctccacggga cacggtcagc gtggagatcg agtgggagct	4260

gcagaacgaa aacagcaaac gctggaatcc cgaaattcag tacacttcca actacaacaa 4320  
gtctgttaat cgtggacttt accgtggata ctaatggcgt gtattcagag cctcgcccca 4380  
ttggcaccag atacctgact cgtaatctgt aattgcttgt taatcaataa accgtttaat 4440  
tcgttttcagt tgaactttgg tctctgcgta tttctttctt atctagtttc catggctacg 4500  
tagataagta gcatggcggg ttaatcatta actacaagga acccctagtg atggagttgg 4560  
ccactccctc tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag gtcgcccgcac 4620  
gcccgggctt tgccccggcg gcctcagtga gcgagcgagc gcgcagagag ggagtgggca 4680  
a 4681

<210> 19  
<211> 4683  
<212> DNA  
<213> AAV-6

<400> 19  
ttggccactc cctctctgcg cgctcgctcg ctactgagg ccgggcgacc aaaggtcgcc 60  
cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgag agagggagtg 120  
gccaactcca tcactagggg ttccctggagg ggtggagtcg tgacgtgaat tacgtcatag 180  
ggttagggag gtcctgtatt agaggtcacg tgagtgtttt gcgacatttt gcgacaccat 240  
gtggtcacgc tgggtattta agcccagagt agcacgcagg gtctccattt tgaagcggga 300  
ggtttgaacg cgcagcgcca tgccgggggt ttacgagatt gtgattaagg tccccagcga 360  
ccttgacgag catctgcccg gcatttctga cagctttgtg aactgggtgg ccgagaagga 420  
atgggagttg ccgccagatt ctgacatgga tctgaatctg attgagcagg caccctgac 480  
cgtggccgag aagctgcagc gcgacttctt ggtccactgg cgccgcgtga gtaaggcccc 540  
ggaggccctc ttctttgttc agttcgagaa gggcgagtcc tacttccacc tccatattct 600  
ggtggagacc acgggggtca aatccatggt gctgggcccgc ttccctgagtc agattagcga 660  
caagctgggtg cagaccatct accgcgggat cgagccgacc ctgcccact ggttcgcggt 720  
gaccaagacg cgtaatggcg ccggaggggg gaacaagggt gtggacgagt gctacatccc 780  
caactacctc ctgcccaga ctcagcccga gctgcagtgg gcgtggacta acatggagga 840  
gtatataagc gcgtgtttta acctggccga gcgcaaacgg ctggtggcgc acgacctgac 900  
ccacgtcagc cagacccagg agcagaacaa ggagaatctg aaccccaatt ctgacgcgcc 960  
tgtcatccgg tcaaaaacct ccgcacgcta catggagctg gtcgggtggc tgggtggaccg 1020  
gggcatcacc tccgagaagc agtggatcca ggaggaccag gcctcgtaca tctccttcaa 1080  
cgccgcctcc aactcgcggt ccagatcaa ggccgctctg gacaatgccg gcaagatcat 1140



ggcgctgacc	aatccgcgc	ccgactacct	ggtaggcccc	gctccgcccc	ccgacattaa	1200
aaccaaccgc	atttaccgca	tcctggagct	gaacggctac	gacctgcct	acgccggctc	1260
cgtctttctc	ggctgggccc	agaaaagggt	cggaaaacgc	aacaccatct	ggctgtttgg	1320
gccggccacc	acgggcaaga	ccaacatcgc	ggaagccatc	gcccacgccg	tgcccttcta	1380
cggctgcgtc	aactggacca	atgagaactt	tcccttcaac	gattgcgtcg	acaagatggt	1440
gatctggtgg	gaggagggca	agatgacggc	caaggtcgtg	gagtcgccca	aggccattct	1500
cggcggcagc	aaggtgcgcg	tggaccaaaa	gtgcaagtcg	tccgcccaga	tcgatcccac	1560
ccccgtgatc	gtcacctcca	acaccaacat	gtgcgccgtg	attgacggga	acagcaccac	1620
cttcgagcac	cagcagccgt	tgcaggaccg	gatgttcaaa	tttgaactca	cccgccgtct	1680
ggagcatgac	tttggcaagg	tgacaaagca	ggaagtcaaa	gagttcttcc	gctgggcgca	1740
ggatcacgtg	accgaggtgg	cgcattgagtt	ctacgtcaga	aagggtggag	ccaacaacag	1800
acccgcccc	gatgacgcgg	ataaaagcga	gccaagcgg	gcctgcccct	cagtcgcgga	1860
tccatcgacg	tcagacgcgg	aaggagctcc	ggtggacttt	gccgacaggt	acaaaaacaa	1920
atgttctcgt	cacgcgggca	tgcttcagat	gctgtttccc	tgcaaaacat	gcgagagaat	1980
gaatcagaat	ttcaacattt	gcttcacgca	cgggaccaga	gactgttcag	aatgtttccc	2040
cggcgtgtca	gaatctcaac	cggtcgtcag	aaagaggacg	tatcggaac	tctgtgccat	2100
tcattcatctg	ctggggcggg	ctcccgagat	tgcttgctcg	gcctgcgac	tgggtcaacgt	2160
ggatctggat	gactgtgttt	ctgagcaata	aatgacttaa	accaggatatg	gctgccgatg	2220
gttatcttcc	agattggctc	gaggacaacc	tctctgaggg	cattcggcag	tgggtgggact	2280
tgaaacctgg	agccccgaaa	cccaaagcca	accagcaaaa	gcaggacgac	ggccggggtc	2340
tgggtgcttcc	tggctacaag	tacctcggac	ccttcaacgg	actcgacaag	ggggagcccc	2400
tcaacgcggc	ggatgcagcg	gccctcgagc	acgacaaggc	ctacgaccag	cagctcaaag	2460
cgggtgacaa	tccgtacctg	cgggtataacc	acgccgacgc	caggtttcag	gagcgtctgc	2520
aagaagatac	gtcttttggg	ggcaacctcg	ggcgagcagt	cttcaggcc	aagaagaggg	2580
ttctcgaacc	ttttggtctg	gttgaggaag	gtgctaagac	ggctcctgga	aagaaacgtc	2640
cggtagagca	gtcgccacaa	gagccagact	cctcctcggg	cattggcaag	acaggccagc	2700
agccccgctaa	aaagagactc	aattttggtc	agactggcga	ctcagagtca	gtccccgacc	2760
cacaacctct	cggagaacct	ccagcaaccc	ccgctgctgt	gggacctact	acaatggctt	2820
caggcgggtg	cgcaccaatg	gcagacaata	acgaaggcgc	cgacggagtg	ggtaatgcct	2880
caggaaattg	gcattgcgat	tccacatggc	tgggcgacag	agtcattacc	accagcacc	2940



gaacatgggc	cttgcccacc	tataacaacc	acctctacaa	gcaaattctcc	agtgccttcaa	3000
cgggggccag	caacgacaac	cactacttcg	gctacagcac	ccctggggg	tattttgatt	3060
tcaacagatt	ccactgccat	ttctcaccac	gtgactggca	gcgactcatc	aacaacaatt	3120
ggggattccg	gccaagaga	ctcaacttca	agctcttcaa	catccaagtc	aaggagggtca	3180
cgacgaatga	tggcgtcacg	accatcgcta	ataaccttac	cagcacgggt	caagtcttgt	3240
cggactcgga	gtaccagttc	ccgtacgtcc	tcggctctgc	gcaccagggc	tgcctccctc	3300
cgttcccggc	ggacgtgttc	atgattccgc	agtacggcta	cctaacgctc	aacaatggca	3360
gccaggcagt	gggacgctca	tccttttact	gcctggaata	tttcccatcg	cagatgctga	3420
gaacgggcaa	taactttacc	ttcagctaca	ccttcgagga	cgtgcctttc	cacagcagct	3480
acgcgcacag	ccagagcctg	gaccggctga	tgaatcctct	catcgaccag	tacctgtatt	3540
acctgaacag	aactcacaat	cagtcaggaa	gtgccccaaa	caaggacttg	ctgttttagcc	3600
gtgggtctcc	agctggcatg	tctgttcagc	ccaaaaactg	gctacctgga	ccctgttacc	3660
ggcagcagcg	cgttttctaaa	acaaaaacag	acaacaacaa	cagcaacttt	acctggactg	3720
gtgcttcaaa	atataacctt	aatgggcgtg	aatctataat	caaccctggc	actgctatgg	3780
cctcacacaa	agacgacaaa	gacaagttct	ttcccatgag	cgggtgtcatg	atttttggaa	3840
aggagagcgc	cggagcttca	aacactgcat	tggacaatgt	catgatcaca	gacgaagagg	3900
aatcaaagc	cactaaccct	gtggccaccg	aaagatttgg	gactgtggca	gtcaatctcc	3960
agagcagcag	cacagaccct	gcgaccggag	atgtgcatgt	tatgggagcc	ttacctggaa	4020
tgggtgtggca	agacagagac	gtatacctgc	agggtcctat	ttgggccaaa	attcctcaca	4080
cggatggaca	ctttcacccg	tctcctctca	tgggcggctt	tggacttaag	caccgcctc	4140
ctcagatcct	catcaaaaac	acgcctgttc	ctgcgaatcc	tccggcagag	ttttcggcta	4200
caaagtttgc	ttcattcatc	accaggtatt	ccacaggaca	agtgagcgtg	gagattgaat	4260
gggagctgca	gaaagaaaac	agcaaacgct	ggaatcccga	agtgcagtat	acatctaact	4320
atgcaaaatc	tgccaacggt	gatttcactg	tggacaacaa	tggactttat	actgagcctc	4380
gccccattgg	caccggttac	ctcacccgtc	ccctgtaatt	gtgtgttaat	caataaaccg	4440
gttaattcgt	gtcagttgaa	ctttgggtctc	atgtccttat	tatcttatct	ggtcaccata	4500
gcaaccgggt	acacattaac	tgcttagttg	cgcttcgcga	atacccctag	tgatggagtt	4560
gccactccc	tctatgcgcg	ctcgctcgct	cgggtggggcc	ggcagagcag	agctctgccg	4620
tctgcggaac	tttgggtccgc	aggccccacc	gagcgagcga	gcgcgcatag	agggagtggc	4680
caa						4683

THE UNIVERSITY OF CHICAGO

```
<210> 20
<211> 16
<212> DNA
<213> rep binding motif
```

```
<400> 20
gctcgctcgc tcgctg
```

16